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Abstract 
The enantioselective imidazolidinone-catalyzed epoxidation of α,β-unsaturated 
aldehydes has been accomplished via a novel 1,4-heteroconjugate addition reaction using 
hypervalent iodine reagents.  Development of an “internal syringe pump” protocol for the 
slow release of iodosobenzene from an iminoiodinane source provides high levels of 
reaction efficiency and enantiomeric control in the asymmetric epoxidation of electron-
deficient olefins.  Fundamental to our studies were 15N NMR experiments that elucidated 
the oxidation pathways that lead to catalyst depletion, thereby providing a mechanistic 
rational for the utilization of iminoiodinanes, which circumvent these catalyst depletion 
pathways.  
We further established iminium catalysis as a valuable strategy for asymmetric 
synthesis in an organocatalytic addition of trifluoro(organo)borates and boronic acids to 
α,β-unsaturated aldehydes.  Inspired by the Petasis reaction and guided by rational 
mechanistic considerations, we discovered a new mode of reactivity for organoboronates 
and a metal-free “coupling” procedure for enantioselective C–C bond construction.  From a 
practical standpoint, this methodology stands to benefit from the structural diversity and 
wide commercial availability of several hundred organoboron reagents accessible to 
organic chemists.  Furthermore, the low toxicity and the air and moisture stability of 
potassium organotrifluoroborates reagents make this powerful new organocatalytic process 
operationally trivial. 
A five-step total synthesis of (+)-frondosin B highlights the stereoselective construction 
of a natural product target using an organocatalytic conjugate addition of a 
trilfluoro(organoboronate) reagent.  This key step unambiguously established the absolute 
configuration of the frondosin B to be the (R)-enantiomer and led to the reassignment of 
naturally occurring frondosin B, thus resolving an existing discrepancy in the literature.  To 
date, this work represents the most effective synthesis of frondosin B, which is accessible 
in only five steps and in a 32% overall yield. 
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C h a p t e r  1  
Enant ioselect ive LUMO–Lowering Organocata lysis  
 
I. Introduction 
 Asymmetric catalysis poses a fundamental challenge to synthetic chemists to 
emulate nature in the synthesis of single-enantiomer products.  It is this challenge that is 
central to the thriving field of asymmetric catalysis, which has arrived at the forefront of 
chemical research in modern organic chemistry.1  In accord with the ever-increasing 
demand for “atom economic” processes,2 single-enantiomer building blocks, and 
complex medicinal agents from the pharmaceutical and fine chemical industries, 3 the 
development of new chiral catalyst systems and asymmetric transformations have 
advanced at an astounding rate over the last 30 years.4 
 Defined by the early successes in metal-catalyzed redox reactions, the 
establishment of chiral transition metal and Lewis-acid catalysts produced rich and 
multifaceted platforms for the invention, discovery, and development of enantioselective 
                                                
1. This is evidenced by the 2001 Nobel Prize in Chemistry, which was awarded for “work on chirally catalyzed 
hydrogenation reactions” and also “chirally catalyzed oxidation reactions.” (a) Knowles, W. S. Angew. Chem. Int. 
Ed. 2002, 41, 1998. (b) Noyori, R. Angew. Chem. Int. Ed. 2002, 41, 2008. (c) Sharpless, K. B. Angew. Chem. Int. 
Ed. 2002, 41, 2024. 
2. Trost, B. M. Angew.Chem., Int. Ed. Engl. 1995, 34, 259.  
3. (a) Collins, A. N.; Sheldrake, G. N.; Crosby, J. Chirality in Industry; Wiley: New York, 1997; Vol. 2. (b) Process 
Chemistry in the Pharmaceutical Industry; Gadamasetti, K. G., Ed.; Marcel Dekker: New York, 1999. 
4. (a) Comprehensive Asymmetric Catalysis I–III; Jacobsen, E. N., Pfaltz, A., Yamamoto, H., Eds.; Springer-Verlag: 
Heidelberg, 1999. (b) Asymmetric Catalysis in Organic Synthesis; Noyori, R., Ed.; Wiley: New York, 1994. (c) 
Catalytic Asymmetric Synthesis, 2nd ed.; Ojima, I., Ed.; Wiley-VCH: New York, 2000. (d) Asymmetric Catalysis on 
Industrial Scale: Challenges, Approaches and Solutions; Blaser, H. U., Schmidt, E., Eds.; Wiley-VCH: Wienheim, 2004. 
 
 
2 
transformations.3,5  As the two primary avenues for enantioselective synthesis were either 
by metal catalysts and biocatalysts (i.e., enzymes), only a few examples in the literature 
recognized the potential for small organic molecules to directly function as catalysts.  
This was surprising considering the advantages—small organic molecules are usually 
more robust, less expensive, readily available, and can be applied in less demanding 
reaction conditions.  Moreover, the absence of a transition metal species eliminates issues 
associated with toxicity and trace metal contamination in industrial processes.  
 Only over the last decade has the use of organic molecules as catalysts emerged as 
a major concept in asymmetric catalysis and into a thriving field of general methods and 
reactivities with wide applicability.6  With historical roots that date back as early as 1912, 
the first enantioselective organocatalytic reaction was carried out by Bredig and Fiske, 
having employed alkaloids for the addition of hydrogen cyanide to benzaldehyde to 
obtain modest optical yields (≤ 10% ee).7  Unfortunately, this work remained fallow for 
nearly fifty years until Pracejus saw the use of alkaloids (such as O-acetylquinine, 1) to 
catalyze the addition of methanol into phenylmethylketene with remarkable selectivity 
(74% ee, eq. 1).8  The next major breakthrough was made in 1971 with the discovery of 
the Hajos-Parrish-Eder-Sauer-Wiechert reaction in which L-proline (2) catalyzed the 
intramolecular aldol condensation and cyclodehydration of an achiral trione to a bicyclic 
                                                
5. (a) Foote, C. S., Ed. Acc. Chem. Res. 2000, 33 (Special Issue), 323. (b) Maruoka, K., Ed. Tetrahedron 2001, 57 
(Symposium-in-print), 805. (c) Santelli, M.; Pons, J. M. Lewis Acids and Selectivity in Organic Synthesis; CRC: Tokyo, 
1996. (d) Narasaka, K. Synthesis 1991, 1. (e) Wills, M. J. Chem. Soc., Perkin Trans. 1 1998, 3101. 
6. (a) Asymmetric Organocatalysis, Berkessel, A., Gröger, H., Eds.; Wiley-VCH: Weinheim, 2005. (b) Houk, K. N., 
List. B., Eds. Acc. Chem. Res. 2004, 37 (Special Issue), 487. (c) Dalko, P. I.; Moisan, L. Angew. Chem. Int. Ed. 
2004, 43, 5138. (d) Gaunt, M. J.; Johansson, C. C. C.; McNally, A.; Vo, N. T. Drug Discovery Today 2007, 12, 8. 
7. Bredig, G.; Fiske, W. S. Biochem Z. 1912, 7. 
8. (a) Pracejus, H. Justus Liebigs Ann. Chem. 1960, 634, 9. (b) Pracejus, H.; Mätje, H. J. Prakt. Chem. 1964, 24, 195. 
 
 
3 
(3–47 mol%)
MeCN, 23–80 °C
(2)
83–100% yield, 71–93% ee
(1 mol%)
methanol (1.1 eq)
toluene, –111 °C
(1)
93% yield, 74% ee
O
Me
Ph
Ph
OMe
Me
O
N
N
OMe
AcO
N
H
CO2H
O
O
O
O
MeMe
Me
O
1
2 3
diketone 3 (also known as the Wieland-Miescher ketone)9 with high enantioselectivities 
(71–93% ee, eq. 2).10   
 As isolated examples of specific catalysts mitigating single transformations 
appeared in the 1960s through the 1980s, the value of organocatalytic chemistry was 
largely unrealized until List and co-workers demonstrated a highly enantioselective 
intermolecular aldol reaction using L-proline as an organocatalyst in 2000 (96% ee, eq. 
3).  This and other recent seminal works (vide infra) had set the stage for an exponential 
(30 mol%)
DMSO, 23 °C
(3)
97% yield, 96% ee
N
H
CO2H
MeMe
O
2
Me
O
Me
Me
OH
H
O
Me
Me
growth of research in the field of organocatalysis as evidenced by the increasing number 
of publications that have been put forth by the greater chemical community over the last 
several years (Figure 1). 
  
                                                
9. Wieland, P.; Miescher, K. Helv. Chim. Acta 1950, 33, 2215. 
10. (a) Eder, U.; Sauer, G.; Wiechert, R. Angew. Chem. 1971, 83, 492; Angew. Chem. Int. Ed. 1971, 10, 496. (b) Hajos, 
Z. G.; Parrish, D. R. J. Org. Chem. 1974, 39, 1615. 
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Figure 1. Publication rate of articles on the topic of organocatalysis.11 
 In fact, the field of organocatalysis has now flourished to include a wide variety of 
catalysts that are applicable to a range of chemical transformations with general 
activation mechanisms through Lewis acidic, Lewis basic, hydrogen-bonding 
interactions, etc.  Some notable organocatalysts that have been landmarks in their 
discoveries and are representative of a class of catalysts are shown in Figure 2.  Phase-
transfer catalysts, such as the Cinchona-derived phase-transfer catalyst 4 first developed 
at Merck,12 have been further explored by Corey13 and later developed by Maruoka for 
enantioselective α-alkylations, as well as aldol and Michael reactions.14   Chiral ketone 
catalysts (5) independently developed by Shi, Yang, and Denmark15 function via in situ 
                                                
11. ISI Web of KnowledgeSM database. http://portal.isiknowledge.com/portal.cgi (accessed April 2007).  Search 
string in Web of Science® was the phrase “organocatalysis” as found in article titles, keywords, and abstracts.  
12. Dolling, U.-H.; Davis, P.; Grabowski, E. J. J. J. Am. Chem. Soc. 1984, 118, 446. 
13. Corey, E. J.; Xu, F.; Noe, M. C. J. Am. Chem. Soc. 1997, 119, 12414.  
14. (a) Maruoka, K.; Ooi, T. Chem. Rev. 2003, 103, 3013. (b) Ooi, T.; Maruoka, K., Acc. Chem. Res. 2004, 37, 526. (c) 
Ooi, T.; Kameda, M.; Maruoka, K. J. Am. Chem. Soc. 1999, 121, 6519. (d) Ooi, T.; Taniguchi, M.; Kameda, M.; 
Maruoka, K. Angew. Chem., Int. Ed. 2002, 41, 4542. (e) Ooi, T.; Doda, K.; Maruoka, K. J. Am. Chem. Soc., 2003, 
125, 2054. (f) Ooi, T.; Doda, K.; Maruoka, K. J. Am. Chem. Soc. 2003, 125, 9022.  
15. (a) Curci, R.; Fiorentino, M.; Serio, M. R. Chem. Commun. 1984, 155. (b) Curci, R.; Daccolti, L.; Fiorentino, M.; 
Rosa, A. Tetrahedron Lett. 1995, 36, 5831. (c) Denmark, S. E.; Wu, Z. C.; Crudden, C. M.; Matsuhashi, H. J. Org. 
Chem. 1997, 62, 8288. (d) Brown, D. S.; Marples, B. A.; Smith, P.; Walton, L. Tetrahedron 1995, 51, 3587. (e) 
Song, C. E.; Kim, Y. H.; Lee, K. C.; Lee, S.; Jin, B. W. Tetrahedron: Asymmetry 1997, 8, 2921. (f) Adam, W.; 
Zhao, C. G. Tetrahedron: Asymmetry 1997, 8, 3995. (g) Yang, D.; Yip, Y. C.; Tang, M. W.; Wong, M. K.; Zheng, 
 
 
5 
formation of chiral dioxiranes used in the epoxidation of olefins.  Lewis base catalysts 
operate through covalent activation of a substrate and can be represented by L-proline (2) 
and the amino acid-derived imidazolidinone catalyst (7) introduced by MacMillan and 
co-workers.16  These catalysts have enabled excellent enantioselectivities to be attained in 
cycloadditions and α− and β–functionalizations of aldehydes and ketones.17  
Additionally, there are the planar chiral DMAP catalysts (6) developed by Fu et al.18 that 
Fe
N
H
N
N
H
S
O
Me2N
t-Bu
H
HO
t-Bu O t-Bu
O
6 9
O
O
R
P
O
OH
R
N
Br
OH
O
O
O
O
O
O
Me
Me
Me
Me
7
10
N
H
CO2H
N
N
H
Me
Bn
Me
O Me
N
H2N
PhPh
Ph
PhPh
4
5
2
8
OH
OH
O
O
Ar
Ar
Me
Ar
Ar
Me
CF3
N
 
Figure 2. Some established organocatalysts. 
                                                
J. H.; Cheung, K. K. J. Am. Chem. Soc. 1996, 118, 491. (h) Tu, Y.; Wang, Z. X.; Shi, Y. J. Am. Chem. Soc. 1996, 
118, 9806. 
16. Ahrendt, K. A.; Borths, C. J.; MacMillan, D. W. C. J. Am. Chem. Soc. 2000, 122, 4243. 
17. Lelais, G.; MacMillan, D. W. C. Aldrichimica Acta 2006, 39, 79. 
18. Ruble, J. C.; Tweddell, J.; Fu, G. C. J. Org. Chem. 1998, 63, 2794.  
 
 
6 
participate in acyl-transfer reactions for kinetic resolutions and desymmetrizations.  
Seminal contributions have been made by Jacobsen and co-workers19 in the use of 
hydrogen bonds to activate organocatalytic reactions using chiral thiourea catalysts (8), 
which successfully catalyze asymmetric Strecker, Mannich, hydrophosphonylation, and 
Pictet- Spengler reactions.20  This mode of activation also mitigates the hydrogen-bond 
promoted hetero-Diels-Alder reaction by the chiral diol (9, R = 1-naphthyl) developed by 
Rawal and co-workers.21  Stronger Brønsted acid catalysts based on the phosphoric acid 
motif (10, R = aryl)22 have been developed by Akiyama23 and Terada24 as efficient 
catalysts.  
 The collective research over the last several years reflects an exciting and 
impressive advancement in the field of asymmetric catalysts.  With many catalysts that 
perform many transformations, the ultimate goal in the field has been towards catalyst 
systems that achieve a “privileged” status,25 in which one asymmetric catalyst promotes 
more than one mechanistically distinct asymmetric reaction.  Although there are several 
recent examples of catalysts that demonstrate more sophisticated utility, future research is 
focused on broadening reaction scope and the design of more powerful and farther-
reaching catalysts. 
 
                                                
19. (a) Sigman, M. S.; Vachal, P.; Jacobsen, E. N. Angew. Chem. Int. Ed. 2000, 39, 1279. (b) Vachal, P.; Jacobsen, E. 
N. Org. Lett. 2000, 2, 867.  
20. Seayad, J.; List, B. Org Biomol. Chem. 2005, 3, 719. 
21. Huang, Y.; Unni, A. K.; Thadani, A. N.; Rawal, V. H. Nature 2003, 424, 146. 
22. Akiyama, T.; Itoh, J.; Fuchibe, K. Adv. Synth. Catal. 2006, 348, 999.  
23. Akiyama, T.; Itoh, J.; Yokota, K.; Fuchibe, K. Angew. Chem. 2004, 116, 1592.  
24. Uraguchi, D.; Terada, M. J. Am. Chem. Soc. 2004, 126, 5356.  
25. Yoon, T. P; Jacobsen, E. N. Science 2003, 299, 1691. 
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II. Iminium–Activation Approach to Enantioselective Organocatalysis 
Iminium-activation is a discreet mode of catalytic activation within the field of 
asymmetric organocatalysis that has borne impressive development since its introduction 
in 2000.  With the disclosure of the first organocatalytic Diels-Alder reaction, the 
MacMillan group had established the conceptual foundations for iminium-activation 
catalysis, wherein secondary amines play a key role in the activation of carbonyl 
compounds.26,27  In analogy to Lewis acid catalysis, chiral amines emulate the equilibrium 
dynamics and π-orbital electronics28 that are inherent to Lewis acid catalysis (eq. 4) 
through the reversible formation of iminium ions with α,β-unsaturated aldehydes 
(4)
(5)
O O
LA
+
LA
substrate catalyst LUMO–activation
O
R
N
H
R
N
R
R
+•HX
(eq. 5).  Thus, iminium formation provides the mechanistic basis for enantioselective 
amine catalysis of cycloaddition and conjugate addition processes via LUMO-lowering 
substrate activation.15 
Imidazolidinone catalysts (Figure 3) have proved to be successful chiral 
secondary amine organocatalysts with demonstrated utility in over 40 discrete 
transformations with high levels of enantiocontrol (≥ 90% ee).25  Derived from an amino 
                                                
26. Ahrendt, K. A.; Borths, C. J.; MacMillan, D. W. C. J. Am. Chem. Soc. 2000, 122, 4243. 
27. Lelais, G.; MacMillan, D. W. C. Aldrichimica Acta 2006, 39, 79. 
28. Fleming, I. Frontier Orbitals and Organic Chemical Reactions; John Wiley & Sons: Chichester, 1976; pp 161–165. 
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acid (L-phenylalanine) and readily available starting materials,29 these catalysts (11, 12, 
Figure 3) are exceedingly robust and straightforward in preparation, storage and 
implementation.30  The imidazolidinone framework is defines the chiral environment of 
the reactive iminium-ion intermediate responsible for enantioinduction. 
N
N
H
O Me
Me
Me
Me
Ph
N
N
H
O Me
Me
Ph
Me
second-generation
imidazolidone catalyst
11
first-generation
imidazolidone catalyst
12
 
Figure 3. MacMillan first- and second-generation imidazolidinone catalysts 
 
Transition state topology of the activated catalyst-substrate iminium complex 
(MM3-13) is defined by the s-trans geometry around the C=C bond and the chiral 
environment provided by the C-2 and C-5 catalyst substituents (Figure 4).  This geometry 
is enforced by the non-bonding interactions imposed by the tert-butyl group and is further 
stabilized by an intramolecular π-stacking interaction between a C-2 tert-butyl group and 
the phenyl ring of the C-5 benzyl substituent of the catalyst (12).31 Enantiofacial 
discrimination of the iminium π-system favors the open Re-face for reaction, thus 
imparting the absolute sense of enantioinduction in the resulting transformation.32  
This platform of reactivity, established on the basic principles of LUMO-lowering 
activation and non-bonding interactions in the iminium ion intermediate, has been  
                                                
29. Notably, catalysts 11 and 12 are both commercially available from Sigma-Aldrich.  
30. These catalysts are relatively insensitive to air and moisture and tolerant to long-term benchtop storage. 
31. NOE experiments support this interaction, see: Park, J. Y. Development of an Enantioselective 
Organocatalytic Michael Addition using Unactivated Nucleophiles. M.S. Thesis, California Institute of 
Technology, Pasadena, CA, 2002. 
32. Notably, this model is in agreement with all observed cases thus far. 
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H+
N
N
H
O Me
Me
Me
Me
Ph
O
catalyst 12
Si-face
blocked
X
Re-face activated
to cycloaddition 
and nucleophiles
MM3-13
5 2
Figure 4. Rationale for catalyst-controlled enantioselectivity. 
successfully applied to enantioselective transformations such as cycloadditions,33 Friedel-
Crafts alkylations,34 Mukaiyama-Michael additions,35 hydrogenations,36 heteroconjugate 
additions,37 cyclopropanations,38 and cascade reactions.39 
 
 
III. Summary of Thesis Research 
The following chapters detail efforts towards further establishing iminium 
catalysis as a viable strategy for organocatalysis with the development of new 
                                                
33. (a) Ahrendt, K. A.; Borths, C. J.; MacMillan, D. W. C. J. Am. Chem. Soc. 2000, 122, 4243.  (b) Jen, W. S.; 
Wiener, J. J. M.; MacMillan, D. W. C. J. Am. Chem. Soc. 2000, 122, 9874. (c) Northrup, A. B.; MacMillan, D. W. 
C. J. Am. Chem. Soc. 2002, 124, 2458. (d) Wilson, R. M.; Jen, W. S.; MacMillan, D. W. C. J. Am. Chem. Soc. 2005, 
127, 11616. 
34. (a) Paras, N. A.; MacMillan, D. W. C. J. Am. Chem. Soc. 2001, 123, 4370. (b) Austin, J. F.; MacMillan, D. W. C. 
J. Am. Chem. Soc. 2002, 124, 1172. (c) Paras, N. A.; MacMillan, D. W. C. J. Am. Chem. Soc. 2002, 124, 7894 (d) 
Brown, S. P; Goodwin, N. C.; MacMillan, D. W. C. J. Am. Chem. Soc. 2003, 125, 1192. 
35. Borths, C. J. Investigations in Enantioselective Catalysis. Development of Novel Asymmetric Organocatalytic 
Reactions. Ph.D. Thesis, California Institute of Technology, Pasadena, CA, 2004. 
36. (a) Ouellet, S. G.; Tuttle, J. B.; MacMillan, D. W. C. J. Am. Chem. Soc., 2005, 127, 32. (b) Tuttle, J. B.; Ouellet, S. 
G.; MacMillan, D. W. C. J. Am. Chem. Soc. 2006, 128, 12662. 
37. Chen, Y. K.; Yoshida, M.; MacMillan, D. W. C.  J. Am. Chem. Soc. 2006, 128, 9328. 
38. Kunz, R. K.; MacMillan, D. W. C. J. Am. Chem. Soc. 2005, 127, 3240. 
39. (a) Huang, Y.; Walji, A. M.; Larsen, C. H.; MacMillan, D. W. C. J. Am. Chem. Soc. 2005, 127, 15051. (b) Walji, 
A. M.; MacMillan, D. W. C. Synlett 2007, 10, 1477. 
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methodologies.  Chapter 2 discusses the development of an enantioselective 
imidazolidinone-catalyzed epoxidation of α,β-unsaturated aldehydes via a novel 1,4-
heteroconjugate addition reaction using hypervalent iodine reagents.  Chapter 3 details 
the organocatalytic addition of trifluoro(organo)borates and boronic acids to α,β-
unsaturated aldehydes as a metal-free “coupling” procedure for enantioselective C–C 
bond construction.  Chapter 4 describes a five-step total synthesis of (+)-frondosin B 
highlighting the utility of the organocatalytic conjugate addition of a 
trilfluoro(organoboronate) reagent. 
C h a p t e r  2  
The Imidazolidinone-Cata lyzed Epoxidat ion of α,β-
Unsaturated Aldehydes*  
 
I. Introduction 
In 2001, a Nobel prize was awarded to Sharpless “for his work on chirally catalyzed 
oxidation reactions,” in recognition that the asymmetric catalytic epoxidation reaction 
stands as one of the most significant transformations in synthetic chemistry.1  
Enantioenriched epoxides in and of themselves are of fundamental importance to organic 
chemistry due to their capacity to transfer stereochemical information with complete 
specificity to provide two vicinal carbon stereocenters upon reaction with a wide variety of 
nucleophiles.  As such, they are preeminent sp3 carbon-electrophiles and powerfully 
versatile synthetic intermediates in the construction of complex enantiorich structures and 
natural product targets.  
The first highly enantioselective epoxidation of olefins (≥ 90% ee) was achieved by 
Sharpless through the use of a titanium-tartrate complex for the oxidation of allylic 
alcohols (eq. 1).2  Prior to this report in 1980, the highest enantioselective excess obtained 
                                                
* For a full article of this work, see: Lee, S.; MacMillan, D. W. C. Tetrahedron 2006, 62, 11413. 
1. Sharpless was awarded ½ the Nobel prize in 2001, see: Sharpless, K. B. Angew. Chem., Int. Ed. 2002, 41, 2024. 
2. (a) Katsuki, T.; Sharpless, K. B. J. Am. Chem. Soc. 1980, 102, 5974. (b) Gao, Y.; Hanson, R. M.; Klunder, J. M.; 
Ko, S. Y.; Masamune, H.; Sharpless, K. B. J. Am. Chem. Soc. 1987, 109, 5765.  
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was 35%.3  With the advent of this catalytic asymmetric epoxidation reaction ensued an 
ever-increasing demand for a generalized catalytic oxidation process that enabled efficient 
and predictable access to enantioenriched oxiranes.4  Subsequently, significant efforts to 
expand the scope of catalytic epoxidations have been directed towards the development of 
methods that were broadly applicable to other olefinic classes.  
R OH R OH
O
Ti(Oi-Pr)4 (1 mol%)
diethyl tartrate (1.2 mol%)
alkyl hydroperoxide
4Å MS
(1)
> 90% ee  
A decade later, Jacobsen5 and Katsuki6 made seminal contributions that advanced 
the scope of catalytic enantioselective epoxidations to include unfunctionalized cis-alkenes.  
Devised to mimic biological oxidation systems,7 these [MnIII(salen)] catalysts effectively 
promoted stereospecific electrophilic metal oxo-transfer to olefinic substrates in the 
presence of a stoichiometric oxidant (eq. 2; Jacobsen: R1 = H, R2 = R3 = t-Bu, X = Cl; 
Katsuki: R1 = Ph, R2 = H, R3 = CH(CH2CH3)Ph, X = PF6).  Though cyclic and acyclic di- 
> 90% ee
OR2
N
Mn
O
N
R2
R3 R3
HH
X
R1R1
Ph Ph
O
(2.5 mol% catalyst)
NaOCl or PhIO
(2)
R R
                                                
3. Kagan, H. B.; Mimoun, H.; Mark, C.; Schurig, V. Angew. Chem. Int. Ed. 1979, 18, 485. 
4. Johnson, R. A.; Sharpless, K. B. In Comprehensive Organic Synthesis; Trost, B. M.; Fleming, I., Eds.; Pergamon 
Press: New York, 1991; vol. 7, p. 389. 
5. Zhang, W.; Loebach, J. L.;  Wilson, S. R.; Jacobsen, E. N. J. Am. Chem. Soc. 1990, 112, 2801. 
6. Irie, R.; Noda, K.; Ito, Y.; Matsumoto, N.; Katsuki, T. Tetrahedron Lett. 1990, 31, 7345. 
7. (a) McMurry, T. J.; Groves, J. T. In Cytochrome P-450: Structure, Mechanism, and Biochemistry, Ortiz de Montellano, 
P. R., Ed.; Plenum Publishing: New York, 1986; Chapter 1. (b) Holland, H. L. Organic Synthesis with Oxidative 
Enzymes; VCH Publishers: New York, 1992. (c) Allain, E. J.; Hager, L. P.; Deng, L.; Jacobsen, E. N. J. Am. 
Chem. Soc. 1993, 115, 4415. 
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and trisubstituted cis-olefins proved to be excellent substrates for the metallosalen-
catalyzed epoxidation, unfunctionalized simple trans-olefins remained elusive.  
A complimentary approach to the more established method of oxyfunctionalization 
via organometallic agents was a novel and elegant organocatalytic strategy.  The 
emergence of organic-based chiral dioxirane catalysts came about in 1984,8 and since then 
moderately successful stoichiometric and catalytic examples have been developed.9  
Significant progress was achieved independently by Yang (using a C2-symmetric, cyclic 
binaphthalenyl ketone catalyst)10 and Shi (using a fructose-derived ketone catalyst, eq. 3)11 
in the discovery of a highly enantioselective epoxidation of simple trans- and trisubstituted 
olefins.  These dioxirane-mediated oxidations were important in bridging a substantial gap 
in existing asymmetric epoxidation methodologies with respect to substrate scope. 
> 90% ee
OO
O
O
O
O
Me
MeMe
Me
R R
O
(30 mol% catalyst)
NaHCO3, OXONE
(3)
R1 R3
R2 R2
R
 
Though newly developed epoxidation methodologies came to encompass several 
olefin classes, there remained a limited applicability towards electron-deficient olefins.  
Due to the predominant focus on electrophilic oxidations, these technologies were not 
applicable towards enones and enals.  Existing strategies for electron-deficient olefins were 
                                                
8. Curci, R.; Fiorentino, M.; Serio, M. R. Chem. Commun. 1984, 155. 
9. (a) Curci, R.; Daccolti, L.; Fiorentino, M.; Rosa, A. Tetrahedron Lett. 1995, 36, 5831. (b) Denmark, S. E.; Wu, Z. 
C.; Crudden, C. M.; Matsuhashi, H. J. Org. Chem. 1997, 62, 8288. (c) Brown, D. S.; Marples, B. A.; Smith, P.; 
Walton, L. Tetrahedron 1995, 51, 3587. (d) Song, C. E.; Kim, Y. H.; Lee, K. C.; Lee, S.; Jin, B. W. Tetrahedron: 
Asymmetry 1997, 8, 2921. (d) Adam, W.; Zhao, C. G. Tetrahedron: Asymmetry 1997, 8, 3995.  
10. Yang, D.; Yip, Y. C.; Tang, M. W.; Wong, M. K.; Zheng, J. H.; Cheung, K. K. J. Am. Chem. Soc. 1996, 118, 491.  
11. Tu, Y.; Wang, Z. X.; Shi, Y. J. Am. Chem. Soc. 1996, 118, 9806. 
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variants of the Weitz-Scheffer12 epoxidation, wherein a nucleophilic chiral peroxide adds to 
an enone, or more specifically to a chalcogen substrate.  This strategy of hydroperoxide 
CMHP or TBHP
4Å MS
(5)
R1 = Me, Ph; R2 = Ph, alkyl
R3 = H, CH2OH
O
O
R3
R2 R2
O
83–94% ee
R1
O O
R1
(5–8 mol%)
LnOi-Pr
(4)
R1 = alkyl, aryl; R2 = Me, Et, aryl
R2 R2
O
81–94% ee
R1
O O
R1MgBu2 ( 10 mol%)
(+)-DET (11 mol%)
TBHP
 
delivery via a homogeneous chiral metal complex has been adopted and developed by 
Enders13 in a stoichiometric manner (using diethylzinc, oxygen, and N-methylephedrine) 
and in a catalytic approach by Jackson (eq. 4)14 and Shibasaki (eq. 5).15  Alternatively, 
asymmetric phase transfer agents have been used to transport a reactive oxo-species from 
the basic aqueous phase into the organic phase of the olefin substrate; this is epitomized in 
the works of Roberts,16 in using a modified Juliá-Colonna polyamino acid procedure,17 in 
iminium salts,18 and in the cinchona alkaloid-derived salts of Lygo19 and 
                                                
12. Weitz, E.; Scheffer, A. Ber. Dtsch. Chem. Ges. 1921, 54, 2327. 
13. (a) Enders, D.; Zhu, J. Q.; Raabe, G. Angew. Chem. Int. Ed. 1996, 35, 1725. (b) Enders, D.; Zhu, J. Q.; 
Kramps, L. Liebigs Ann. Chem. 1997, 1101. 
14. Elston, C. L.; Jackson, R. F. W.; MacDonald, S. J. F.; Murray, P. J. Angew. Chem. Int. Ed. 1997, 36, 410. 
15. Bougauchi, M.; Watanabe, S.; Arai, T.; Sasai, H.; Shibasaki, M. J. Am. Chem. Soc. 1997, 119, 2329. 
16. Dhanda, A.; Drauz, K.-H.; Geller, T. P; Roberts, S. M. Chirality 2000, 12, 313. 
17. (a) Juliá, S.; Masana, J.; Vega, J. C. Angew. Chem. Int. Ed. 1980, 19, 929. (b) Julia, S.; Guixer, J.; Masana, J.; Rocas, 
J.; Colonna, S.; Annuziata, R.; Molinari, H. J. Chem. Soc., Perkin Trans. 1 1982, 1317. 
18. (a) Wong, M.-K.; Ho, L.-M.; Zheng, Y.-S.; Ho, C.-H.; Yang, D. Org. Lett. 2001, 3, 2587.  (b) Page, P. C. B.; 
Rassias, D.; Barros, D.; Ardakani, A.; Buckley, B.; Bethell, D.; Smith, T. A. D.; Slawin, A. M. Z. J. Org. Chem. 
2001, 66, 6926 
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(10 mol% catalyst)
KOCl
(6)
R1 = Ph; R2 = aryl, c-C6H11, n-C5H11
N
Me
N
Br
OBn
R2 R2
O
R1
O O
R1
91–99% ee
 
Corey (eq. 6).20  Though these described methodologies successfully address the 
epoxidation of some electron-deficient alkenes, they are generally limited to s-cis-
chalogens and have yet to include the full range of electron-deficient alkene substrates such 
as s-trans-enones, unsaturated amides, esters, aldehydes, and nitrile systems. 
More recently, in 2005, Jørgensen and co-workers21 forayed into the open realm of 
enal olefin epoxidations by demonstrating the asymmetric organocatalytic epoxidation of 
α,β-unsaturated aldehydes using iminium catalysis (eq. 7).22  In these elegant studies, a 
variety of enals rapidly underwent asymmetric epoxidation using hydrogen peroxide or 
urea hydrogen peroxide as the stoichiometric oxidant in the presence of a proline-derived, 
bis(3,5-bistrifluoromethylphenyl)trimethylsilanyloxymethyl] pyrrolidine) catalyst. 
N
H
OTMS
CF3
CF3
CF3F3C
H2O2 or UHP
(7)
R1 = H, Me 
R2 = alkyl, aryl, CO2Me
R2 R2
O
H
O O
R1
75–98% ee
R1 (10 mol%)
  
                                                                                                                                            
19. (a) Lygo, B.; Wainwright, P. G. Tetrahedron Lett. 1998, 39, 1599. (b) Lygo, B.; Wainwright, P. G. Tetrahedron 
1999, 55, 6289. 
20. Corey, E. J.; Zhang, F.-Y. Org. Lett. 1999, 1, 1287. 
21. (a) Marigo, M.; Franzen, J.; Poulsen, T. B.; Zhuang, W.; Jørgensen, K. A. J. Am. Chem. Soc. 2005, 127, 6964. (b) 
Zhuang, W.; Marigo, M.; Jørgensen, K. A. Org. Biomol. Chem. 2005, 3, 3883. (c) Carlone, A.; Marigo, M.; North, 
C.; Landa, A.; Jørgensen, K. A. Chem. Commun. 2006, 4928. 
22. This work was published subsequent to our own epoxidation studies, which were initiated in 2002 and later 
published: Lee, S.; MacMillan, D. W. C. Tetrahedron 2006, 62, 11413. 
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II. A Mechanism-Based Organocatalytic Epoxidation Strategy 
In 2002, we initiated studies to develop a novel organocatalytic methodology for 
the asymmetric epoxidation of α,β-unsaturated aldehydes based upon the activation 
principle of iminium catalysis (vide Chapter 1) with the goal of providing rapid access to 
enantioenriched 1,2-trans-formyl epoxides, an ambiphilic class of electrophile of known 
value in chemical synthesis.23  Having demonstrated the capacity of chiral amines to 
function as asymmetric catalysts, and building on previous successes in cycloadditions and 
1,4-conjugate additions,19 there was strong precedence for the mechanism-based design of 
an organocatalytic epoxidation reaction.  It was envisaged that a nucleophilic oxygen, 
incorporated with a suitable leaving group, could add with enantiofacial selectivity to an 
iminium-activated complex formed from the condensation an α,β-unsaturated aldehyde 
with an amine catalyst (Figure 1).  Subsequent enamine formation, followed by 
N
N
O Me
Me
Me
Me
Ph
R
X
catalyst-aldehyde 
iminium complex
Re-face
exposed
O LG
Si-face
blocked
X
1
 
Figure 1.  Rational of catalyst-controlled enantioselectivity utilizing a 
              MM3-2 model of the catalyst-aldehyde iminium complex 
intramolecular trapping of the pendent electrophilic oxygen with concomitant expulsion of 
the oxygen-tethered leaving group (LG), would then produce an oxirane (Figure 2).  The 
                                                
23. Antoniotti, S.; Dunach, E. Synthesis 2003, 18, 2753. 
                                                   17 
feasibility of this proposed catalytic cycle is then contingent on judicious selection of an 
ambiphilic oxygen source that must dually function as a viable nucleophile for the 
conjugate addition step and then be suitably electrophilic (via incorporation of an 
electronegative nucleofuge with high leaving group ability) to enable intramolecular  
RO
O R
O
H2OH2O catalyst 2
LG O LG
N
N
H
OMe
Me
Me
Me
Ph
N
N
OMe
Me
Me
Me
Ph
R
XN
N
OMe
Me
Me
Me
Ph
R
X
•HX
iminium
N
N
OMe
Me
Me
Me
Ph
R
O
LG
enamine
O
 
Figure 2.  Proposed organocatalytic cycle for oxirane formation 
    and the generation of an α,β-epoxy aldehyde 
enamine cyclization and oxirane formation.  As such, preliminary investigations were 
focused on defining potential oxygen sources that would participate in the requisite 1,4-
heteroconjugate addition and enamine cyclization sequence of reactions.  Initial 
experiments were carried out under a standard system consisting of crotonaldehyde and a 
variety of commercially available oxidants in the presence of catalyst 2⋅TFA (Table 1).  
The first candidate chosen was pyridinium N-oxide, given that it bears a relatively good 
leaving group and the oxygen of the N–O ylide is known to nucleophilically add to 
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Michael-acceptors.24  Gratifyingly, pyridinium N-oxide gave the desired 2,3-epoxy-
crotonaldehyde product (3) in 12% yield at room temperature.  However, the observed 
reaction was completely suppressed when conducted at subambient temperatures (entry 
1).  It was immediately apparent that the amine by-product (pyridine) inhibited the 
organocatalytic cycle via proton abstraction from the requisite acid co-catalyst.  
Consequently, this placed a theoretical limit on this reaction based on the acid co-catalyst 
loading.  Notably, other commercially available N-oxides were evaluated (such as triethyl 
amine N-oxide, N-methyl-N-morpholine oxide, 4-nitro, and 4-methoxy pyridinium N-
oxide) and were found to be less productive reagents. 
Table 1.  Initial Survey of Oxygen Sources for Epoxidation 
entry
MeOO Me
20 mol% catalyst 2•TFA
oxidant (1 eq)
CH2Cl2 (0.2 M) 
18 hr, –30 °C
O
(3 eq)
1
2
3
4
5
6
7
% conversiona
NR 
34
35
9
NR
9
43
% eeb
--
73
69
59
--
0
72
oxidant
H2O2
d
pyridine N-oxide
t-BuOOHc
m-CPBA
OXONE®
3
NaOCle
a Conversion determined by GC relative to methyl benzyl ether. b Enantiomeric excess
determined by chiral GC analysis (Chiraldex !-TA). c Used as 5 M solution in decane. 
d Used as a 50% solution in water. e Used as a 30% solution in water.
PhIO
 
Peroxides were next examined in the epoxidation reaction and were found to 
readily provide 3 (Table 1, entries 2–4).  Evaluation of m-CPBA under identical reaction 
                                                
24. Katritzky, A. R. Quart. Rev., Chem. Soc. 1956, 10, 395. 
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conditions produced encouraging levels of selectivity (73% ee, entry 2); however, studies 
to define the utility of this reagent (by modification of reaction parameters such as 
solvent and temperature) resulted in little improvement in overall enantiocontrol.  The 
use of peroxides, such as tert-butyl hydrogen and hydrogen peroxide also furnished the 
desired oxirane with notable enantioselectivities (69% and 59% ee, entries 3 and 4).  
However, attempts to extend these reactions to less reactive substrates (such as 
cinnamaldehyde) unfortunately resulted in substantial levels of catalyst N-oxidation and 
therefore, these reagents were not further pursued.  Other simple oxidants were also 
found to be unviable reagents for this process (Table 1, entries 5 and 6).  Notably, at 
ambient temperature OXONE® gave the desired transformation to 3 in 55% conversion 
and 13% ee, however upon cooling showed no reactivity (entry 5).  Additionally, NaOCl 
demonstrated some reactivity but yielded racemic product at 23 °C and also at –30 °C 
(entry 6).  
Having exhausted the possibility of using a more conventional oxidant, we next 
considered the use of hypervalent λ3-iodanes as potential oxidants for this organocatalytic 
epoxidation reaction.  With well-known involvement in alkene epoxidations, one of the 
most important oxygen transfer agents in metal-oxo-mediated oxy-functionalization is 
iodosobenzene.25  Though, the oxidative properties of these reagents are predominantly 
attributed to the electrophilic nature of the hypervalent iodine, there are a few 
precedented cases, where the oxygen in iodosobenzene is reported to possess sufficient 
                                                
25. For excellent reviews on hypervalent iodine, see: (a) Stang, P. Chem. Rev. 1996, 96, 1123. (b) Wirth, T.; Ochiai, 
M.; Varvgolis, A.; Zhdankin, V. V.; Koser, G. F.; Tohma, H.; Kita, Y. Topics in Current Chemistry: Hypervalent 
Iodine Chemistry–Modern Developments in Organic Synthesis; Springer-Verlag, Berlin, 2002; vol. 224, pp. 1–248. (c) 
Varvoglis, A. Hypervalent Iodine Chemistry in Organic Synthesis; Academic Press: London. 1997; pp. 1–223. 
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ylide character to participate in nucleophilic addition.26  From the outset, we 
hypothesized that the remarkable lability of the phenyliodonio moiety (which is ~106 
times better leaving group ability than triflate)25b would enable rapid oxirane ring 
formation and thereby minimize the intervention of a reversible oxo-conjugate addition 
(an equilibrium process that would diminish kinetic enantiocontrol).  Another attractive 
feature of this reagent is the presence of a phenyl ring, which could serve as a handle for 
electronic modification and potentially serve as a key point of interaction with the benzyl 
group of the catalyst-complex (1) that could enhance the selectivity of the 
enantiodetermining step.  Moreover, we presumed that the oxidation byproduct, 
iodobenzene, would have no deleterious impact on the organocatalytic cycle (Figure 2).  
To our immediate delight, we were indeed validated when application of iodosobenzene 
in the proposed 1,4-heteroconjugate addition afforded 3 with a 43% conversion and an 
encouraging level of enantiocontrol (72% ee, Table 1, entry 7). 
To gain insight into this initial result with iodosobenzene, the reaction parameters 
of the crotonaldehyde epoxidation were thoroughly examined.  A survey of reaction 
media (Table 2) revealed that solvents with high dielectric constants typically enabled 
higher efficiencies (87–41% conversion, entries 1–3) while lower dielectric systems 
provided higher levels of asymmetric induction (64–82% ee, entries 4–9).  Balancing this 
apparent dichotomy, dichloromethane (80% ee, entry 4) and chloroform (82% ee, entry 
7) demonstrated useful efficiencies while maintaining optimal enantioselectivity.  On this 
                                                
26. For an example of a 1,4-addition with iodosobenzene, see: (a) Pettus, L. P; Van De Water, R. W.; Pettus, T. R. 
R. Org. Lett. 2001, 3, 905. For examples of nucleophilic attack by the oxygen of iodosobenzene, see: (a) Ono, 
T.; Henderson, P. Tetrahedron Lett. 2002, 43, 7961. (c) Moriarty, R. M.; Gupta, S. C.; Hu, H.; Berenschot, D. R.; 
White, K. B. J. Am. Chem. Soc. 1981, 103, 686. (d) Zefirov, N.S.; Kozhushkov, S. I.; Zhdankin, V. V.; Safronov, 
S. O. Zh. Org. Khim. 1989, 25, 1109.  
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basis, these halogenated solvents were selected as optimal reaction media for the 
epoxidation reaction.  It is also noteworthy that a reaction carried out in dry THF and in  
Table 2.  Effect of Solvent on the Epoxidation Reaction with Iodosobenzene  
a CRC Handbook of Chemistry and Physics, 81st ed.; Lide, D. R., Ed.; CRC Press: Boca
Raton, 2000. b Conversion determined by GC relative to tridecane. c Enantiomeric excess 
determined by chiral GC analysis (Chiraldex !-TA).
entry
1
2
3
4
5
6
7
8
9
% conversionb
87
55
41
50
14
12
45
29
63
% eec
25
33
42
80
76
75
82
63
64
solvent
O Me
20 mol% catalyst 2•TFA
PhIO (1 eq)
solvent (0.2 M) 
20 hr, –30 °C(3 eq)
"a
DMF (10% H2O) 
MeCN
acetone
CH2Cl2
THF
THF (10% H2O) 
chloroform
ether
toluene
--
37
21
8.9
7.5
--
4.8
4.3
2.4
MeO
O
3
 
the presence of 10% water (entries 5 and 6) irrespectively had similar levels of conversion 
and enantioselectivity, which suggests that water is a non-detrimental factor in this 
reaction. 
Heterogeneity remained an issue in these solvent studies, because iodosobenzene 
exists as a oligomer in most organic solvents (eq. 8).25a  Though, soluble in alcohols (such 
as trifluoroethanol and methanol) iodosobenzene is only moderately soluable in water, 
DMF, DMSO, and nitromethane.  Efforts to identify homogenous reaction conditions using 
mixed alcohol and pure alcohol solvent systems, unfortunately produced complex reaction 
profiles that were plagued with indiscriminant acetal formation as an unavoidable side 
product.  To alleviate issues with insolubility, the reaction was found to 
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I
O
I
O
I
*
O
I
O
*
O
2.04 Å
2.3
7 Å
114°
n
I
O
oligomeric
(8)
perform best under more dilute conditions (≥ 0.5 M) to better solubilize iodosobenzene in 
the reaction.  
The impact of the Brønsted acid co-catalyst component on this organocatalytic 
epoxidation was next examined.  As revealed in Table 3, an apparent correlation was 
observed between reaction conversion and enantiocontrol to the pKa of the acid co-catalyst.  
Table 3.  Effect of Acid co-Catalyst on the Epoxidation Reaction using Iodosobenzene 
 a Smith, M. B.; March, J. Advanced Organic Chemistry, 5th ed.; Wiley & Sons: New 
York, 2001. b Conversion determined by GC relative to benzyl ether. c Enantiomeric
excess determined by chiral GC analysis (Chiraldex !-TA).
entry
1
2
3
4
5
6
% conversionb
74
68
50
42
27
27
% eec
87
88
76
72
72
69
HX
O Me
20 mol% catalyst 2•HX
PhIO (1 eq)
CH2Cl2 (0.2 M) 
18 hr, –30 °C
DCA
TFA
TfOH
p-TSA
CNA
(3 eq)
pKa
a
1.3
–0.3
–14
–2.6
2.5
MeO
O
3
HClO4 –10
 
More specifically, stronger acids, such as TfOH and HClO4, provided the epoxide adduct 
with enhanced selectivities and conversions (pKa –14 to –10, 74–68% conversion, 87–88% 
ee, entries 1 and 2), while acids with higher pKa resulted in poorer conversions (pKa 1.3 to 
2.5, 27% conversion, 69–72% ee, entries 5 and 6).  This trend can be rationalized on the 
basis that the stronger acid co-catalyst enables a higher equilibrium content of the catalyst 
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substrate iminium adduct (1), which is observable by 1H NMR.  In the case of TfOH, the 
equilibrium lies entirely in favor of the iminium species 1, thus the rate of the addition-
cyclization sequence is subsequently accelerated.  Moreover, the observed 
enantioselectivity appears to track with the reaction efficiency according to traditional 
requirements for the catalyst-controlled pathway to kinetically out-compete the non-
catalyzed (racemic) process.  As a result, the more acidic co-catalysts were deemed optimal 
for this reaction and further optimization studies were carried out with TfOH and HClO4. 
The influence of temperature on this epoxidation protocol was next investigated 
(Table 4).  An apparent trend of improving enantioselectivity was realized upon lowering 
the reaction temperature.  More surprisingly, however, was the corresponding increase in 
reaction efficiency with the same temperature trend.  Subsequent studies (vide infra) have  
Table 4.  Effect of Temperature on Reaction Efficiency and Selectivities 
 a Conversion determined by GC relative to benzyl ether. b Enantiomeric excess 
determined by chiral GC analysis (Chiraldex !-TA).
entry
1
2
3
4
% conversiona
49
74
98
100
% eeb
83
87
89
93
T (°C)
O Me
20 mol% catalyst 2•TfOH
PhIO (1 eq)
CH2Cl2 (0.2 M) 
T (°C)(3 eq)
time (hr)
MeO
O
3
–20
–30
–40
–50
15
20
15
15
 
revealed that lower temperatures are essential to avoid detrimental catalyst oxidation 
pathways.  Additionally, it is possible that lower temperatures are necessary to preclude 
substrate decomposition pathways that may arise from the presence of a two-fold excess of 
aldehyde. 
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Having established optimal epoxidation conditions, we next examined the scope of 
the olefin component in the organocatalytic oxirane formation.  As revealed in Table 5, 
α,β-unsaturated aldehydes that incorporate alkyl group substituents are susceptible to 
iodosobenzene epoxidation with good efficiency and enantioselectivities (80–93% ee, 
entries 1–3).  However, substrates that form more stabilized iminium species with catalyst 
2 (such as cinnamaldehyde, entry 5) demonstrated diminished conversion and lower levels 
of asymmetric induction.  At this juncture, it was hypothesized that a catalytic cycle 
wherein the 1,4-oxygen addition step is rate determining would be consistent with these 
findings.  Moreover, we rationalized that implementation of a more nucleophilic 
iodosobenzene source should therefore provide an increase in both reaction rate and 
enantioselectivity.  To this end, we initiated additional studies aimed at increasing the 
reactivity of iodosobenzene and further evaluating the reactivity profile of iodosobenzene 
reagents for this organocatalytic transform. 
Table 5.  Organocatalytic Epoxidations with Iodosobenzene: Initial Studies 
a Enantiomeric excesses were determined by chiral GC analysis (Chiraldex G-TA). b 3 
eq of starting aldehyde in CH2Cl2 (0.075 M).
c 1 eq of aldehyde in CHCl3 (0.25 M).
d Yield based on NMR analysis using benzyl ether as a standard. e Yield based on
isolation of corresponding epoxy alcohol. f Stereochemical determination via
correlation to literature, see supporting information.
RO
O R
20 mol% catalyst 2•TfOH
PhIO (1.0 eq)
T (°C)
O
Meb
n-Prb
i-Prc
Phc
CO2Me
entry
1
2
3
4
5
% yield
100d
 93e
 86e
 78f
45
10
15
15
15
15
time (hr) % eea
93
88
80
73
85
R
–50
–50
–40
–40
–50
T (°C)
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III. Alternative Iodosobenzene Sources 
The substituent effects of iodosobenzene have been studied by Basolo with respect 
to the aptitude of oxygen transfer to metals relative to electronic modification on the phenyl 
ring.27  In their studies, the IR stretching frequencies of the I–O bond on iodosobenzene 
with electron-donating groups on the phenyl ring resulted in higher frequencies (longer and 
more polarized I–O bond) relative to electron-withdrawing groups which gave lower 
frequencies (shorter and less polarized I–O bond).  Therefore, IR data predicts that 
electron-donating substituents enhance the nucleophilicity of the oxygen in iodosobenzene.  
With this in mind, we prepared a variety of electronically differentiated substituted 
iodosobenzenes with p-Me, o-Me, o-Cl, p-NO2 on the benzene ring.28  To our great 
surprise, all other functionalized iodosobenzenes gave much poorer yielding results relative 
to unfunctionalized iodosobenzene. 
As p-Me iodosobenzene was synthesized with the expectation of being a more 
nucleophilic version of iodosobenzene, it was unforseen that a test epoxidation reaction 
with hexenal would be much lower yielding than the analogous reaction with 
iodosobenzene (Ar = p-MePh, 21% yield, eq. 9).  This highly unexpected result prompted a 
1H NMR investigation of this reaction (eq. 10) wherein each component of the reaction was 
(9)O
15 hr, –40 °C
O
O
Me Me
Ar = Ph: 93% yield, 88% ee
Ar = p-MePh: 21% yield, 85% ee
4
20 mol% 1•TfOH
ArIO (1 eq)
 
                                                
27. (a) Harden, G. J. J. Chem. Soc., Perkins Trans. 2 1995, 1883. (b) Gao, Y.; Jiao. X.; Fan, W.; Shen, J.-K.; Shiu, Q.; 
Basolo, F. J. Coord. Chem. 1993, 29, 349. 
28. All iodosobenzene substrates were prepared using a modified procedure outlined in Sawaguchi, M.; Aruba, S.; 
Hara, S. Synthesis 2002, 13, 1802, using an appropriately functionalized iodobenzene starting material. 
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followed over the course of 24 hours (using modified reaction conditions tailored to this 1H 
NMR study in order to conduct the reaction at a higher temperature and lower overall 
concentration).  The NMR profile of the crude reaction of hexenal with iodosobenzene 
demonstrated good progression (54% conversion, 81% ee) and a persistent level of reactive 
iminium (20%, graph 1, Scheme 1) over 24 hours.  In contrast, the reaction of hexanal with 
Scheme 1. 1H NMR study of the reaction components in the epoxidation of hexenal 
         
(10)O
20 mol% 1•TfOH
ArIO (1.0 eq)
CD2Cl2 (0.1 M) 
24 hr, –10 °C
O
O
Me Me
Ar = Ph: 54% conversion, 81% ee
Ar = p-MePh: 20% conversion, 83% ee
(1 eq)
4
 
p-Me iodosobenzene after 24 hours did not advance beyond 20% conversion (and 83% ee) 
to epoxide 4.  In fact, the reaction was complete after only 6 hours since additional 
progression to product was not possible due to the absence of reactive iminium complex 
(0%, graph 2, Scheme 1). 
With focus on potential catalyst and oxidant interactions, additional 1H NMR 
studies were undertaken with p-Me iodosobenzene and catalyst 2 in the absence of an 
aldehyde substrate.  It was revealed that a rapid depletive imidazolidinone oxidation 
pathway compromised the integrity of the catalyst (Ar = p-MePh, eq. 11).  Intriguingly, a 
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N
N
OMe
Me
Me
Me
Ph
N
N
H
OMe
Me
Me
Me
Ph
•TfOH
CD2Cl2 (0.075M) 
10 hr, –30 °C
 2
ArIO
Ar = Ph, 99%
Ar = p-MePh, 47%
Ar = Ph, 1%
Ar = p-MePh, 53%
(11)
N
N
H
OMe
Me
Me
Me
Ph
 slower variant of the same catalyst decomposition pathway was observed using 
iodosobenzene as the reaction oxidant (Ar = Ph, eq. 10) to a much lesser extent.  We 
surmised that the increased nucleophilicity of the oxygen in the p-Me iodosobenzene, 
consequently lead to increased electrophilicity of the iodine, making the system more 
susceptible to attack by the catalyst free amine (eq. 12); Thus, the ensuing reductive β-
elimination gives rise to the observed oxidation product, imine 5.  
CD2Cl2 (0.075M) 
10 hr, –30 °C
(12)
5
p-MePhI=O – p-MePhI
•TfOH
 2
N
N
H
OMe
Me
Me
Me
Ph
N
N
OMe
Me
Me
Me
Ph
IHO Ph
– H2O
N
N
OMe
Me
Me
Me
Ph
  
At this stage, we presumed that the diminished enantioselectivities observed in the 
cinnamaldehyde epoxidation case (Table 5, entry 4) could be attributed to the intervention 
of a catalyst oxidation pathway that is competitive with the iminium-catalyzed addition-
cyclization step.  With respect to the relative capacities of iodosobenzene and p-Me 
iodosobenzene to function as catalyst oxidants, we have determined that the tolyl-derived 
system is more soluble under the reaction conditions than its polymeric phenyl iodide 
counterpart.  As a result, the relative concentration of p-Me iodosobenzene in solution was 
found to be much higher, a scenario that dramatically increases the rate of catalyst 
oxidation and leads to greatly diminished conversions with this iodane.  On this basis, we 
began to focus upon identifying alternative sources of hypervalent iodine, which could be 
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H2O
or dilute H+
–2X
I
X
X
(13)I
O
monomeric
 
employed to slowly generate reactive iodosobenzene monomer in situ, and in doing so 
function as a type of “internal syringe pump” (eq. 13).  In this manner, we hoped the 
imidazolidinone 2 would be partitioned exclusively towards iminium formation with the 
aldehyde substrate and thereby avoid catalyst oxidation. 
We next examined a range of hypervalent λ3-iodane sources that we expected 
would slowly release iodosobenzene monomer when subjected to water or mildly acidic 
conditions in accessing an equilibrium content of iodosobenzene (Table 6).  These studies 
were specifically performed with cinnamaldehyde with the anticipation that an 
improvement in enantioselectivity with this substrate would be observed as compared to an  
Table 6.  Alternative Iodosobenzene Sources 
a Conversion determined by 1H NMR analysis using methyl benzyl ether as a
standard. b Enantiomeric excess determined by chiral GC analysis (Chiraldex !-TA). 
c Koser's salt = [(hydroxy)(tosyloxy)iodo]benzene.
entry
1
2
3c
4
% conversiona
68
10
7
oxidant
O
20 mol% 2•HClO4
oxidant (1.5 eq)
CHCl3 (0.25 M) 
–30 °C
O
O
(1 eq) 6
additive
I
OAc
OAc
I
OCOCF3
OCOCF3
I
OH
OTs
I
N Ns
water
water
water
water
1M AcOH
71
100
% eeb
84
71
 76
80
92
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analogous experiment with iodosobenzene (73% ee, Table 5, entry 4).  As revealed in 
Table 6, the use of commercially available diacetoxy iodosobenzene in the presence of 
water did indeed provide the desired epoxide with enhanced levels of enantiocontrol (84% 
ee, entry 1); however, bis(trifluoroacetoxy) iodosobenzene and Koser’s salt provided the 
oxirane 6 with poor efficiency (7–10% yield, entries 2 and 3).  Given that hypervalent I–N 
systems have been established to be less stable than the corresponding I–O class of 
reagents,25a we next examined the use of iminoiodanes as potential iodosobenzene 
surrogates in the presence of water or acid.  To our great delight, exposure of 
cinnamaldehyde to [(nosylimino)iodo]benzene (NsNIPh) in the presence of catalyst 2 and 
1M acetic acid (20 vol% to facilitate the hydrolysis of the sulfonamide) did indeed furnish 
epoxide 6 with excellent levels of conversion and enantiocontrol (100% conversion, 92% 
ee, entry 4).  It is noteworthy that arylsulfonylimino(aryl)iodanes are stable, easily storable 
compounds25a that we have determined will function as controlled release iodosobenzene 
oxidants in the presence of dilute acid (vide infra). 
 
IV. NMR Studies on the Mechanism of the Internal Syringe Pump Effect 
In an attempt to gain further insight into the inherent advantages of using NsNIPh 
in comparison to iodosobenzene in this organocatalytic epoxidation, various NMR studies 
were undertaken to examine: (1) the controlled release of monomeric iodosobenzene from 
NsNIPh and (2) the subsequent effect of the monomeric iodosobenzene concentration on 
the rate of imidazolidinone catalyst oxidation. 
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A low-temperature 1H NMR study (–30 °C) was performed to investigate the 
conversion of NsNIPh to monomeric iodosobenzene in the presence of deuterated 
chloroform and 1M acetic acid (AcOD).29  As revealed in Figure 3, the iminoiodane 
(NsNIPh) does indeed undergo slow hydrolysis to provide a steady increase in the 
concentration of monomeric iodosobenzene over the course of six hours.  It is important to 
note that constant concentrations of diacetoxy iodosobenzene (5%) and hemi-hydrolyzed 
Figure 3. The solution content of monomeric iodosobenzene from NsNIPh as monitored by NMR  
monomeric
I
O
CDCl3-1M AcOD
–30 °C
oligomeric
I
N Ns
CDCl3-1M AcOD
–30 °C
oligomeric monomeric
I
O
I
O
%
 P
hI
O 
in
 so
lu
tio
n
hours
0
10
20
30
40
50
1 2 3 4 5 6
 
nosyliodosobenzene (1%) were also present in the reaction solution.  In contrast, when the 
analogous 1H NMR experiment was performed with oligomeric iodosobenzene, we 
observed the immediate formation of a relatively high concentration of iodosobenzene 
monomer (38%) that remained constant over the course of this six-hour study.  Again, a 
                                                
29. Concentrations of iodosobenzene species were calculated relative to benzyl methyl ether (internal standard) 
and determined after removal of oligomeric iodosobenzene by filtration through celite. 
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minimal concentration of diacetoxy iodosobenzene (2%) was also detected in this 
experiment.  These 1H NMR studies clearly demonstrate that the proposed slow release of 
monomeric iodosobenzene from NsNIPh (“internal syringe pump” effect) is not only 
feasible, but likely operational. 
We next turned to 15N NMR studies to examine the mode of catalyst depletion and 
to investigate the role of monomeric iodosobenzene concentration on catalyst depletion (via 
a variety of presumed amine oxidation pathways).  In this context, we first investigated the 
use of 15N isotopically-labeled imidazolidinone 7 as a catalyst for the epoxidation of 
cinnamaldehyde using: (a) NsNIPh and (b) oligomeric iodosobenzene as the respective 
reaction oxidants (Scheme 2).  It should be noted that in both cases, reaction efficiencies 
and enantioselectivities were observed that were within the experimental error of the 
corresponding results observed with a catalyst having a natural abundance of nitrogen.  
With respect to catalyst depletion, we observed striking differences in both the rate and 
nature of imidazolidinone decomposition as a function of these two oxidants and the 
relevant iodosobenzene monomer concentration.  As illustrated in Scheme 2, the use of 
Scheme 2. Mode of catalyst degradation when utilizing NsNIPh or PhIO as observed by 15N NMR 
9 + 10
NsNIPh
CDCl3-1M AcOD    
–30 °C, 6 hr
•HClO4
7
9 108
PhIO
CDCl3-1M AcOD
–30 °C, 6 hr
0%
26% 18% 31%
8
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N
N
OMe
Me
Me
Me
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1515
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N
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OMe
Me
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oligomeric iodosobenzene leads to the formation of three catalyst-derived amines over the 
course of the reaction, namely imine 8, aminol 9, and the corresponding trans catalyst 
isomer 10.  In contrast, the analogous reaction that employs NsNIPh leads only to the 
formation of the corresponding imine 8.  It should be noted that isolation and separate 
resubjection of catalyst derivatives 8, 9, and 10 to the outlined epoxidation conditions has 
confirmed that each of these amine species is catalytically inactive.  More important, 
however, is that the rate of catalyst consumption appears to be a function of the source of  
7
9
10
cis
catalyst
trans
catalyst
8
8
(b)
N
N
OMe
Me
Me
Me
Ph
15
15
N
N
H
OMe
Me
Me
Me
Ph
N
N
OMe
Me
Me
Me Ph
15
15
N
N
H
OMe
Me
Me
Me Ph15
N
N
H
OMe
Me
Me
Me Ph
HO
(a)
 
Figure 4. 15N-VT NMR experiments of the 15N-labeled catalyst (7) at  –30 °C showing the 
                       catalyst species that are present using iodosobenzene after (a) 20 min and (b) 6 hr 
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monomeric iodosobenzene.  As revealed in Figures 4 and 5, real time 15N NMR studies 
performed on a low temperature epoxidation reaction with oligomeric iodosobenzene 
clearly demonstrates that the formation of imine 8 occurs within the first 20 minutes of the 
reaction protocol (Figure 4(a)).  Moreover, after six hours there is almost complete 
conversion of the catalyst to amine derivatives 8, 9, and 10 (Figure 4(b)).  We presume that 
these secondary oxidized catalysts species originate from imine 8, which gives rise to the  
8
7
8
7
(a)
(b)
N
N
OMe
Me
Me
Me Ph
15
15
N
N
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Me
Me
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15
N
N
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Me
Me
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N
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Me
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Figure 5. 15N-VT NMR experiments of the 15N-labeled catalyst (7) at  –30 °C showing the catalyst 
             species that are present using [(nosylimino)iodo]benzene after (a) 20 min and (b) 6 hr 
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hydroxy addition product 930 and the isomerized trans-catalyst (10) by way of a non- 
selective addition and elimination of water.  In contrast, the use of the slow release oxidant 
NsNIPh results in minimal catalyst oxidation after 20 minutes (Figure 5(a)), and only 
imine adduct 8 is formed in observable quantities after six hours (Figure 5(b)).  Notably, 
significant quantities of the active catalyst 7 remain after six hours when NsNIPh is 
employed, highlighting that the “internal syringe pump” concept is key to achieving useful 
levels of catalyst efficiency within this epoxidation protocol. 
 
V. Organocatalytic Epoxidation Substrate Scope 
Having developed optimal epoxidation conditions, we sought to extend this 
methodology to other α,β-unsaturated aldehydes.  As revealed in Table 7, a variety of enal 
olefins can be successfully utilized with both high levels of reactivity and enantiomeric 
control in the presence of NsNIPh.  Most impressively, the cinnamaldehyde epoxidation 
reaction that had previously been 78% yield and 73% ee (entry 4) with iodosobenzene is 
now dramatically improved to excellent levels, 92% yield and 92% ee (entry 7).  Electronic 
variation on the phenyl ring reveals that electronic electron-poor (entry 8) and electron-rich 
(entry 9) substitution is well tolerated.  Exploring systems with alkyl substituents (entries 
1–3) with varying steric demand shows good reactivity in the range of 72–88% and 
selectivities in the range of 88–93% ee.  Examples of compatible functional groups for this 
                                                
30. α-Oxidation by iodosobenzene is known to occur in the presence of acid or halogen salts, see: (a) Huang, W.-
J.; Singh, O. V.; Chen, C.-H.; Choiu, S.-Y.; Lee, S.-S. Helv. Chim. Acta 2002, 85, 1069. (b) Tohma, H.; Maegawa, 
T.; Takizawa, Kita, Y. Adv. Synth. Catal. 2002, 344, 328.  (c) Ueno, M.; Nabana, T.; Togo, H. J. Org. Chem. 2003, 
68, 6424. (d) Sohmiya, H.; Kimura, T.; Fujita, M.; Ando, T. Tetrahedron 1998, 54, 13737. 
                                                   35 
reaction manifold include esters (entry 6) and heterocyclic substituted amines (entry 5), 
provided that amine is protected with an electron-withdrawing protecting group.  
Additionally, unactivated olefins (entry 4) remain unoxidized under these reaction 
conditions in this chemoselective epoxidation by iodosobenzene.  It should be noted that 
when a substrate is significantly electron-withdrawing (CH2OBz, entry 5) the system is 
overly active to 1,4-addition and the nosyl-protected aziridine product can be formed 
Table 7.  Enantioselective Organocatalyzed Epoxidation: Scope 
a Products are a single diastereomers, except in entry 1 (dr = 1:7). b Enantiomeric
excess determined by chiral GC and SFC analysis. c Yield determined by NMR
analysis. d CHCl3 was used as solvent. 
e Iodosobenzene was used as the oxidant at 
–40 °C.
O R
20 mol% 1•HClO4 
NsNIPh (1.5 eq)
RO
O
CH2Cl2-AcOH (0.15 M) 
 –30 °C
entry
1
2
3
4
5
6
7
8
9
10
% yielda
88c
72
77
95d
89e
86
86
92d
89d
93d
10
15
13
16
15
11
12
12
6
8
time (hr) % eeb
93
88
92
92
85
87
90
92
97
93
R
(1 eq)
Me
Me
3
MeO2C
N
BOC
BzO
O2N
Br
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competitively when NsNIPh is used as the oxidant (1:1.6 aziridine:epoxide).  In the 
extreme case, where the olefin is doubly activated (R = CO2Me, eq. 14) the aziridine is the 
(14)N
H
O O
H
OMe
O
OMe
O
S
O
O
NO2
4:1 aziridine:epoxide
63% conversion
90% ee
20 mol% 1•p-TSA
NsNIPh (1.5 eq)
CH2Cl2 (0.25 M)  
–30 °C, 24 hr 11
 
major product when the reaction is conducted with the exclusion of a dilute acid (1M 
AcOH) to minimize the hydrolysis of the NsNIPh to iodosobenzene.  Further efforts to 
optimize this reaction for the exclusive formation of the aziridine product have not been 
successful due to the unavoidable hydrolysis of NsNIPh in this organocatalytic reaction.31 
 
IV. Conclusion 
In summary, we have further established iminium catalysis as a valuable strategy 
for asymmetric synthesis in the context of an enantioselective enal epoxidation protocol.  
This new organocatalytic reaction allows for the enantioselective formation of oxiranes 
from a wide array of electronically and sterically diverse α,β-unsaturated aldehydes.  
Fundamental to these studies has been the recognition that hypervalent iodine reagents are 
suitable oxidants for organocatalytic epoxidations using imidazolidinone catalyst 1.  
Optimal levels of reaction efficiency and enantiocontrol have been accomplished using an 
“internal syringe pump” protocol wherein the slow release of monomeric iodosobenzene 
                                                
31. Since our report of this result, other organocatalytic aziridination methodologies have been reported: (a) 
Vesely, J.; Ibrahem, I.; Zhao, G. L.; Rios, R.; Cordova, A. Angew. Chem., Int. Ed. 2007, 46, 778. (b) Armstrong, 
A.; Baxter, C. A.; Lamont, S. G.; Pape, A. R.; Wincewicz, R. Org. Lett. 2007, 9, 351. 
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from an in situ iminoiodane source is accomplished using a mild acid.  NMR studies (15N) 
have revealed that this slow, in situ production of monomeric iodosobenzene from NsNIPh 
is central to alleviating losses in catalytic efficiency arising from a variety of 
imidazolidinone oxidation pathways. 
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S u p p o r t i n g  I n f o r m a t i o n  
General Information.  Commercial reagents were purified prior to use following 
the guidelines of Perrin and Armarego.32  Iodosobenzene reagents were synthesized and 
iodometrically titrated for purity prior to use.33  All solvents were purified according to the 
method of Grubbs.34  Organic solutions were concentrated under reduced pressure on a 
Büchi rotary evaporator using an ice-water bath for volatile compounds.  Chromatographic 
purification of products was accomplished using force-flow chromatography on ICN 60 
32-64 mesh silica gel 63 according to the method of Still,35 and, where noted, Iatrobeads 
6RS-8060 was used in place of silica gel.  Thin-layer chromatography (TLC) was 
performed on EM Reagents 0.25 mm silica gel 60-F plates.  Visualization of the developed 
chromatogram was performed by fluorescence quenching, anisaldehyde, KMnO4, or 
ninhydrin stain. 
1H and 13C NMR spectra were recorded on a Mercury 300 (300 MHz or 75 MHz) 
or an Inova 500 (500MHz and 125 MHz) as noted, and are internally referenced to residual 
protio solvent signals.  Data for 1H NMR are reported as follows: chemical shift (δ ppm), 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), integration, 
coupling constant (Hz), and assignment.  Data for 13C NMR are reported in terms of 
chemical shift.  15N NMR spectra were externally referenced to 7M nitromethane in 
                                                
32. Perrin, D. D.; Armarego, W. L. F. Purification of Laboratory Chemicals; 3rd ed.; Pergamon Press: Oxford, 1988.  
33. (a) Saltzman, H.; Sharefkin, J. G. Org. Synth. 1973, 5, 658. (b) Simàndi, L. I.; Nèmeth, S.; Besenyei, G. 
Tetrahedron Lett. 1993, 34, 6105.  
34. Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics, 1996, 15, 1518. 
35. Still, W. C.; Kahn, M.; Mitra, A. J. J. Org. Chem. 1978, 43, 2923. 
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deuterated chloroform and are reported in terms of chemical shift.  IR spectra were 
recorded on a Perkin Elmer Paragon 1000 spectrometer and are reported in terms of 
frequency of absorption (cm-1).  Mass spectra were obtained from the California Institute of 
Technology Mass Spectral facility.  Gas liquid chromatography (GLC) was performed on 
Hewlett-Packard 6850 and 6890 Series gas chromatographs equipped with split-mode 
capillary injection system and flame ionization detectors using Bodman Chiraldex Γ-TA 
and Varian Chirasil-Dex-CB (30 m x 0.25 mm) columns.  High pressure liquid 
chromatography (HPLC) was preformed on a Hewlett-Packard 1100 series chromatograph 
using a Chiralcel OD-H column (25 cm) and OD guard (5 cm) as noted.  Supercritical fluid 
chromatography (SFC) was performed on a Berger Minigram equipped with a variable-
wavelength UV detector using a Chiralpak AD-H column (25 cm) and AD guard (5 cm). 
 
General epoxidation procedure A (using iodosobenzene):  A solution of the 
trifluoromethanesulfonic acid salt of (2R, 5R)-2-tert-butyl-5-benzyl-3-methylimidazolidin-
4-one (0.2 eq) in dichloromethane (0.075M) is prepared in a scintillation vial equipped with 
a magnetic stir bar at –50 or –40 °C (as noted) for 10 minutes.  The aldehyde (3 eq) and 
iodosobenzene (1 eq) are added to form a light yellow suspension and the reaction is stirred 
at constant temperature for 10–15 hours until no further reaction progression is observed.  
The cold reaction is filtered through celite, washed with ether and concentrated in vacuo.  
The resulting residue is purified by column chromatography (solvents noted) to provide the 
title compounds. 
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General epoxidation procedure B  (using NsNIPh):  A scintillation vial equipped 
with a magnetic stir bar was charged with perchloric acid (70 wt%, 0.2 eq), 
dichloromethane and 20 vol% of 1M AcOH (0.15 M) and (2R, 5R)-2-tert-butyl-5-benzyl-3-
methylimidazolidin-4-one (0.2 eq) and allowed to stir for ten minutes at –30 °C.  The 
aldehyde (1 eq) and [(nosylimino)iodo]benzene (1.5 eq) are added to form a light yellow 
suspension in an icy solution, which is stirred at constant temperature for 6–16 hours until 
complete consumption of the starting material is observed.  The cold reaction is quenched 
by adding pH 7 buffer, filtration through celite, and extraction with ether (2 x 4 mL).  The 
organic layer was dried over Na2SO4 and concentrated in vacuo and the resulting residue is 
purified by column chromatography (solvents as noted) to provide the title compounds.  
MeO
O
 
((2R, 3S)-3-Methyl-oxirane-2-carbaldehyde (3).  Prepared according to general 
epoxidation procedure A using crotonaldehyde (296 µL, 3.57 mmol) in CD2Cl2 at –50 °C 
with benzyl ether as an internal standard to establish NMR yield, after filtration through 
silica gel.  The title compound was obtained in a 100% NMR yield and 93% ee.   
Also prepared according to general epoxidation procedure B with crotonaldehyde 
(296 µL, 3.57 mmol) in CD2Cl2 and mesitylene as an internal standard to establish NMR 
yield.  After filtration through silica gel, the title compound was obtained in an 88% NMR 
yield and 93% ee.  Material for characterization was obtained by flash chromatography 
(Iatrobeads, 20% ether in pentane).  IR (film) 3416, 2965, 2929, 1443, 1380, 1124, 871 
cm-1; 1H NMR (300 MHz, CDCl3) δ 9.00 (d, 1H, J = 6.0 Hz, CHO), 3.30 (qd, 1H, J = 2.1, 
5.1 Hz, CH oxirane), 3.08 (dd, 1H, J = 2.1, 6.3 Hz, CH oxirane), 1.42 (d, 3H, J = 5.1 Hz, 
CH3); 13C NMR (75 MHz, CDCl3) δ 198.6, 60.23, 53.06, 17.06;  HRMS (EI+) exact mass 
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calculated for [M]+ (C4H6O2) requires m/z 86.03678, found m/z 86.03649; [α]D= +47.9 (c = 
2.7, CHCl3).  The enantiomeric purity was determined on the alcohol product, which is 
prepared by a NaBH4 reduction, and analyzed by GLC analysis using a Bodman Γ-TA 
column (40 °C isotherm, 12 psi); (2S, 3R) isomer tr = 57.1 min, (2S, 3R) isomer tr = 58.7 
min. 
O
O
Me  
(2R, 3S)-3-Propyloxirane-2-carbaldehyde (4).  Prepared according to general 
epoxidation procedure A using (E)-hex-2-enal (591 µL, 5.09 mmol) at –50°C.  After 
stirring for 15 hrs, this reaction was filtered through silica, washed with dichloromethane 
(30 mL), and cooled to 0 °C.  Reduction to the alcohol was performed on the crude reaction 
solution by adding ethanol (1 mL) and NaBH4 (770 mg, 20.4 mmol).  The reaction was 
quenched with a saturated solution of Rochelle’s salt (30 mL) on completion as judged by 
TLC.  The alcohol product was extracted with dichloromethane (3 x 30 mL) and 
concentrated in vacuo at 0 °C, before purifying by flash chromatography (silica gel, 50% 
ether in pentane) to afford the title compound as a clear, colorless oil in 93% yield (182 mg, 
1.57 mmol), 88 % ee. 
Also prepared according to general epoxidation procedure B using (E)-hex-2-enal 
(234 mL, 2.0 mmol) to afford the title compound as a clear, colorless oil (162 mg, 72% 
yield, 88% ee) after chromatography (silica gel, 30% to 70% ether in pentanes, linear 
gradient).  IR (film) 2962, 2935, 2875, 1731, 1671, 1534, 1458, 1378, 1350, 1125, 1092, 
1044, 915.1, 737.5 cm-1; 1H NMR (300 MHz, CDCl3) δ 9.01 (d, 1H, J = 6.3 Hz, CHO), 
3.23 (td, 1H, J = 2.1, 5.1, 7.8 Hz, CH oxirane), 3.13 (dd, 1H, J = 1.8, 6.3 Hz, CH oxirane), 
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1.69–1.50 (m, 4H, CH2CH2), 0.98 (t, 3H, J = 7.2 Hz, CH3); 13C NMR (75 MHz, CDCl3) δ 
198.8, 59.34, 56.83, 33.39, 19.39, 13.98; HRMS (EI+) exact mass calculated for [M-H]+ 
(C6H9O2) requires m/z 113.0603, found m/z 113.0602; [α]D= +11.4 (c = 2.38, CHCl3).  The 
enantiomeric purity was determined by GLC using a Bodman Γ-TA column (70 °C 
isotherm, 15 psi, flow = 1.3 mL/min); (2S, 3R) isomer tr = 8.87 min, (2R, 3S) isomer tr = 
9.79 min. 
CH2Cl2-MeOH, 0 °C
NaBH4
O
O
Me HO
O
Me
 
Determination of the absolute stereochemistry of (2R, 3S)-3-Propyloxirane-2-
carbaldehyde by correlation to ((2R, 3R)-3-propyloxiran-2-yl)methanol.36  Reduction 
of the aldehyde to the alcohol by NaBH4 (2.6 mmol) in dichloromethane (5.0 mL) with 
catalytic ethanol (0.2 mL) was performed at 0 °C.  The reduction was quenched by a 
saturated solution of Rochelle’s salt  (5.0 mL) and extracted with ether (2.0 x 5 mL) and 
concentrated in vacuo at 0 °C, before purifying by flash chromatography (silica gel, 50% 
ether in pentanes) to afford alcohol as a clear, colorless oil.  IR (film) 2922, 1700, 1521, 
1458, 1020, cm-1; 1H NMR (300 MHz, CDCl3) δ 3.95 (ddd, 1H, J = 2.4, 5.1, 12.3 Hz, 
CHOH), 3.67 (ddd, 1H, J = 4.5, 7.8, 12.6 Hz, CHOH), 3.02–2.94 (m, 2H, CH oxirane), 
1.65–1.47 (m, 4H, CH2CH2), 1.03 (t, 3H, J = 3.0 Hz); 13C NMR (75 MHz, CDCl3) δ 61.86, 
58.70, 55.96, 33.54, 19.21, 13.84; HRMS (EI+) exact mass calculated for [M+H]+ 
(C6H13O2) requires m/z 117.0916, found m/z 117.0917; [α]D= –13.2 (c = 0.42, CHCl3).  1H 
                                                
36. (a) Gao, Y.; Hanson, R. M.; Klunder, J. M.; Ko, S. Y.; Masamume, H.; Sharpless, B. M. J. Am. Chem. Soc. 1987, 
109, 5765. (b) Hill, J. G.; Sharpless, B. M.; Exon, C. M.; Regenye, R. Org. Synth. 1984, 63, 66. 
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NMR matched the reported values and the literature [α]D= –46.3 (c = 3.87, CHCl3).  This 
enantiomerically enriched compound is also commercially available from Sigma-Aldrich. 
O
O
Me
Me  
 ((2R, 3S)-3-Isopropyloxiran-2-yl)methanol (Table 5, entry 3).  Prepared 
according to general epoxidation procedure A using (E)-4-methylpent-2-enal (592 µL, 5.09 
mmol) and iodosobenzene (1.52 g, 6.92 mmol) in dichloromethane (18.3 mL) at –40 °C.  
After stirring for 15 hrs, this reaction was filtered through silica gel, washed with 
dichloromethane (50 mL) and cooled to 0 °C.  Reduction to the alcohol was performed on 
the crude reaction solution by adding ethanol (1.0 mL) and NaBH4 (770 mg, 20.4 mmol).  
The reaction was quenched with a saturated solution of Rochelle’s salt (30 mL) on 
completion as judged by TLC.  The alcohol product was extracted with dichloromethane 
(3.0 x 30 mL) and concentrated in vacuo at 0 °C, before purifying by flash chromatography 
(silica gel, 30% to 50% ether in pentanes, linear gradient) to afford the title compound as a 
clear, colorless oil in 86% yield (505 mg, 4.35 mmol), 80 % ee.  IR (film) 2963, 2930, 
1459, 1067, 895.1, 669.3 cm-1; 1H NMR (300 MHz, CDCl3) δ 3.99 (ddd, 1H, J = 2.4, 5.7, 
12.3 Hz, CHOH), 3.70 (ddd, 1H, J = 4.2, 7.2, 12.3 Hz, CHOH), 3.02 (dt, 1H, J = 3.0, 3.9 
Hz, CH oxirane), 2.81 (dd, 1H, J = 2.4, 6.9 Hz, CH oxirane), 1.70–1.59 (m, 1H, CHMe2), 
1.08 (d, 3H, J = 6.6 Hz, CH3), 1.02 (d, 3H, J = 6.9 Hz, CH3); 13C NMR (75 MHz, CDCl3) 
δ 61.86, 61.14, 57.36, 30.07, 19.02, 18.37; HRMS (EI+) exact mass calculated for [M-H]+ 
(C6H11O2) requires m/z 115.0759, found m/z 115.0702; [α]D= –14.0 (c = 0.74, CHCl3).  The 
enantiomeric purity was on the crude alcohol product determined by GLC analysis using a 
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Bodman Γ-TA column (60 °C isotherm, 12 psi); (2S, 3R) isomer tr = 12.8, (2R, 3S) isomer 
tr = 16.2 min. 
O
O
 
(2R, 3S)-3-Phenyloxirane-2-carbaldehyde (6).  Prepared using general 
epoxidation procedure A using cinnamaldehyde (159 µL, 1.26 mmol) and iodosobenzene 
(378 mg, 1.72 mmol) in dichloromethane (5.04 mL) at –40 °C.  Flash chromatography 
(silica gel, 30% ether in pentane) afforded the title compound as a clear, light yellow oil in 
a 71% yield (133 mg, 0.90 mmol), 78 % ee.  
Prepared according to general epoxidation procedure B using cinnamaldehyde (94.4 
µL, 0.75 mmol) using 1M AcOH (0.75 mL) and chloroform (3.0 mL).  Flash 
chromatography (silica gel, 30% ether in pentane) afforded the title compound as a clear, 
light yellow oil (101 mg, 92% yield, 92% ee).  IR (film) 1726, 1460, 1137, 990.8, 754.3, 
697.9 cm-1; 1H NMR (300 MHz, CDCl3) δ 9.20 (d, 1H, J = 6.0 Hz, CHO), 7.39–7.28 (m, 5 
H, aryl H), 4.17 (d, 1H, J = 2.1 Hz, CH oxirane), 3.45 (dd, 1H, J = 2.1, 6.0 Hz, CH 
oxirane); 13C NMR (75 MHz, CDCl3) δ 197.1, 129.4, 129.0, 125.9, 63.2, 56.9; HRMS 
(EI+) exact mass calculated for [M]+ (C9H8O2) requires m/z 148.0524, found m/z 148.0522; 
[α]D= +35.8 (c = 0.76, CHCl3).  The enantiomeric purity was determined by GLC analysis 
using a Bodman G-TA column (90 °C isotherm, 15 psi, flow = 1.0 mL/min); (2S, 3R) 
isomer tr = 29.9 min, (2R, 3S) isomer tr = 33.1 min. 
O
O
OMe
O  
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Methyl 3-((2R, 3S)-3-formyloxiran-2-yl)propanoate (Table 5, entry 5).  Prepared 
according to general epoxidation procedure B using (E)-methyl 5-formylpent-4-enoate37  
(142 mg, 1.0 mol) to afford the title compound as a clear, colorless oil (137 mg, 86% yield, 
90% ee) after flash chromatography (silica gel, 40% ether in pentanes).  IR (film) 1731, 
1438, 1175 cm-1; 1H NMR (300 MHz, CDCl3) δ 9.03 (d, 1H, J = 6.3 Hz, CHO), 3.72 (s, 
3H, CO2CH3), 3.38–3.34 (m, 1H, CH oxirane), 3.20 (dd, 1H, J = 2.0, 6.0 Hz, CH oxirane), 
2.52 (t, 2H, J = 6.9 Hz, CH2CO2Me), 2.15–1.88 (m, 2H, CH2CH2CO2Me); 13C NMR (75 
MHz, CDCl3) δ 198.1, 151.1, 59.29, 55.81, 52.16, 30.11, 26.66; HRMS (EI+) exact mass 
calculated for [M-H]+ (C7H9O4) requires m/z 157.0501, found m/z 157.0501; [α]D= +27.3 
(c = 1.25, CHCl3).  The enantiomeric purity was determined by GLC using a Chirasil-DEX 
CB column (90 °C isotherm, 15 psi, flow = 1.0 mL/min); (2R, 3S) isomer tr = 60.62 min, 
(2S, 3R) isomer tr = 62.23 min. 
15
N
N
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15N-labeled (2R, 5R)-2-tert-butyl-5-benzyl-3-methylimidazolidin-4-one (7).  D-
phenylalanine (98% 15N-labeled, 3g, 18.05 mmol) in a three-neck 100 mL round-bottom 
flask equipped with a reflux condenser and magnetic stirrer is suspended in methanol (36 
mL) under an Ar atmosphere.  Thionyl chloride (3.3 mL, 45.1 mmol) is added dropwise 
and the reaction becomes homogenous upon exotherm and evolution of gas.  The reaction 
is refluxed for 12 hours and then cooled to room temperature and partitioned with aqueous 
NaHCO3 (30 mL) and ethyl acetate (2.0 x 30 mL).  The separated organic layers are 
                                                
37. Kukovinets, O. S.; Kasradze, V. G.; Chernukha, E. V.; Odinokov, V. N.; Dolidze, A. V.; Galin, F. Z.; 
Spirikhin, L. B.; Abdullin, M. I.; Tolstikov, G. A. Russ. J. Org. Chem. 1999, 35, 1156. 
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combined, dried over Na2SO4 and concentrated in vacuo.  The resulting residue is purified 
on a short plug of silica gel and washed with ethyl acetate (20 mL) to yield 15N-labeled (R)-
methyl 2-amino-3-phenylpropanoate as a clear oil (3.22 g, quantitative yield).   
The methyl ester (3.2 g, 18.1 mmol) and methylamine (8M in ethanol, 10 mL) in a 
25 mL round-bottom flask are magnetically stirred at room temperature for 12 hours under 
an Ar atmosphere.  The reaction is diluted with 0.5M HCl (20 mL) and partitioned by ethyl 
acetate (2.0 x 20 mL).  The separated organic layers are combined, dried over Na2SO4, and 
concentrated in vacuo to give 15N-labeled (R)-2-amino-N-methyl-3-phenylpropanamide as 
a clear oil (3.2 g, quantitative yield). 
To a dry, three-necked 100 mL round-bottom flask equipped with a reflux 
condenser, Dean-Stark trap, and magnetic stir bar is added FeCl3 (586 mg, 3.6 mmol) under 
a N2 atmosphere.  A solution of the amide (3.2 g, 18.1 mmol) and pivaldehyde (2.1 mL, 
18.1 mmol) in toluene (36 mL) is added by cannula addition to the flask containing FeCl3.  
The reaction is refluxed for 12 hours under an Ar atmosphere and cooled to room 
temperature before dilution with brine (50 mL) and partitioning with ethyl acetate (2.0 x 30 
mL).  The separated organic layers are combined, dried over Na2SO4 and concentrated in 
vacuo to give a brown oil.  1H NMR shows a cis : trans ratio of 1.2 to 1.0.  The desired cis-
isomer is purified from the trans-isomer by flash chromatography (silica gel, 50% ethyl 
acetate in hexanes) to yield the title compound as a yellow crystalline solid (2.13 g, 48% 
yield).  IR (film) 3338, 2958, 1700, 1395, 1101, 700 cm-1; 1H NMR (500 MHz, CDCl3) δ 
7.32–7.22 (m, 5H, aryl H), 4.07 (s, 1H, N, N-acetal H), 3.72-3.71 (br m, 1H, α-amide H), 
3.17 (dt, 1H, J = 3.8, 13.5 Hz, benzyl H), 2.95 (ddd, 1H, J = 2.5, 8.0, 13.5 Hz, benzyl H), 
2.30 (s, 3H, N-CH3), 1.76 (br s, 1H, NH), 0.85 (s, 3H, C(CH3)3); 13C NMR (125 MHz, 
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CDCl3) δ 175.46, 142.90, 138.06, 129.78, 128.76, 126.82, 82.65 (d, J15N-C = 3.02 Hz), 
59.58 (d, J15N-C = 3.64 Hz), 38.43 (d, J15N-C = 2.39 Hz), 35.19 (d, J15N-C = 1.76 Hz), 25.51 
(d, J15N-C = 1.13 Hz); 15N NMR (50 MHz, CDCl3) δ –337.08; 15N NMR (50 MHz, CDCl3-
1M AcOH) for the HClO4 salt of the title compound, δ –336.35; HRMS (FAB+) exact 
mass calculated for [M]+ (C15H22N15NO) requires m/z 247.1703, found m/z 247.1726; 
[α]D= –46.4 (c = 1.10, CHCl3).  
N
N
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(R)-2-tert-butyl-4-benzyl-1-methyl-1H-imidazol-5(4H)-one (5). A scintillation 
vial equipped a stir bar is charged with dichloromethane (5 mL), iodobenzene diacetate 
(403 mg, 1.25 mmol) and activated 3Å molecular sieves (500 mg).  After 10 minutes, ((2R, 
5R)-2-tert-butyl-5-benzyl-3-methylimidazolidin-4-one (61.6 mg, 0.25 mmol) is added to 
the vial and the reaction is stirred for 3 hours at room temperature.  The reaction is filtered 
through celite, concentrated in vacuo and purified by flash chromatography (Iatrobeads, 
50% ether in pentanes) to yield the title compound as a clear oil (51.9 mg, 85% yield).  It 
should be noted that the crude reaction (as observed by NMR) initially produces the acetate 
addition product of the imine, which upon workup and purification causes elimination of 
the acetate to yield the imine product. IR (film) 2961, 1706, 1636, 1495, 1425, 1395, 1366, 
1232, 701, 665 cm-1; 1H NMR (500MHz, CDCl3); 13C NMR (125 MHz, CDCl3) δ 169.12, 
165.44, 135.72, 130.99, 129.58, 128.72, 126.98, 91.85, 36.76, 31.26, 26.34;  HRMS (EI+) 
exact mass calculated for [M]+ (C15H20N2O) requires m/z 244.1576, found m/z 244.1586; 
[α]D= –76.3 (c = 1.22, CHCl3).   
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The title compound was additionally synthesized using 15N-labeled ((2R, 5R)-2-
tert-butyl-5-benzyl-3-methylimidazolidin-4-one using the above procedure to yield 8.  15N 
NMR (50 MHz, CDCl3-1M AcOD) δ –40.78. 
•HClN
N
H
OMe
Me
Me
Me Ph
HO
 
(5R)-2-tert-butyl-5-benzyl-2-hydroxy-3-methylimidazolidin-4-one HCl salt (9).  
A scintillation vial equipped with a stir bar is charged with dichloromethane (5 mL) and 
1M AcOH (1ML), iodosobenzene (161Mg, 0.5 mmol), and ((2R, 5R)-2-tert-butyl-5-
benzyl-3-methylimidazolidin-4-one (61.6 mg, 0.25 mmol).  The reaction is stirred for 2 
hours at room temperature before filtration and concentration in vacuo.  Purification was by 
flash chromatography (silica gel, 40% ethyl acetate in hexanes) and the isolated residue is 
dissolved in HCl (2M in ether, 125 mL) and dichloromethane (12.5 mL) and cooled to –70 
°C to facilitate precipitation.  The precipitate is filtered and washed with cold ether and 
dried under reduced pressure to yield the title compound as a white solid (18 mg, 24% 
yield).  IR (KBr) 2961, 1780, 1657, 1495, 1253, 706 cm-1; 1H NMR (300 MHz, CDCl3) δ 
7.35-7.23 (m, 5H, aryl H), 4.79 (dd, 1H, J = 3.0, 5.4 Hz, α-amide H), 4.00 (dd, 1H, J = 
5.4, 13.8 Hz, benzyl H), 3.35 (dd, 1H, J = 3.0, 13.5 Hz, benzyl H), 3.09 (s, 3H, N-CH3), 
1.29 (s, 3H, C(CH3)3); 13C NMR (125 MHz, CDCl3) δ 178.98, 175.16, 132.28, 130.27, 
129.19, 128.59, 128.17, 61.052, 35.91, 35.86, 29.10, 28.54, 26.62;  HRMS (FAB+) exact 
mass calculated for [M+H]+ (C15H21N2O2) requires m/z 261.1603, found m/z 261.1605; 
[α]D= +4.2 (c = 1.24, CHCl3).  
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The title compound was additionally synthesized using 15N-labeled ((2R, 5R)-2-
tert-butyl-5-benzyl-3-methylimidazolidin-4-one using the above procedure to yield the HCl 
salt.  Notably, this compound was hydrolyzed using 0.5M NH4OH to the corresponding 
free base prior to use in the 15N NMR studies.  15N NMR (50 MHz, CDCl3-1M AcOD) δ –
133.20. 
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15N-labeled ((2S, 5R)-2-tert-butyl-5-benzyl-3-methylimidazolidin-4-one (10).  
The title compound is prepared and isolated from the procedure for 15N-labeled (2R, 5R)-2-
tert-butyl-5-benzyl-3-methylimidazolidin-4-one as a yellow crystalline solid (1.57 g, 35% 
yield). IR (film) 3306, 2953, 1684, 1394, 1096, 700 cm-1; 1H NMR (300 MHz, CDCl3) δ 
7.33–7.22 (m, 5H, aryl H), 3.85–3.83 (br m, 1H, α-amide H), 3.81 (t, 1H, J = 1.5 Hz, N, N-
acetal H), 3.11 (dt, 1H, J = 3.6, 14.1 Hz, benzyl H), 2.89 (ddd, 1H, J = 2.7, 6.9, 14.1 Hz, 
benzyl H), 2.89 (s, 3H, N-CH3), 1.86 (br s, 1H, NH), 0.90 (s, 3H, C(CH3)3); 13C NMR (75 
MHz, CDCl3) δ 175.53, 137.68, 129.70, 128.74, 126.89, 83.62 (d, J15N-C = 3.02 Hz), 59.71 
(d, J15N-C = 4.08 Hz), 38.77, 37.93, 31.54, 25.57; 15N NMR (50 MHz, CDCl3) δ –337.68;   
HRMS (FAB+) exact mass calculated for [M+H]+ (C15H23N15NO) requires m/z 248.1781, 
found m/z 247.1790; [α]D= –60.0 (c = 1.13, CHCl3). 
O
O
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 (2R, 3S)-3-Cyclohexyloxirane-2-carbaldehyde (Table 7, entry 3).  Prepared 
according to general epoxidation procedure B using 3-cyclohexylacrylaldehyde38 (147 mg, 
1.06 mmol) to afford the title compound as a clear, colorless oil (124 mg, 77% yield, 92% 
ee) after flash chromatography (silica gel, 20% ether in pentanes with 1% Et3N).  IR (film) 
2928, 2853, 1730, 1450 cm-1; 1H NMR (300 MHz, CDCl3) δ 8.98 (d, 1H, J = 6.0 Hz, 
CHO), 3.17 (dd, 1H, J = 1.8, 6.3 Hz, CH oxirane), 3.02 (dd, 1H, J = 2.1, 6.6 Hz, CH 
oxirane), 1.85–1.66 (m, 5H), 1.41–1.30 (m, 1H), 1.26-1.05 (m, 5H); 13C NMR (75 MHz, 
CDCl3) δ 198.9, 61.05, 58.28, 39.51, 29.72, 28.91, 26.24, 25.68, 25.60; HRMS (EI+) exact 
mass calculated for [M-H]+ (C9H13O2) requires m/z 153.0916, found m/z 153.0910; [α]D= 
+75.6 (c = 1.02, CHCl3).  The enantiomeric purity was determined by GLC using a Varian 
Chirasil-Dex-CB column (80 °C isotherm, 15 psi, flow = 1.0 mL/min); (2S, 3R) isomer tr = 
42.07 min, (2R, 3S) isomer tr = 46.87 min. 
O
O
 
(2R, 3S)-3-(pent-4-enyl)oxirane-2-carbaldehyde (Table 7, entry 4). Prepared 
according to general epoxidation procedure B using 3-(E)-octa-2,7-dienal39 (270 mg, 2.18 
mol) to afford the title compound as a clear, colorless oil (292 mg, 95% yield, 92% ee) after 
flash chromatography (silica gel, 20% ether in pentanes).  IR (film) 1729, 1440, 1148, 
993.1, 914.4, 849.0 cm-1; 1H NMR (300 MHz, CDCl3) δ 8.99 (d, 1H, J = 6.3 Hz, CHO), 
5.82-5.69 (m, 1H, CH=CH2), 5.04-4.94 (m, 2H, CH=CH2), 3.11 (dd, 1H, J = 1.8, 6.3 Hz, 
CH oxirane), 3.23-3.19 (m, 1H, CH oxirane), 2.10 (q, 2H, J = 6.9 Hz, CH2), 1.71-1.52 (m, 
                                                
38. Martin, S. F.; Garrison, P. J. Tetrahedron Lett. 1977, 44, 3875. 
39. Singh, O. V.; Han, H. Org. Lett. 2004, 6, 3067. 
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4H, CH2-CH2); 13C NMR (75 MHz, CDCl3) δ 198.9, 61.05, 58.28, 39.51, 29.72, 28.91, 
26.24, 25.68, 25.60; HRMS (EI+) exact mass calculated for [M-H]+ (C8H11O2) requires m/z 
139.0760, found m/z 139.0759; [α]D= +48.8 (c = 1.10, CHCl3).  The enantiomeric purity 
was determined by GLC using a Chirasil-DEX CB column (80 °C isotherm, 15 psi, flow = 
1.0 mL/min); (2R, 3S) isomer tr = 21.75 min, (2S, 3R) isomer tr = 22.27 min. 
O
O
O
O  
((2R, 3S)-3-formyloxiran-2-yl)methyl benzoate (Table 7, entry 5).  Prepared 
according to general epoxidation procedure A using (E)-3-formylallyl benzoate40  (104 mg, 
0.55 mol) to afford the title compound as a clear, colorless oil (101Mg, 89% yield, 85% ee) 
after flash chromatography (silica gel, 20% ethyl acetate in hexanes).  IR (film) 3447, 1723, 
1273, 1111, 710 cm-1; 1H NMR (300 MHz, CDCl3) δ 9.10 (d, 1H, J = 6.3 Hz, CHO), 8.08–
8.04 (m, 2H, aryl H), 7.63–7.57 (m, 1H, aryl H), 7.49–7.44 (m, 2H, aryl H), 4.75 (dd, 1H, J 
= 3.0, 12.6 Hz, CH2), 4.34 (dd, 1H, J = 5.4, 12.6 Hz, CH2), 3.68 (m, 1H, CH oxirane), 3.44 
(dd, 1H, J = 2.1, 6.3 Hz, CH oxirane); 13C NMR (75 MHz, CDCl3) δ 197.01, 166.15, 
133.72, 129.97, 129.35, 128.73, 63.13, 56.73, 54.0; HRMS (EI+) exact mass calculated for 
[M]+ (C11H10O4) requires m/z 206.0579, found m/z 206.0581; [α]D= +16.0 (c = 1.12, 
CHCl3).  The enantiomeric purity was determined by SFC using a Chiralpak AD-H column 
(5% to 50% ethanol in hexanes, linear gradient, 100 bar, 35°C oven, flow = 4.0 mL/min); 
(2R, 3S) isomer tr = 4.19 min, (2S, 3R) isomer tr = 4.96 min. 
                                                
40. Guziec, F. S.; Luzzio, F. A. J. Org. Chem. 1982, 47, 1787. 
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tert-Butyl 4-(((2R, 3S)-3-formyloxiran-2-yl)methyl)piperdine-1-carboxylate 
(Table 7, entry 6).  A solution of tert-butyl 4-((E)-3-methoxycarbonyl)allyl)piperdine-1-
carboxylate41 (1.8 g, 6.68 mmol) in ether (60 mL) in a 100 mL round-bottom flask 
equipped with a magnetic stir bar was cooled to –78 °C.  DIBAL (1M in hexanes, 13.4 mL) 
was added dropwise to the flask and the reaction is stirred at constant temperature for 15 
minutes before warming to 0 °C.  After 3 hours, the reaction is quenched by the addition of 
a saturated solution of Rochelle’s salt (30 mL) and is stirred at room temperature until the 
biphasic solution no longer effervesces and both layers become clear.  The organic layer is 
extracted, dried, and concentrated in vacuo.  The resulting oil is purified by flash 
chromatography (silica gel, 20% ethyl acetate in hexanes) to yield tert-butyl 4-((E)-3-
hydroxybut-2-enyl))piperdine-1-carboxylate as a clear oil (1.1 g, 61% yield).  IR (film) 
3436, 2915, 1669, 1429, 1160 cm-1; 1H NMR (300 MHz, CDCl3) δ 5.65–5.62 (m, 2H, 
CH=CH), 4.08 (t, 2H, α-hydroxy CH2), 4.03 (br s, 1H, OH), 3.20 (br t, 2H, J = 12.0 Hz, 
piperdine CH2), 1.98 (t, 2H, J = 6.0 Hz, CH=CH-CH2), 1.65 (br s, 1H, piperdine CH2), 
1.60 (br s, 1H, piperdine CH2), 1.40 (s, 9H, C(CH3)3), 1.27 (m, 1H, piperdine CH2), 1.07 
(ddd, 2H, J = 4.2, 12.0, 24.6 Hz, piperdine CH2); 13C NMR (75 MHz, CDCl3) δ 155.10, 
130.99, 130.69, 79.45, 63.80, 39.42, 36.31, 32.09, 43.92, 39.42, 36.31, 32.09, 31.14, 28.67; 
HRMS (EI+) exact mass calculated for [M]+ (C14H25NO3) requires m/z 255.1834, found 
m/z 255.1837. 
                                                
41. Orlek, B.S. Syn. Lett. 1993, 10, 758. 
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In a scintillation vial equipped with a magnetic stir bar is a solution of tert-Butyl 4-
((E)-3-hydroxybut-2-enyl))piperdine-1-carboxylate (198 mg, 0.78 mmol), N-
methylmorpholine N-oxide (96 mg, 0.82 mmol) and activated 3Å molecular sieves (150 
mg) in dichloromethane (4 mL) at room temperature.  After 5 minutes, 
tetrapropylammonium perruthenate (14 mg, 0.04 mmol) is added in one portion.  The 
reaction is complete after 30 minutes and is filtered through a pad of celite, concentrated in 
vacuo, and purified by flash chromatography (silica gel, 20% acetone in pentanes) to yield 
tert-butyl 4-((E)-3-formylallyl)piperidine-1-carboxylate as a light yellow oil (160 mg, 80% 
yield).  IR (film) 2929, 1691, 1417, 1365, 1240, 1163, 976, 866, 769 cm-1; 1H NMR (300 
MHz, CDCl3) δ  9.48 (d, 1H, J = 8.1 Hz, CHO), 6.78 (dt, 1H, J = 7.2, 15.9 Hz,  CH=CH), 
6.01 (ddd, 1H, J = 1.2, 2.7, 9.0 Hz, CHO-CH=CH), 3.20 (br d, 2H, J = 11.1 Hz, piperidine 
CH2), 2.66 (br t, 2H, J = 12.0 Hz, piperidine CH2), 2.24 (t, 2H, J = 7.5 Hz, piperidine 
CH2), 1.67 ( br s, 1H, piperidine CH2), 1.64 (br s, 1H, piperdine CH2), 1.39 (s, 9H, 
C(CH3)3), 1.07 (ddd, 2H, J = 3.0, 13.8, 25.8 Hz, piperdine CH2); 13C NMR (75 MHz, 
CDCl3) δ 193.90, 156.20, 154.95, 134.64, 79.62, 43.92, 39.76, 35.73, 32.08, 28.62; HRMS 
(EI+) exact mass calculated for [M]+ (C14H23NO3) requires m/z 253.1678, found m/z 
253.1671.  
The title compound was prepared according to general epoxidation procedure B 
using tert-butyl 4-((E)-3-formylallyl)piperidine-1-carboxylate (156 mg, 0.62 mmol) to 
afford the title compound as a clear, yellow oil (134 mg, 86% yield, 87% ee) after flash  
chromatography (silica gel, 25% ethyl acetate in hexanes).  IR (film) 3436, 2915, 2361, 
1678, 1413, 1164, 852 cm-1; 1H NMR (300 MHz. CDCl3) δ 8.99 (d, 1H, J = 18.0 Hz, 
CHO), 4.08 (br d, 2H, J = 10.5 Hz, piperdine CH2), 3.26–3.21 (m, 1H, CH oxirane), 3.09 
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(dd, 1H, J = 1.8, 6.3 Hz, CH oxirane), 3.72–3.63 (m, 2H, piperdine CH2), 1.72-1.61 (m, 
3H, piperdine CH2), 1.42 (s, 9H, C(CH3)3), 1.21–1.15 (m, 2H, piperdine CH2); 13C NMR 
(75 MHz, CDCl3) δ 198.36, 151.03, 79.63, 59.29, 55.27, 43.92, 38.31, 34.44, 32.38, 32.03, 
28.64; HRMS (EI+) exact mass calculated for [M]+ (C14H23NO4) requires m/z 269.1627, 
found m/z 269.1628; [α]D= +30.9 (c = 0.95, CHCl3).  The enantiomeric purity was 
determined by SFC analysis using a Chiralpak AD-H column (5% to 50% ethanol in 
hexanes, linear gradient, 100 bar, 35°C oven, flow = 4.0 mL/min); (2R, 3S) isomer tr = 6.97 
min, (2S, 3R) isomer tr = 7.74 min. 
O
O
OMe
O  
Methyl 3-((2S,3R)-3-formyloxiran-2-yl)propanoate (Table 7, entry 7).  Prepared 
according to general epoxidation procedure B using (E)-methyl 6-oxohex-4-enoate42 (142 
mg, 1.0 mmol) using 1M AcOH (1.33 mL) and dichloromethane (5.34 mL).  Flash 
chromatography (silica gel, 60% ether in hexanes with 10% dichloromethane) afforded the 
title compound as a light yellow oil (137 mg, 86% yield, 90% ee).  IR (film) 1731, 1438, 
1175 cm-1; 1H NMR (300 MHz, CDCl3) δ 9.03 (d, 1H, J = 6.3 Hz, CHO), 3.72 (s, 3H, 
OCH3), 3.38–3.34 (m, 1H, CH oxirane), 3.19 (dd, 1H, J = 2.1, 6.0 Hz, CH oxirane), 2.52 
(t, 2H, J = 6.9 Hz, α-CH2), 2.15–1.88 (m, 2H, β-CH2); 13C NMR (75 MHz, CDCl3) δ 
198.1, 151.1, 59.29, 55.81, 52.16, 30.11, 26.66; HRMS (EI+) exact mass calculated for 
[M]+ (C7H9O4) requires m/z 158.0501, found m/z 157.0502; [α]D= +27.3 (c = 1.25, CHCl3).  
                                                
42. (a) Dygos, J. H.; Adamek, J. P.; Babiak, K. A.; Behling, J. R.; Medich, J. R.; Ng, J. S.; Wieczork, J. J. J. Org. 
Chem. 1991, 56, 2549. (b) Kukovinets, O. S.; Kasradze, V. G.; Chernukha, E. V.; Odinokov, V. N.; Dolidze, A. 
V.; Galin, F. Z.; Spirikhin, L. B.; Abdullin, M. I.; Tolstikov, G. A. Zh. Org. Khim. 1999, 35, 1156. (c) Ku, T. W.; 
McCarthy, M. E.; Weichman, B. M.; Gleason, J. G. J. Med. Chem. 1985, 28, 1847. 
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The enantiomeric purity was determined by GLC analysis using a Chirasil-DEX CB 
column (90 °C isotherm, 15 psi, flow = 1.0 mL/min); (2R, 3S) isomer tr = 60.6 min, (2S, 
3R) isomer tr = 62.2 min. 
O
O
NO2  
(2S, 3R)-3-(4-Nitrophenyl)oxirane-2-carbaldehyde (Table 7, entry 9).  Prepared 
according to general epoxidation procedure B using 4-nitrocinnamaldehyde (138 mg, 0.75 
mmol) using 1M AcOH (0.75 mL) and chloroform (3.0 mL).  Flash chromatography (silica 
gel, 40% ether in hexanes with 2% NEt3) afforded the title compound as a light yellow 
solid (154 mg, 89% yield, 97% ee).  IR (film) 1727, 1605, 1520, 1349 cm-1; 1H NMR (300 
MHz, CDCl3) δ 9.19 (d, 1H, J = 6.0 Hz, CHO), 8.21 (dd, 2H, J = 2.4, 9.1 Hz, aryl H), 7.46 
(dd, 2H, J = 2.4, 9.1 Hz, aryl H), 4.26 (d, 1H, J = 1.8 Hz, CH oxirane), 3.41 (dd, 1H, J = 
1.8, 5.7 Hz, CH oxirane); 13C NMR (75 MHz, CDCl3) δ 195.4, 141.2, 126.3, 123.8, 62.5, 
55.3; HRMS (EI+) exact mass calculated for [M]+ (C9H7NO4) requires m/z 193.0375, 
found m/z 193.0374; [α]D= –13.0 (c = 1.18, CHCl3).  The enantiomeric purity was 
determined by GLC analysis using a Chirasil-DEX CB column (120 °C ramp 5 °C/min to 
145 °C, 15 psi, flow = 1.0 mL/min); (2R, 3S) isomer tr = 74.8 min, (2S, 3R) isomer tr = 75.9 
min. 
O
O
Br  
(2S, 3R)-3-(4-Bromophenyl)oxirane-2-carbaldehyde (Table 7, entry 10).  
Prepared according to general epoxidation procedure B using 4-bromocinnamaldehyde 
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(158 mg, 0.75 mmol) using 1M AcOH (0.75 mL) and chloroform (3.0 mL).  Flash 
chromatography (silica gel, 30% ether in pentane with 2% NEt3) afforded the title 
compound as a clear oil (158 mg, 93% yield, 93% ee).  IR (film) 1727, 1490, 1070, 1011, 
824.6 cm-1; 1H NMR (300 MHz, CDCl3) δ 9.16 (d, 1H, J = 6.0 Hz, CHO), 7.48 (d, 2 H, J 
= 9.0 Hz, aryl H), 7.14 (d, 2H, J = 9.0 Hz, aryl H), 4.11 (d, 1H, J = 1.8 Hz, CH oxirane), 
3.37 (dd, 1H, J = 1.7, 6.2 Hz, CH oxirane); 13C NMR (75 MHz, CDCl3) δ 196.6, 132.2, 
127.5, 62.92, 56.28; HRMS (EI+) exact mass calculated for [M]+ (C9H7O2Br) requires m/z 
225.9629, found m/z 225.9626; [α]D= –10.5 (c = 0.945, CHCl3).  The enantiomeric purity 
was determined by HPLC analysis of the alcohol using a Chiralpak AD column (5% 
ethanol in hexanes, flow = 1.0 mL/min); (2R, 3S) isomer tr = 33.7 min, (2S, 3R) isomer tr = 
36.9 min. 
N
O
H
OMe
O
S
O
O
NO2
 
(2S,3S)-methyl 3-formyl-1-(4-nitrophenylsulfonyl)aziridine-2-carboxylate (11).  
Prepared according to general epoxidation procedure B using (E)-methyl 4-oxobut-2-
enoate (170 mg, 1.5 mmol) in dichloromethane (3.0 mL, in the absence of 1M AcOH) and 
using p-TSA as the acid co-catalyst.  After 24 hours, the reaction was quenched with pH 7 
buffer (5.0 mL), filtered through celite, and washed with chloroform (3 x 5.0 mL).  The 
reaction conversion and ratio of epoxide to aziridine was determined by 1H NMR of this 
crude reaction mixture to be 1:4 (63% conversion to the aziridine product, 90% ee).  
Purification was achieved in three steps: (1) column chromatography (silica gel, 65% ether 
in pentane), then (2) NaBH4 reduction of the collected impure fractions containing product, 
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and (3) prep TLC (20% ethyl acetate in hexanes) to afford the alcohol of the title 
compound as a yellow oil.  1H NMR (300 MHz, CDCl3) δ 8.41–8.39 (m, 2H, aryl H), 
8.20–8.17 (m, 2 H, aryl H), 4.28 (dd, 1H, J = 3.0, 13.5 Hz, HOCH2), 4.12 (dd, 1H, J = 7.5, 
13.5 Hz, HOCH2), 3.75 (s, 3H, CO2CH3), 3.66 (d, 1H, J = 7.3 Hz, CH aziridine), 3.47 (m, 
1H, CH aziridine); 13C NMR (75 MHz, CDCl3) δ 166.5, 145.1, 129.0, 124.7, 59.98, 53.38, 
50.65, 41.87; HRMS (FAB+) exact mass calculated for [M+H]+ (C11H13N2O7S) requires 
m/z 317.0443, found m/z 317.0437.  The enantiomeric purity was determined by HPLC 
analysis of the benzoyl functionalized alcohol using a Chiralcel OD-H column (10% 
ethanol in hexanes, flow = 1.0 mL/min); (2R, 3R) isomer tr = 30.1 min, (2S, 3S) isomer tr = 
35.3 min. 
C h a p t e r  3  
Organocata lyt ic Addit ion of Organoboron Reagents 
 
I. Introduction 
The Petasis multicomponent reaction provides a powerful and convenient method 
for the one-pot synthesis of unnatural amino acid derivatives from the union of three 
simple componentsan amine, an aldehyde and an organoboronic acid (eq. 1).1  Over the 
last decade the Petasis reaction has met considerable success as a powerful synthetic tool, 
particularly in regard to the construction of combinatorial libraries.2  However, 
O
N
R3
R1 R2
H
OH
OH
R1
N
H
R2
allylic or benzylic amines
(1)B(OH)2R
3
R1 = R2 = alkyl; R3 = alkenyl, aryl, heteroaryl
!
 
despite the wide appeal of the Petasis reaction as a mild method for the preparation of 
allylic or benzylic amines, there has been limited research devoted to the development of 
stereoselective variants.  Thus far, diastereoselective methodologies have employed 
either homochiral aldehydes or amines as reaction components, such that the source of 
                                                
1. (a) Petasis, N. A.; Akritopoulou I. Tetrahedron Lett. 1993, 34, 583. (b) Petasis, N. A.; Zavialov, I. A. J. Am. Chem. 
Soc. 1997, 119, 445. (c) Petasis, N. A.; Zavialov, I. A. J. Am. Chem. Soc.  1998, 120, 11798. 
2. (a) Gravel, M.; Thompson, K. A.; Zak, M.; Berube, C.; Hall, D. G. J. Org. Chem. 2002, 67, 3. (b) Pulici, M.; Cervi, 
G.; Martina, K.; Quartieri, F. Comb. Chem. High Throughput Screen 2003, 6, 693.  
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chiral induction is incorporated in the final product.3  Unfortunately, the alternative 
approach of employing chiral boronic esters has met relative nonsuccess.4  As of yet, 
there has been no enantioselective or catalytic variants of this important multicomponent 
coupling reaction.5 
Aside from the Petasis boronic acid-Mannich reaction, carbon–carbon bond 
forming reactions using organoboron reagents still remain predominantly transition metal-
mediated processes.6  Though it is evident from the Petasis reaction that boronic acids are 
indeed capable nucleophiles, there has been minimal progress in the development of 
reactions to advance this observed mode of reactivity.7  In part, this is due to the fact that 
the mechanism of the Petasis reaction remains relatively ambiguous.  It is hypothesized that 
the nucleophilicity of the boronic acid is manifested upon complexation to an α-hydroxy 
(2)
R1
N
R2
H
O
B
HO OH
R3
O
H
OH
R1
N
H
R2
B(OH)2R
3
                                                
3. (a) Petasis, N. A.; Zavialov, I. A. J. Am. Chem. Soc. 1998, 120, 11798. (b) Harwood, L. M.; Currie, G. S.; Drew, 
M. G. B.; Luke, R. W. A. Chem. Commun. 1996, 1953.  
4. (a) Koolmeister, T.; Sodergren, M.; Scobie, M. Tetrahedron Lett. 2002, 43, 5969. (b) Southwood, T. J.; Curry, M. 
C.; Hutton, C. A. Tetrahedron 2006, 62, 236. 
5. This excludes results from our laboratories in which an enantioselective, organocatalytic Petasis reaction has 
been discovered: Ni, Y.; Warkentin, A. unpublished results.  
6. (a) Miyaura, N.; Yanagi, T.; Suzuki, A. Synth. Commun. 1981, 11, 513. (b) Suzuki, A. Acc. Chem. Res. 1982, 15, 178. 
(c) Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457. (d) Suzuki, A. J. Organomet. Chem. 1999, 576, 147. (e) 
Kotha, S.; Lahiri, K.; Kashinath, D. Tetrahedron 2002, 58, 9633. (f) Suzuki, A. Proc. Jpn. Acad., Ser. B 2004, 80, 
359.  (h) Bellina, F.; Carpita, A.; Rossi, R. Synthesis 2004, 2419. (g) For a review of rhodium-catalyzed 1,4-
additions, see: Hayashi, T.; Yamasaki, K. Chem. Rev. 2003, 103, 2829 and Hayashi, T. Synlett 2001, SI, 879. 
7. (a) Tremblay-Morin, J. P.; Raeppel, S.; Gaudette, F. Tetrahedron Lett. 2004, 45, 3471. (b) For a recently developed 
methodology utilizing metal-free boronic ester addition reactions, see: Wu, T. R.; Chong, J. M. J. Am. Chem. Soc. 
2005, 127, 3244 and Wu, T. R.; Chong, J. M. J. Am. Chem. Soc. 2007, ASAP. 
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donor group to form an electron-rich ate-complex (eq. 2), which then reacts with the 
iminium ion by an intramolecular addition.8  This hypothesis is substantiated by the fact 
that aldehydes containing only α- or ortho-activating groups participate in this reaction.   
On the basis of this mechanism, we postulated that the advancement of this concept 
towards an iminium-activated π-system would enable the development of a vinylogous 
addition (eq. 3), wherein the amine component of the reaction would gain the capacity to 
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!+ !–
R1
N
R2
H
O
B
HO OH
Ar
(3)
B
HO OH
Ar
function as a catalyst.  This modification of the standard Petasis reaction offers the potential 
for a chiral amine to catalyze an enantioselective addition of organoboron reagents. 
 
II. An Organocatalytic Strategy for the Addition of Boronic Acids 
Inspired by the Petasis reaction, we initiated studies to develop an organocatalytic 
methodology for the asymmetric conjugate addition of boronic acids to α,β-unsaturated 
aldehydes based upon the activation principle of iminium catalysis (vide Chapter 1).  
Having established chiral secondary amines as enantioselective LUMO-lowering catalysts,9 
we sought to develop the first asymmetric, organocatalytic 1,4-addition of activated 
                                                
8. (a) Petasis, N. A.; Zavialov, I. A. Tetrahedron Lett. 1996, 37, 567. (b) Wang, Q.; Finn, M. G. Org. Lett. 2000, 2, 
4063. (c) Schlienger, N.; Bryce, M. R.; Hansen, T. K. Tetrahedron 2000, 56, 10023. 
9. Lelais, G.; MacMillan, D. W. C. Aldrichimica Acta, 2006, 39, 79. 
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organoboronate nucleophiles to α,β-unsaturated aldehydes for the incorporation of simple 
olefins and heteroaromatics in a broad platform of β-functionalization. 
In our initial design plan, we focused on replicating the in situ formation of a tetra-
coordinate boronate complex (from the Petasis reaction, eq. 3) by employing an aldehyde 
appropriately functionalized with an α-heteroatom adjacent to the reaction site (2, Figure 
1).  We envisioned the condensation of aldehyde 2 with imidazolidinone catalyst 1 would 
generate iminium adduct 3, wherein the pendent ether tether would engage the boronic acid  
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Figure 1. Proposed catalytic cycle and formation of  
                  an activated iminum-boronate complex (5) 
(4) to form an activated boronate species (5).  Subsequently, the activated iminium-
boronate complex (5) initiates an intramolecular vinyl transfer into the iminium π-system 
giving rise to a newly formed β-carbon stereocenter.  Enantioinduction in this key bond-
forming event results from a Re-face addition to complex 5 due to the stereochemical 
environment created by catalyst architecture, which shields the Si-face from nucleophilic 
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attack.  Hydrolysis of the resultant adduct would release the enantioenriched product and 
concomitantly regenerate the secondary amine catalyst 1, thereby completing the catalytic 
cycle. 
To our great delight, when we prepared a benzyl ether functionalized aldehyde 
substrate (6) to react with boronic acid 4, we obtained the desired adduct 7 (50% 
conversion, 63% ee, eq. 4) in the presence of imidazolidinone catalyst 1.  Importantly, this 
CH2Cl2, 25 °C, 36 hr
50% conversion, 63% ee
TfOH•catalyst 1 (20 mol%)(HO)2B
O
O Ph
O
O Ph
(4)
6 4 7
initial result validated our hypothesis—activated boronic acids can indeed function as 
competent nucleophiles.  We sought to further substantiate our hypothesis by defining the 
key features of this reaction.  First, we verified that there was no detectable background 
reaction in the absence of the secondary amine catalyst 1 (after 48 hours of reaction time at 
ambient temperature).  Along with the fact that proline-derived catalysts were non-
functional in this reaction,10 we concluded that iminium-activation was indeed a 
prerequisite for reactivity.  Secondly, it was determined that this reaction was exclusive to 
aldehyde substrates functionalized with a pendant heteroatom to engage the boronic acid in 
a complexation event (and thus form the active ate-complex 5) in order to activate the 
system towards addition.  This was made apparent when enal substrates lacking oxy-
functionalization, such as crotonaldehyde and cinnamaldehyde, were found to be 
completely unreactive to 4 under identical reaction conditions.  Thus, we presumed 
formation of the doubly activated iminium-boronate complex (5) was requisite for product  
                                                
10. Proline is typically a poor catalyst for iminium-activated processes, see: Kunz, R. K.; MacMillan, D. W. C. J. 
Am. Chem. Soc. 2005, 127, 3240. 
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formation. 
Having defined the requirements for reactivity, namely the iminium-activation of 
the aldehyde substrate and the activation of the boronic acid the boronate, we considered 
the extension of these concepts towards an intermolecular reaction.  Circumvention of the 
required intramolecular activation of the boronic acid (via the formation of 5) would open 
the possibility for an activated iminium species to react directly with a boronate (eq. 5). 
R1
N
R2
H
R3
X
(5)
B
X X
Ar
R1
N
R2
H
RO
!+ !–B
HO OH
Ar
More importantly, an intermolecular reaction offers potential for greater variation in the 
enal substrate by eliminating the structural requirement of an ether tether.  Thus, 
replacement of the boronic acid by a boronate would expand this methodology to include 
simple α,β-unsaturated aldehydes.  To this end, we sought to investigate boronate species 
that could participate in this organocatalytic conjugate addition reaction. 
 
III. Organotrifluoroborate Salts 
In recent years, there have been great advancements in the application of 
organotrifluoroborate salts to new methodologies.11  This stems from the highly desirable 
                                                
11. For excellent reviews on potassium organotrifluoroborates, see: (a) Molander, G. A.; Figueroa, R. Aldrichimica 
Acta. 2005, 38, 49. (b) Darses, S.; Genêt, J.-P. Eur. J. Org. Chem. 2003, 22, 4313. (c) Stefani, H. A.; Cella, R.; 
Vieira, A. S. Tetrahedron 2007, 63, 3623. 
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features that are characteristic of these organoboron reagents, e.g., (1) greater 
nucleophilicity than their boronic acid or ester counterparts;12 (2) high functional group 
compatibility; (3) commercial availability and straightforward preparation; (4) low toxicity; 
and (5) impressive stability to air and moisture.  
In 1995, Vedejs and co-workers first described a convenient procedure for the 
preparation of potassium trifluoroborate salts from the corresponding boronic acid (eq. 6).13 
solvent, rt
KHF2 (3 eq), H2O
R(HO)2B (6)RKF3B
This discovery vastly simplified the previously known multi-step method for the 
preparation of these compounds and subsequently made a significant impact in the 
development of chemistries associated with these compounds.14,15   
Recently, trifluoroborate salts have found major application as a surrogate to 
boronic acids in transmetallation reactions in transition metal-mediated methodologies.  In 
this regard, organotrifluoroborate salts are widely employed as coupling partners in Suzuki 
cross-coupling reactions and are generally more reactive than the corresponding boronic 
acids (eq. 7).  Impressively, examples of aryl-, alkynyl-, alkenyl-, and alkyltrifluoroborates 
as successful coupling partners to a variety of aryl and vinyl bromides using palladium(II) 
                                                
12. Unlike trivalent boron substituents, trifluoroborate is an electron-donating substituent, see: Frohn, H.-J.; 
Franke, H.; Fritzen, P.; Bardin, V. V. J. Organomet. Chem. 2000, 598, 127.   
13. Vedejs, E.; Chapman, R. W.; Fields, S. C.; Lin, S.; Schrimpf, M. R. J. Org. Chem. 1995, 60, 3020.  
14. Initially, organotrifluoroborate salts were prepared from the reaction of organodihaloboranes with aqueous 
KF.  These highly unstable dihalo(organo)boranes were generally generated in situ from organostanane 
precursors. 
15. Organotrifluoroborate salts are commercially available or readily synthesized from the corresponding boronic 
acids or esters, see: (a) Molander, G. A.; Bernardi, C. R. J. Org. Chem. 2005, 70, 3950.  (b) Molander, G. A.; 
Fumagalli, T. J. Org. Chem. 2006, 71, 5743.  (c) Vedejs, E.; Chapman, R. W.; Fields, S. C.; Lin, S.; Schrimpf, M. 
R. J. Org. Chem. 1995, 60, 3020.  (d) Vedejs, E.; Fields, S. C.; Hayashi, R.; Hitchcock, S. R.; Powell, D. R.; 
Schrimpf, M. R. J. Am. Chem. Soc. 1999, 121, 2460. 
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catalysts have been demonstrated.16  Another major application of trifluoroborate salts has 
been in rhodium(I)-catalyzed conjugate addition reactions to electron-deficient olefins (eq. 
8).17  As these reactions are amenable to modification by asymmetric ligand systems, 
PR3 (6 mol%), K2CO3 
  MeOH or H2O, !
KF3B (7)
(R)- or (S)-binap  
toluene-H2O, 110 °C
Rh(cod)2PF6 (3 mol%)
(8)
O
R
Br
R
Pd(OAc)2 (2 mol%)
KF3B
R
O
R
*
enantioselective 1,4-additions have been achieved with enones and α,β-unsaturated amides 
for the efficient construction of β-chiral stereocenters.  
Trifluoro(organo)borates are also utilized as mild nucleophiles in Lewis acid-
mediated methodologies.  For example the allylation of aldehydes has been achieved with 
potassium allyl- and crotyltrifluoroborates in the presence of a various Lewis acids to 
afford valuable homoallylic alcohol products (eq. 9).18  Likewise, homoallylic amines were 
prepared in the allylation of aliphatic, aromatic and heterocyclic N-tosylamines (eq. 10).19  
Additionally, potassium trifluoro(organoborate) salts have been employed as successful 
nucleophiles in an extension of the Petasis boronic-Mannich reaction to yield the desired 
                                                
16. (a) For the first Suzuki-Miyaura reaction involving organotrifluoroborate salts, see: Darses, S.; Genêt, J.-P.; 
Brayer, J.-L.; Demoute, J.-P Tetrahedron Lett. 1997, 38, 4393. (b) For subsequent applications, see: Molander, G. 
A.; Ellis, N. Acc. Chem. Res. 2007, ASAP. 
17. (a) Pucheault, M.; Darses, S.; Genêt, J.-P. Tetrahedron 2002, 43, 6155. (b) Pucheault, M.; Darses, S.; Genêt, J.-P. 
Eur. J. Org. Chem. 2002, 3552. (c) For a review of 1,4- and 1,2-additions by BF3K salts, see ref. 11c. (d) For a 
review of rhodium-catalyzed conjugate additions, see: Hayashi, T.; Yamasaki, K. Chem. Rev. 2003, 103, 2829.  
18. (a) Batey, R. A.; Thadani, A. N.; Smil, D. V.; Lough, A. J. Synthesis, 2000, 990. (b) Batey, R. A.; Thadani, A. N.; 
Smil, D. V. Tetrahedron Lett. 1999, 40, 4289.   
19. (a) Solin, N.; Wallner, O. A.; Szabó, J. K. Org. Lett. 2005, 7, 689. (b) Wallner, O. A.; Szabó, J. K. Chem. Eur. J. 
2006, 12, 6976. 
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toluene, 90 °C
58–91% yield
BF3•Et2O
R2KF3B (11)
R1
O
H
R2N
R1
NH
Ph Ph
CH2Cl2, –78 °C
74–96% yield, dr > 96:4
BF3•Et2O
R3
R2KF3B
OH
R1
O
(9)
CH2Cl2, –78 °C
64–99% yield
 dr = <2:98 to >98:2
BF3•Et2O
(10)
R1
R3R2
H
R1
NTs
H
R3
R2KF3B
NTs
R1
R3R2
coupled products (eq. 11).20  
In short, potassium trifluoro(organo)borate salts have recently emerged as highly 
stable and reactive alternatives to organoboronic acids and esters.  As such, they have 
found considerable application as effective organometallic reagents in numerous carbon–
carbon bond forming methodologies. 
 
IV. The Imidazolidinone-Catalyzed Addition of Organotrifluoroboronate Salts 
Having demonstrated that organoboronates (generated in situ) were competent 
nucleophiles in an organocatalytic conjugate addition reaction (eq. 4), we recognized that 
an ate-complex could directly participate in an intermolecular reaction (eq. 5).  In this 
context, we sought to employ potassium trifluoro(organo)borate salts, which preexist in the 
desired oxidation state.  By employing a preformed ate-complex, such as potassium 
                                                
20. (a) Schlienger, N.; Ryce, M. R.; Hansen, T. K. Tetrahedron Lett. 2000, 41, 1303. (b) Billard, T; Langlois, B. R. J. 
Org. Chem. 2002, 67, 997. (c) Trembley-Morin, J.-P.; Raeppel, S.; Gaudette, F. Tetrahedron Lett. 2004, 45, 3471. 
(d) Kabalka, G. W.; Venkataiah, B.; Dong, G. Tetrahedron Lett. 2004, 45, 729. 
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CH2Cl2, 4 °C, 24 hr
83% conversion, 6% ee
KF3B
O
O Ph
O
O Ph
(12)
6 8 7
TfOH•catalyst 1 (20 mol%)
styryltrifluoroborate (8) in a reaction with aldehyde 6 at 4 °C, we witnessed exceptional 
reactivity, albeit with low enantioselectivity (83% conversion, 6% ee, eq. 12).  
Nevertheless, we were encouraged by the increased levels of reactivity observed when the 
trifluoroborate salt was used in place of the boronic acid (eq. 4).  
To test the premise that the boronate salt reacts via an intermolecular process, we 
next attempted the 1,4-addition reaction with an unfunctionalized aldehyde substrate (such 
as crotonaldehyde) that could not proceed via an intramolecular pathway.  To our delight, 
exposure of crotonaldehyde to 8 resulted in the formation of the desired adduct (9) in 
moderate yield and enantioselectivity (32% conversion, 46% ee, eq. 13).21  Notably, the 
CH2Cl2, 25 °C, 24 hr
32% conversion, 46% ee
KF3B
O
Me
MeO (13)
8 9
TfOH•catalyst 1 (20 mol%)
 
analogous reaction with styrylboronic acid and crotonaldehyde was found to be completely 
unreactive.  These results implicated that a greater potential scope for this methodology 
was possible with the use of potassium trifluoroborate salts—by elimination of the 
structural requirement of an ether tether in the enal substrate, simple α,β-unsaturated 
aldehydes (like crotonaldehyde) are viable substrates.  
                                                
21. There was also no background reaction in the absence of the imidazolidinone catalyst 1.  Additionally, the 
reaction performed with catalytic BF3⋅OEt2 (in place of TfOH⋅catalyst 1) did not yield the desired product (9).  
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Efforts were next focused on obtaining higher levels of reaction efficiency.  As low 
levels of enantioselectivity were observed in our initial experiments, we sought to directly 
impact the enantiodiscriminating step of this reaction by modification of catalyst structure.  
Being that a number of catalyst architectures have been established within our group, a 
survey of these catalysts was carried out in Table 1.  An apparent trend was observed  
Table 1. Survey of Imidazolidinone Catalysts for the Organocatalytic Conjugate Addition 
N
N
H
O MeH
N
•HClO4
Me
Me
Me
N
N
H
O Me
N
N
H
O Me
•TfOH
Me
Me
Me
a Conversion determined by 1H NMR relative to methyl benzyl ether. b Enantiomeric 
excess determined by chiral SFC analysis (Chiracel OD-H) on the corresponding
purified alcohol product.
entry
1
2
3
4
5
6
% conversiona
22
5.3
53
32
38
42
% eeb
13
27
38
46
54
56
catalyst
O Me
20 mol% catalyst 
styryl BF3K salt (8)
CH2Cl2 (0.25 M) 
15 hr, 25 °C(3 eq) 9
O
Me
N
N
H
O Me
N
•HClO4
Me
Me
Me
•HClO4
N
N
H
O Me
Me
Me
•TfOH
10
11
N
N
H
O Me
•TfOH
Me
Me
Me
1
 
between the enantioselectivity of the reaction (13–56% ee, entries 1–6) and the relative 
steric bulk of the catalyst substituents.  Specifically, tryptophan-derived catalysts (54–56% 
ee, entries 5 and 6) were more selective than the phenylalanine-based catalysts (27–46% 
ee, entries 2–4).  This trend can be rationalized on comparison of the MM3 force-field 
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calculations of the catalyst-substrate iminium complexes (MM3-12 and MM3-13) for 
catalyst 1 and 10 (Figure 2).  The increased enantiofacial discrimination achieved using 
catalyst 10 results from the introduction of the indole shielding group in MM3-1322.  Since 
indoles are known to have a more negative electrostatic potential surface (32.6 kcal/mol) 
N
N
O Me
Me
Me
Me
R
Me
MM3-13
Re-face
further 
energetically
favored
Re-face
open
R = 2-indolyl
MM3-12
R = benzyl
Si-face
further
blocked
Si-face
blocked
catalyst-substrate
iminium complex  
Figure 2. MM3 structures of iminium complexes of crotonaldehyde and catalysts 1 and 10 
than that of benzene (27.1 kcal/mol), the tryptophan-derived catalyst 10 has a more 
favorable electrostatic interaction with the iminium π-system relative to catalyst 1.23  This 
increased cation-π stabilization in iminium complex MM3-13 provides a greater 
population of the blocked π-face confirmation and thus leads to more selective reaction.  
As catalyst 11 demonstrated the highest levels of enantioselectivity (56% ee, entry 6), it 
was chosen as the optimal catalyst for this transformation and was used in all subsequent 
studies. 
Further optimization of the catalyst system was accomplished by studying the 
impact of the Brønsted acid co-catalyst.  As shown in Table 2, it was immediately apparent 
                                                
22. Austin, J. F.; Kim, S. G.; Sinz, C. J.; Xiao, W. J.; MacMillan, D. W. C. Proc. Nat. Acad. Sci. USA, 2004, 101, 
5482. 
23. (a) Ma, J. C.; Dougherty, D. A. Chem. Rev. 1997, 97, 1303. (b) Gallivan, J. P.; Dougherty, D. A. Proc. Natl. Acad. 
Sci. U. S. A. 1999, 96, 9459 (c) For relevant calculations on iminium intermediate MM3-12, see:  Allemann, C.; 
Gordillo, R.; Clemente, F. R.; Cheong, P. H.-Y.; Houk, K. N. Acc. Chem. Res. 2004, 37, 558. 
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that co-catalysts with lower pKa values (pKa < –2, entries 1–4) were required for this 
transformation.  More specifically, stronger acids provided the desired product 9 with 
higher conversions (27–40% conversion, entries 1–4) while weaker acids yielded poorer 
results (1–3% conversion, entries 5–7).  This was rationalized on the following basis: (1) 
that stronger acid co-catalysts enable a higher equilibrium content of the catalyst-substrate 
iminium adduct and (2) the more electronegative character of the conjugate base of the co-
catalyst results in a more reactive iminium-ion intermediate.24  Thus, the combination of 
these two factors resulted in more productive reactions when stronger acids, such as triflic 
acid (TfOH) and hydrochloric acid (HCl) were employed.  Since the reaction performed 
with HCl exhibited a slight improvement in the conversion (40% conversion, entry 3), 
Table 2. Impact of the Acid Co-Catalyst on the Organocatalytic Conjugate Addition 
entry
O Me
20 mol% catalyst 11•HX
styryl BF3K salt (8)
CH2Cl2 (0.25 M) 
20 hr, 25 °C(3 eq)
1
2
3
4
5
6
7
% conversionb
38
33
40
27
3
1
3
% eec
54
54
51
50
--
--
--
HX
9
a Smith, M. B.; March, J. Advanced Organic Chemistry, 5th ed.; Wiley & Sons: New 
York, 2001. b Conversion determined by GC relative to tridecane. c Enantiomeric
excess determined by chiral SFC analysis (Chiracel OD-H) on the corresponding
purified alcohol product.
O
Me
TfOH
HClO4
HCl
p-TSA
TFA
DCA
2,4-DNBA
pKa
a
–14
–10
–8.0
–2.0
–0.3
1.3
3.4
 
                                                
24. 1H NMR studies using more electronegative counterions result in a downfield chemical shift in the iminium 
proton, which could be suggestive of a more activated system, see: Mayr, H.; Ofial, A. R.; Würthwein, E.-U.; 
Aust, N. C. J. Am. Chem. Soc. 1997, 119, 12727.  
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further optimization studies were conducted with this acid co-catalyst. 
A variety of solvents were next evaluated for the organocatalytic conjugate addition 
reaction.  As evident from Table 3, there was no empirical correlation between the 
dielectric constant of the reaction media and the extent of product formation.  However, it 
was apparent that dichloromethane provided higher conversions albeit with moderate 
enantiodiscrimination (40% conversion, 51% ee, entry 4).  Contrastingly, the reaction 
conducted in 1,2-dimethoxyethane (DME) demonstrated substantially higher levels of 
induction but with low levels of product formation (17% conversion, 83% ee, entry 6).  
Though the reaction was moderately functional in most examined solvents, we focused on 
DME as the optimal solvent, having provided higher levels of enantioinduction. 
To address concerns pertaining to reaction efficiency, NMR studies were  
Table 3. Solvent Effect on the Imidazolidinone-Catalyzed Addition of Organotrifluoroborate Salts 
entry
O Me
20 mol% catalyst 11•HCl
styryl BF3K salt (8)
solvent (0.25 M) 
15 hr, 25 °C(3 eq)
1
2
3
4
5
6
7
8
9
% conversionb
4.0
11
16
40
14
17
21
3.2
13
% eec
--
65
72
51
72
83
74
--
63
solvent
9
a CRC Handbook of Chemistry and Physics, 81st ed.; Lide, D. R., Ed.; CRC Press: Boca 
Raton, 2000. b Conversion determined by GC relative to tridecane. c Enantiomeric
excess determined by chiral SFC analysis (Chiracel OD-H) on the corresponding
purified alcohol product.
O
Me
DMF
MeCN
acetone
CH2Cl2
THF
DME
EtOAc
ether
toluene
!a
38
37
21
9.1
7.5
7.1
6.0
4.3
2.4
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undertaken to identify potential issues impeding reaction progression.  We chose to conduct 
11B NMR experiments on the basis of boron chemical shifts being distinctive and highly 
dependent on the nature of the complexing ligands.25  Monitoring the crude reaction of 
crotonaldehyde with 8 over the course of 36 hours, we observed three peaks by 11B NMR: 
(1) unreacted starting material 8 (δ 3.1), (2) boron trifluoride (BF3) (δ –0.8), and (3) an 
unidentified boron complex (δ 28.1).26  Presumably, interaction of the BF3 byproduct from 
the conjugate addition reaction with water or the Lewis basic nitrogen of the catalyst gave 
rise to the unknown boron complex.27  Thus, catalyst inhibition by the reaction byproduct 
was identified as a probable cause for the observed low reaction efficiency.  We 
hypothesized removal of this byproduct would lead to increased reaction. 
With the aim of improving reaction efficiency, we explored a variety of Lewis basic 
additives to sequester the BF3 byproduct from the conjugate addition reaction.  As revealed 
in Table 4, water and simple alcohols were ineffective additives that did not have any 
marked affect on the reaction (11–12% conversion, 78% ee, entries 2–4).  Similarly, the 
addition of a buffered tertiary amine salt lead to slightly lower reaction efficiencies (10% 
conversion, 73% ee, entry 5).  As fluoride anions are also considered Lewis bases, a variety 
of fluorine sources were examined (entries 6–10).  Prototypical fluoride anion sources, 
such as TBAF and KF, were found to be detrimental to the reaction resulting in lower 
levels of conversion (0–10% conversion, entries 8–10).  In these cases, we presumed that 
the basicity of the fluoride anion interfered with the catalytic cycle via proton abstraction 
                                                
25. (a) Siedle, A. R. Annu. Rep. NMR Spectrosc. 1988, 20, 205. (b) Wrackmeyer, B. Annu. Rep. NMR Spectrosc. 1988, 
20, 61. 
26. 11B NMR experiments were carried out in CH2Cl2 and were externally referenced to BF3⋅Et2O (δ 0.00). 
27. Typically, the chemical shift associated with BF2⋅L (L = N, O) complexes is expected to be 17–30. 
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Table 4. Evaluation of Reaction Additives 
entry
O Me
20 mol% catalyst 11•HCl
styryl BF3K salt (8)
additive (1 eq)            
DME, 24 hr, 25 °C(3 eq)
1
2
3
4
5
6
7
8
9
10
% conversiona
17
12
11
16
10
36d
25
5.7
10
0
% eeb
83
78
78
79
73
76
73
81
78
--
additive
9
a Conversion determined by GC relative to tridecane. b Enantiomeric excess
determined by chiral SFC analysis (Chiracel OD-H) on the corresponding purified
alcohol product. c Used as 48 wt% solution in H2O. 
d Reaction was complete after 12 
hr. e Used as 1M solution in THF.
O
Me
none
water
i-PrOH
catechol
Et3N•HCl
HFc
cyanuric acid
KHF2
KF
TBAFe
 
from the acid co-catalyst.  In contrast, the use of acidic sources of fluorine,28 such as 
hydrofluoric acid (HF) and cyanuric acid,29 led to improved reaction progression (25–36% 
conversion, entries 6 and 7).  More significantly, employing HF accelerated the rate of 
reaction such that maximum conversion was obtained after 12 hours at ambient 
temperature.30  
Intrigued by the increased rate of reaction observed in the presence of HF, we were 
motivated to conduct 19F NMR studies to further probe this result (Table 4, entry 6).  In a 
                                                
28. pKa (HF) = 3.2 and pKa (cyanuric acid) = 6.8 (Koppenol, W. H.; Moreno, J. J.; Pryor, W. A.; Ischiropoulos, 
H.; Beckman, J. S. Chem. Res. Toxicol. 1992, 5, 834.) 
29. Cyanuric acid has been demonstrated to be a capable fluorine source, see: Hara, S.; Shudoh, H.; Ishimura, S.; 
Suzuki, A. Bull. Chem. Soc. Jpn. 1998, 71, 2403, and Olah, G. A.; Nojima, M.; Kerekes, I. Synthesis 1973, 487. 
30. Notably, additional equivalents of HF did not yield any added rate acceleration or increase in conversion. 
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crude reaction monitored by 19F NMR, we observed the formation of potassium 
tetrafluoroborate salt (BF4K) as the reaction byproduct.31  This validated our hypothesis 
that a reaction additive could indeed sequester the BF3 generated from the conjugate 
addition reaction (in this case by formation of an inert BF4K salt).32  Thus, HF successfully 
moderates BF3 inhibition and subsequently increases the rate and efficiency of the reaction. 
We next investigated the impact of concentration on the organocatalytic conjugate 
addition.  As revealed in Table 5, the influence of concentration proved to have a profound 
effect on the reaction rate and overall efficiency.  As the reaction was typically conducted  
Table 5. Effect of Concentration on the Organocatalytic Conjugate Addition 
entry
O Me
20 mol% catalyst 11•HCl
styryl BF3K salt (8)
HF  (1 eq)                  
DME, 25 °C(3 eq)
1
2
3
4
5
% conversiona
12
26
36
78
100
% eeb
75
76
76
76
76
concentration
9
a Conversion determined by GC relative to tridecane. b Enantiomeric excess determined 
by chiral SFC analysis (Chiracel OD-H) on the corresponding purified alcohol product.
O
Me
0.05 M
0.125 M
0.25 M
0.5 M
1.0 M
t (hr)
20
20
12
6
3
 
at 0.25M (entry 3) in our previous studies, lower concentrations were relatively poorer 
yielding (12–26% conversion, 0.05–0.125M, entries 1 and 2).  Conversely, a reaction 
conducted at a concentration of 1.0M demonstrated quantitative conversion to 9 in only 
                                                
31. 19F NMR experiments were carried out in d6-acetone (to obtain an homogeneous reaction) and externally 
referenced to HF(aq) (δ –204.0).  Authentic BF4K was found to have a chemical shift of δ –167.6 whereas 
synthetic BF4K from a crude reaction sample had a chemical shift of δ –167.5. 
32. Notably, as the reaction progresses (in DME) the precipitation of BF4K is observed.  
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three hours at room temperature (100% conversion, 76% ee, entry 5).  Based on these 
results, further optimization studies were carried out at higher reaction concentrations.  
Having attained high levels of reaction efficiency, temperature studies were 
undertaken with the aim of improving the selectivity of the reaction (Table 6).  As 
expected, the enantioselectivity was found to be temperature dependent, with lower 
reaction temperatures favoring a more selective process.  However, this trend was limited  
Table 6. Temperature dependence on the Organocatalytic Conjugate Addition Reaction  
entry
O Me
20 mol% catalyst 11•HCl
styryl BF3K salt (8)
HF  (1 eq)                  
DME (1 M), T (°C)(3 eq)
1
2
3
4
% conversiona
100
100
100
6.0
% eeb
76
79
87
88
temperature (°C)
9
a Conversion determined by GC relative to tridecane. b Enantiomeric excess determined 
by chiral SFC analysis (Chiracel OD-H) on the corresponding purified alcohol product.
O
Me
+25
+4
–20
–40
t (hr)
3
5
20
20
 
to temperatures above –40 °C, as the reaction was inhibited at lower temperatures due to 
issues from insolubility (6% conversion, 88% ee, entry 4).  The optimum temperature for 
this reaction was determined to be –20 °C, which demonstrated high levels of 
enantioselection while maintaining excellent reaction efficiency (100% conversion, 87% 
ee, entry 3). 
At this juncture, optimal reaction conditions were defined for the organocatalytic 
conjugate addition reaction.  However, an additional solvent screen was conducted to 
determine the compatibility of optimized conditions with solvents other than DME (Table 
7).  We were pleased to discover that the reaction was tolerant to multiple solvent systems  
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Table 7. Secondary Solvent Evaluation for the Organocatalytic Conjugate Addition Reaction 
O Me
20 mol% catalyst 11•HCl 
styryl BF3K salt (8)
solvent (1 M) 
15 hr, –20 °C(3 eq) 9
O
Me
entry
1
2
3
4
5
% conversiona
28
100
92
100
100
% eeb
64
72
78
87
87
MeCN
CH2Cl2
EtOAc
toluene
DME
solvent
a Conversion determined by GC relative to tridecane. b Enantiomeric excess determined 
by chiral SFC analysis (Chiracel OD-H) on the corresponding purified alcohol product.  
(92–100% conversion, entries 2–4), though the selectivity of the reaction remained highest 
in DME (87% ee, entry 5).  Alternatively, DME could be interchangeably used with 
toluene, as both solvents produced identical results (87% ee, entry 4). 
 
V. Scope of the Organocatalytic Conjugate Addition of Trifluoroborate Salts 
With optimized reaction parameters in hand, the scope of the 
organo(trifluoro)borate salt addition with crotonaldehyde was examined (Table 8).  
Styryltrifluoroborate salts, with varied substitution on the benzene ring, were successful 
reaction partners in the generation of allylic methyl stereocenters (96–91% yield, 87–95% 
ee, entries 1–3).  α-Methyl substitution on the styryl nucleophile was well tolerated (84% 
yield, 82% ee, entry 4), though notably, the analogous reaction conducted with a β-methyl 
styryl nucleophile was found to be completely unreactive.  Unfortunately, the reaction was 
found to be specific to styryltrifluoroborate salts, as attempts to employ other alkenyl  
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Table 8. Variation of the Nucleophile: The Scope of the Potassium Trifluoroborate Salt 
O Me
20 mol% catalyst 11•HCl
HF (1 eq)         
DME, 15 hr, –20 °C(3 eq)
RO
Me
entry
1
2
3
4
5
6
7
8
% yielda
96
70c
91c
84d
85
90
94
79e
% eeb
87
88
95
82
95
97
92
91
product
24
20
24
24
24
20
24
24
time (h)
OMe
Ph
Me
O
Me
O
Me
O
a Absolute stereochemistry assigned by chemical correlation and crystal structure. b 
Enantiomeric excess determined by chiral SFC analysis. c Reaction was conducted
at –40 °C.  d Reaction was conducted at –50 °C. e 40 mol% catalyst was used.
O
O
Me
O
Me
O CHO
O
O
Me
N
O
Me
OMe
BOC
Me
O
Me
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systems met with no success.33  Other trifluoroborate salts with alkyl,34 alkynyl,35 allylic,36 
and phenyl37functionalities were found to be unsuitable reaction partners. 
Heteroaromatic systems were amenable to this chemistry.38  Extension of this 
reaction to include heteroaromatic frameworks showcases the powerful versatility of this 
methodology, which simultaneously introduces a benzylic stereocenter and gives rapid 
entry into a new structural architecture (Table 8, entries 5–8).  In this regard, furanyl39 
(entry 5) and benzofuranyl substrates (85–94% yield, 92–95% ee, entries 6 and 7) were 
found to be excellent in this reaction.  Moreover, as a result of functionalization to the 
potassium trifluoroborate salt, we are able to alter the typical Friedel-Crafts reactivity of an 
indole40 by a site-specific activation of the 2′-carbon.  Thus, we were able to achieve 
alkylation at the 2′-position of a BOC-protected indole over an unsubstituted 3′-position 
with complete regioselective control and in high enantioselectivity (79% yield, 91% ee, 
entry 8).41  
                                                
33. Attempted alkenyl substrates: potassium (E)-3-phenylprop-1-enyl-, (E)-2-cyclohexyl-, (E)-pent-1-enyl-, (E)-
non-1-enyl-, 2-methylprop-1-enyl-, 1-phenylvinyl-, cyclopentenyl-, (E)-3-chloroprop-1-enyl-, (E)-3-
(ethanoyloxy)prop-1-enyltrifluoroborate salts.  
34. e.g., Potassium isopropyltrifluoroborate salt 
35. e.g., Potassium 3,3-dimethylbut-1-ynyltrifluoroborate salt 
36. Exposure of a potassium allyltrifluoroborate salt to reaction conditions resulted in a non-selective 1,2-addition 
to the aldehyde. 
37. Attempted aryl substrates: potassium p-tolyl-, 4-methoxyphenyl-, 2-methoxyphenyl-, 2,4,6-trimethoxyphenyl-, 
benzo[d][1,3]dioxol-5-yltrifluoroborate salts. 
38. Systems that demonstrated no reaction with crotonaldehyde were: potassium 1-benzyl-1H-pyrazol-4-yl-, 3,5-
dimethylisoxazol-4-yl, 5-methylthiophen-2-yl-, benzo[b]thiophen-2-yl-, 2-phenyloxazol-5-yl-, benzo[d]oxazol-
2-yl-, quinolin-3-yltrifluoroborate salts. 
39. Notably, the reaction with potassium 2-furanyltrifluoroborate salt resulted in bis-alkylation. 
40. (a) Lei, F.; Chen Y.-J.; Yong, S.; Liu, L.; Wang, D. Synlett 2003, 8, 1160. (b) vide ref. 22. 
41. Notably, the analogous reaction with the potassium 1-(tert-butoxycarbonyl)-1H-indol-3-yltrifluoroborate salt 
was plagued by competitive protodeborylation. 
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The vast potential of structural motifs accessible from differentially functionalized 
organotrifluoroborates and aldehyde substrates offers a versatile and modular approach in 
the rapid assembly of molecular complexity.  A survey of the electrophilic component of 
the reaction encompassed a representative scope of α,β-unsaturated aldehydes (Table 9) 
inclusive of both alkyl (90–97% yield, 93–97% ee, entries 1 and 2) and aryl substituents  
Table 9. Scope of the Electrophile 
O
entry
O R
20 mol% catalyst 11•HCl
2-benzofuranyl BF3K
HF (1 eq)      
DME (1 M), T (°C)(3 eq)
1
2
3
4
5
% yield
90
97
93
75
69
% eea
97
93
88
89
92
R
a Enantiomeric excess determined by chiral SFC analysis. b Bz = 4-NO2PhC(O).
O
R
Me
n-Pr
MeO2C
BzOCH2
b
p-NO2Ph
T (°C)
–20
4
–20
–20
25
 
(69% yield, 92% ee, entry 5).42  Additionally, significant variation of aldehyde 
functionality from a methyl ester group (93% yield, 88% ee, entry 3) to a pendent, 
protected alcohol (75% yield, 89% ee, entry 4)43 was well tolerated.  Notably, the optimal 
reaction temperature of the reaction was modulated with the reactivity of aldehyde 
substrate such that less reactive substrates were conducted at higher temperatures.   
                                                
42. Without the activation of the system by the p-NO2 group, cinnamaldehyde was significantly less reactive, only 
progressing to approximately 20% conversion.  
43. Without the activation of the system by the p-NO2 group, (E)-4-oxobut-2-enyl benzoate was significantly less 
reactive providing the desired product in 50% conversion and 76% ee at room temperature. 
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On the basis of these results, we considered the direct addition of boronic acids via 
an in situ formation of a boronate species through the introduction of an activating additive.  
This notion was validated when in the presence of hydrofluoric acid (eq. 14), we achieved 
HF (1 eq), DME 
25 °C, 36 hr
51% yield, 92% ee
MeO
14
HCl•catalyst 11 (20 mol%)
O
O
Me
(14)
OB
HO
OH
the addition of a boronic acid to crotonaldehyde to yield the corresponding adduct, 14 (51% 
yield, 92% ee).44  This result demonstrates the extension of this methodology towards 
unfunctionalized aldehyde substrates that would otherwise be unreactive toward boronic 
acids (vide supra).  
 
V. Conclusion 
In summary, we have further established iminium catalysis as a valuable strategy 
for asymmetric synthesis in the context of the first example of organocatalytic addition of 
trifluoro(organo)borates and boronic acids to α,β-unsaturated aldehydes.  We envision this 
new mode of reactivity for organotrifluoroborates will prove invaluable as a robust metal-
free “coupling” procedure for enantioselective C–C bond construction.  From a practical 
standpoint, this methodology stands to benefit from the structural diversity and wide 
commercial availability of several hundred organoboron reagents accessible to organic 
chemists.  Furthermore, the low toxicity and the air and moisture stability of potassium 
                                                
44. The analogous reaction of crotonaldehyde and an unfunctionalized benzofuran (under identical conditions 
noted in eq. 14) did not yield 14. 
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organotrifluoroborates reagents make this powerful new organocatalytic process 
operationally trivial. 
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S u p p o r t i n g  I n f o r m a t i o n  
General Information.  Commercial reagents were purified prior to use following 
the guidelines of Perrin and Armarego.45  All solvents were purified according to the 
method of Grubbs.46  Organic solutions were concentrated under reduced pressure on a 
Büchi rotary evaporator using an ice-water bath for volatile compounds.  Potassium 
trifluoroborate salts were synthesized from commercially available boronic acids or esters 
using a modified Molander procedure.47  Chromatographic purification of products was 
accomplished using force-flow chromatography on Silicycle silica gel according to the 
method of Still48 and where noted, Iatrobeads 6RS-8060 was used in place of silica gel.  
Thin-layer chromatography (TLC) was performed on Silicycle 250 mm silica gel plates.  
Visualization of the developed chromatogram was performed by fluorescence quenching 
and anisaldehyde stain. 
1H and 13C NMR spectra were recorded on a Varian Mercury 300 (300 MHz or 75 
MHz), Mercury 400 (400 MHz or 100 MHz), or an Inova 500 (500MHz and 125 MHz) as 
noted, and are internally referenced to residual protio solvent signals (note: CDCl3 
referenced at δ 7.24).  Data for 1H NMR are reported as follows: chemical shift (δ ppm), 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), integration, 
coupling constant (Hz), and assignment.  Data for 13C NMR are reported in terms of 
                                                
45. Perrin, D. D.; Armarego, W. L. F. Purification of Laboratory Chemicals; 3rd ed.; Pergamon Press: Oxford, 1988.  
46. Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics, 1996, 15, 1518. 
47. (a) Molander, G. A.; Ito, T. Org. Lett. 2001, 3, 393. (b)  Molander, G. A.; Biolatto, B. Org. Lett.  2002, 4, 1867.  
Note: The cited procedures were found to be more efficient when reaction slurries were sonicated. 
48. Still, W. C.; Kahn, M.; Mitra, A. J. J. Org. Chem. 1978, 43, 2923. 
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chemical shift.  IR spectra were recorded on a Perkin Elmer Paragon 1000 spectrometer 
and are reported in terms of frequency of absorption (cm-1).  Mass spectra were obtained 
from the California Institute of Technology Mass Spectral Facility and the Princeton Mass 
Spectroscopy Facility.  Gas liquid chromatography (GLC) was performed on Hewlett-
Packard 6850 and 6890 Series gas chromatographs equipped with split-mode capillary 
injection system and flame ionization detectors using Bodman Chiraldex γ-TA (30 m x 
0.25 mm) column.  Supercritical fluid chromatography (SFC) was performed on a Berger 
Minigram equipped with a diode array UV detector (λ = 214–258 nm) using a chiral 
column (25 cm) and guard column (5 cm) as noted for each compound.  
General procedure:  To a plastic vial (Wheaton HDPE) was added HF (48 wt%, 
1.0 eq) followed by 1,2-dimethoxyethane (DME) (1M, relative to aldehyde) and a magnetic 
stir bar.  The catalyst and acid co-catalyst were charged to the vial with the addition of 
(2S,5S)-2-tert-butyl-5-((1-benzyl-1H-indol-3-yl)methyl)-3-methylimidazolidin-4-one (0.2 
eq) and HCl (0.2 eq) and was then cooled to temperature (as noted).  The reaction was 
started with the addition of the aldehyde (3.0 eq) to the DME solution immediately 
followed by the addition of the trifluoroborate salt  (1.0 eq).  The reaction was stirred at 
temperature (for approximately 20–24 hr, as noted) and was often worked-up by an 
aqueous quench, which was then partitioned with dichloromethane, chloroform, or ether, as 
noted.  The combined organic layers are dried over Na2SO4 and concentrated in vacuo.  
The crude oil was then purified by column chromatography (conditions noted) to yield the 
desired product.  
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O
Me
 
(3R,4E)-3-methyl-5-phenylpent-4-enal (7).  Prepared according to the general 
procedure using crotonaldehyde and potassium trans-styryltrifluoroborate salt.  To a plastic 
vial was added HF (48 wt%, 7.00 mg, 0.167 mmol) followed by DME (500 µL) and a 
magnetic stir bar.  The catalyst and acid co-catalyst were charged to the vial with the 
addition of (2S,5S)-2-tert-butyl-5-((1-benzyl-1H-indol-3-yl)methyl)-3-methylimidazolidin-
4-one (12.5 mg, 0.033 mmol) and HCl (4N in dioxane, 8.30 µL, 0.033 mmol) and was then 
cooled to –20 °C.  Crotonaldehyde (58.0 µL, 0.50 mmol) was charged to the DME solution 
followed by the addition of potassium 2-benzofuranyltrifluoroborate salt (37.3 mg, 0.167 
mmol).  The reaction was stirred at –20 °C for 24 hours, quenched with 1M HCl (1.0 mL) 
and was stirred with chloroform (1.5 mL) for 30 minutes.  The organic layer was extracted 
with CH2Cl2 (2 x 2.0 mL), dried over Na2SO4, filtered through celite (ether wash) and 
concentrated in vacuo.  Purification by flash chromatography (silica gel, 20% ether in 
pentanes) yielded the title compound as clear oil (27.9 mg, 96% yield, 87% ee).  IR (film) 
2962, 1718, 965.0, 747.0, 692.5 cm-1; 1H NMR (300 MHz, CDCl3) δ 9.76 (t, 1H, J = 2.1 
Hz, CHO), 7.34–7.19 (m, 5H, aryl H), 6.42 (dd, 1H, J = 0.6, 15.9 Hz, CH=CH), 6.14 (dd, 
1H, J = 7.5, 15.9 Hz, CH=CH), 2.94 (m, 1H, CHCH3), 2.50 (ddd, 2H, J = 2.1, 6.9, 16.5 
Hz, CH2), 1.16 (d, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ 202.33, 134.16, 129.32, 
128.76, 127.50, 126.33, 50.60, 32.08, 20.65; HRMS (EI+) exact mass calculated for [M]+• 
(C12H14O) requires m/z 174.1045, found m/z 174.1051; [α]D= –49.1 (c = 0.45, CHCl3).  The 
enantiomeric excess was determined on the alcohol product, which was prepared by a 
NaBH4 reduction and analyzed by SFC analysis using a Chiralcel OD-H column (5% to 
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35% IPA, linear gradient, 100 bar, 35 °C oven, flow = 4.0 mL/min); (S) isomer tr = 4.75 
min, (R) isomer tr = 5.35 min. 
2. TMSCHN2           
     benzene-MeOH
1. OXONE®, DMF
O
Me
O
MeOMe
 
Determination of the absolute stereochemistry of (3R,4E)-3-methyl-5-
phenylpent-4-enal by correlation to methyl [1-((E)-styryl)ethyl]acetate.  Aldehyde 7 
(22.0 mg, 0.126 mmol) was subjected to oxidation49 using Oxone® (77.6 mg, 0.126 mmol) 
in DMF (1.26 mL) to quantitatively produce the corresponding acid (24.0 mg, 0.126 
mmol).  Subsequently, the acid was esterified using TMS diazomethane (2M in hexane, 
130 µL) in a solution of 25% methanol in benzene (1.0 mL) at room temperature.  
Purification was accomplished via chromatography (prep TLC, 20% ether in pentanes) and 
yielded (3R,4E)-methyl 3-methyl-5-phenylpent-4-enoate in 34% isolated yield.  1H NMR 
and 13C NMR (500 MHz, CCl4 with TMS internal reference) spectral data matched 
literature values.50  1H NMR (400 MHz, CDCl3) δ 7.34–7.18 (m, 5H, aryl H), 6.38 (d, 1H, 
J = 15.6 Hz, CH=CH), 6.12 (dd, 1H, J = 7.6, 15.9 Hz, CH=CH), 6.14 (dd, 1H, J = 7.5, 
16.0 Hz, CH=CH), 3.65 (s, 3H, OCH3), 2.84 (septet, 1H, J = 7.2 Hz, CHCH2), 2.39 (ddd, 
2H, J = 7.2, 14.4, 21.6 Hz, CH2) 1.13 (d, 3H, J = 6.4 Hz, CH3); 13C NMR (100 MHz, 
CDCl3) δ 173.1, 134.4, 129.1, 128.7, 127.4, 126.3, 51.74, 41.73, 34.22, 20.42; [α]D= –57.8 
(c = 0.502, CCl4).  
                                                
49. Travis, B. R.; Sivakumar, M.; Hollist, G. O.; Borhan, B. Org. Lett. 2003, 5, 1031. 
50. Hayashi, T.; Yamamoto, A.; Hagihara, T. J. Org. Chem. 1986, 51, 723 (reported [α]D= –49.2 (c = 1.3, CCl4) for 
a product that was 79% ee). 
                                                 86 
O
Me
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(3R,4E)-5-(4-methoxyphenyl)-3-methylpent-4-enal (Table 8, entry 2).  Prepared 
according to the general procedure using crotonaldehyde and potassium trans-2-(4-
methoxyphenyl)trifluoroborate salt.  To a plastic vial was added HF (48 wt%, 3.5 mg, 
0.083 mmol) followed by DME (250 µL) and a magnetic stir bar.  The catalyst and acid co-
catalyst were charged to the vial with the addition of (2S,5S)-2-tert-butyl-5-((1-benzyl-1H-
indol-3-yl)methyl)-3-methylimidazolidin-4-one (6.25 mg, 0.017 mmol) and HCl (4N in 
dioxane, 4.2 µL, 0.017 mmol) and was then cooled to –40 °C.  Crotonaldehyde (21.0 µL, 
0.25 mmol) was charged to the DME solution followed by the addition of potassium trans-
2-(4-methoxyphenyl)trifluoroborate salt (20.0 mg, 0.083 mmol).  The reaction was stirred 
at –40 °C for 20 hours, quenched with 1M HCl (1.0 mL) and was stirred with chloroform 
(1.5 mL) for 30 minutes.  The organic layer was extracted with CH2Cl2 (2 x 2.0 mL), dried 
over Na2SO4, filtered through celite (ether wash) and concentrated in vacuo.  Purification 
by chromatography (prep TLC, 10% ether in pentanes) yielded the title compound as clear 
oil (13.9 mg, 70% yield, 88% ee).  IR (film) 2954, 1720, 1605, 1510, 1243, 1174, 1030, 
964.8, 804.7 cm-1; 1H NMR (300 MHz, CDCl3) δ 9.77 (t, 1H, J = 2.1 Hz, CHO), 7.27 (d, 
2H, J = 8.4 Hz, aryl H), 6.84 (d, 2H, J = 9.0 Hz, aryl H), 6.36 (d, 1H, J = 15.9 Hz, 
CH=CH), 6.01 (dd, 1H, J = 7.5, 15.9 Hz, CH=CH), 3.80 (s, 3H, OCH3), 2.93 (m, 1H, 
CHCH2), 2.50 (ddd, 2H, J = 2.1, 7.2, 16.2 Hz, CH2), 1.17 (d, 3H, J = 6.6 Hz, CH3); 13C 
NMR (75 MHz, CDCl3) δ 202.54, 159.17, 132.01, 130.11, 128.68, 127.44, 114.15, 55.51, 
50.73, 32.11, 20.79; HRMS (EI+) exact mass calculated for [M]+• (C13H16O2) requires m/z 
204.1150, found m/z 204.1150; [α]D= –44.0 (c = 1.26, CHCl3).  The enantiomeric excess 
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was determined by SFC analysis using a Chiralpak AS-H column (5% to 10% MeCN, 
linear gradient, 100 bar, 35 °C oven, flow = 4.0 mL/min); (S) isomer tr = 4.03 min, (R) 
isomer tr = 4.68 min. 
O
Me
 
(3R,4E)-5-(4-biphenyl)-3-methylpent-4-enal (Table 8, entry 3).  Prepared 
according to the general procedure using crotonaldehyde and potassium trans-2-
(biphenyl)trifluoroborate salt.  To a plastic vial was added HF (48 wt%, 6.3 mg, 0.15 
mmol) followed by DME (450 µL) and a magnetic stir bar.  The catalyst and acid co-
catalyst were charged to the vial with the addition of (2S,5S)-2-tert-butyl-5-((1-benzyl-1H-
indol-3-yl)methyl)-3-methylimidazolidin-4-one (11.3 mg, 0.03 mmol) and HCl (4N in 
dioxane, 7.5 µL, 0.03 mmol) and was then cooled to –40 °C.  Crotonaldehyde (37.5 µL, 
0.45 mmol) was charged to the DME solution followed by the addition of potassium trans-
2-(4-biphenyl)trifluoroborate salt (42.9 mg, 0.15 mmol).  The reaction was stirred at –40 °C 
for 24 hours and was directly subjected to purification by flash chromatography 
(Iatrobeads, 1% acetone and 5% ether in pentanes) to yield the title compound as light, 
yellow solid (20.6 mg, 91% yield, 95% ee).  IR (film) 2924, 2854, 1724, 972.3, 761.7, 
694.4 cm-1; 1H NMR (500 MHz, CDCl3) δ 9.78 (t, 1H, J = 2.0 Hz, CHO), 7.58–7.52 (m, 
4H, aryl H), 7.43–7.39 (m, 4H, aryl H), 7.33–7.24 (m, 1H, aryl H), 6.44 (d, 1H, J = 16.0 
Hz, CH=CH), 6.19 (dd, 1H, J = 7.5, 16.0 Hz, CH=CH), 2.97 (septet, 2H, J = 7.0 Hz, 
CHCH2), 2.52 (ddd, 2H, J = 2.0, 7.0, 16.5 Hz, CH2), 1.18 (d, 3H, J = 7.0 Hz, CH3); 13C 
NMR (125 MHz, CDCl3) δ 202.21, 140.95, 140.31, 136.41, 134.34, 128.99, 128.93, 
                                                 88 
127.46, 127.12, 126.77, 50.65, 32.15, 29.92, 20.67; HRMS (EI+) exact mass calculated for 
[M]+• (C13H16O2) requires m/z 250.1358, found m/z 250.1349; [α]D= –13.6 (c = 1.29, 
CHCl3).  The enantiomeric excess was determined by SFC analysis using a Chiralcel OJ-H 
column (5% to 15% MeCN, 2%/min gradient, 100 bar, 35 °C oven, flow = 4.0 mL/min); 
(S) isomer tr = 2.97 min, (R) isomer tr = 3.23 min. 
O
Me Me
 
(3R,4E)-3-methyl-5-phenylhex-4-enal (Table 8, entry 4).  Prepared according to 
the general procedure using crotonaldehyde and potassium (E)-(2-phenylprop-1-enyl) 
trifluoroborate salt.51  To a plastic vial was added HF (48 wt%, 3.5 mg, 0.083 mmol) 
followed by DME (250 µL) and a magnetic stir bar.  The catalyst and acid co-catalyst were 
charged to the vial with the addition of (2S,5S)-2-tert-butyl-5-((1-benzyl-1H-indol-3-
yl)methyl)-3-methylimidazolidin-4-one (6.25 mg, 0.017 mmol) and HCl (4N in dioxane, 
4.2 µL, 0.017 mmol) and was then cooled to –20 °C.  Crotonaldehyde (21.0 µL, 0.25 
mmol) was charged to the DME solution followed by the addition of potassium (E)-(2-
phenylprop-1-enyl) trifluoroborate salt (18.7 mg, 0.083 mmol).  The reaction was stirred at 
–50 °C for 24 hours, quenched with 1M HCl (1.0 mL) and was stirred with 
dichloromethane (1.5 mL) for 30 minutes.  The organic layer was extracted with 
dichloromethane (2 x 2.0 mL), dried over Na2SO4 and concentrated in vacuo.  Purification 
by flash chromatography (silica gel, 10% ethyl acetate in hexanes) yielded the title 
                                                
51. (a) Prepared via synthesis of the corresponding boronic ester using a literature procedure, see: Coapes, R. B.; 
Souza, F. E. S.; Thomas, R. L.; Hall, J. J.; Marder, T. B. Chem. Commun. 2003, 614. (b) Petasis N. A.; Yudin, A. 
K.; Zavialov, I. A.; Prakash, G. K. S.; Olah, G. A. Synlett 1997, 606.  
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compound as a clear, light yellow oil (13.1 mg, 84% yield, 82% ee).  This is a known 
compound that has previously been synthesized as a racemate.52  Notably, all spectroscopic 
data are in accord with literature values.  IR (film) 2961, 1724, 1444, 758.0, 697.7 cm-1; 1H 
NMR (300 MHz, CDCl3) δ 9.73 (t, 1H, J = 2.1 Hz, CHO), 7.38–7.22 (m, 5H, aryl H), 5.58 
(dd, 1H, J = 1.5, 9.6 Hz, C=CH), 3.16 (m, 1H, CHCH3), 2.46 (dd, 2H, J = 2.1, 7.2 Hz, 
CH2), 2.08 (d, 3H, J = 1.2 Hz, CH3), 1.17 (d, 3H, J = 6.6 Hz, CH3); 13C NMR (75 MHz, 
CDCl3) δ 202.83, 132.61, 128.41, 127.05, 125.95, 51.25, 28.62, 20.93, 16.12; HRMS (EI+) 
exact mass calculated for [M+•] (C13H16O) requires m/z 188.1201, found m/z 188.1197; 
[α]D= –70.1 (c = 0.96, CHCl3).  The enantiomeric excess was determined on the alcohol 
product, which was prepared by a NaBH4 reduction and analyzed by SFC analysis using a 
Chiralpak AD-H column (0% to 10% IPA, linear gradient, 100 bar, 35 °C oven, flow = 4.0 
mL/min); (S) isomer tr = 5.79 min, (R) isomer tr = 6.32 min. 
O
Me
O CHO
 
(3R)-5-(4-oxobutan-2-yl)furan-2-carbaldehyde (Table 8, entry 5).  Prepared 
according to the general procedure using crotonaldehyde and potassium 2-(5-formylfuran-
2-yl) trifluoroborate salt.  To a plastic vial was added HF (48 wt%, 3.5 mg, 0.083 mmol) 
followed by DME (250 µL) and a magnetic stir bar.  The catalyst and acid co-catalyst were 
charged to the vial with the addition of (2S,5S)-2-tert-butyl-5-((1-benzyl-1H-indol-3-
yl)methyl)-3-methylimidazolidin-4-one (6.25 mg, 0.017 mmol) and HCl (4N in dioxane, 
4.2 µL, 0.017 mmol) and was then cooled to –20 °C.  Crotonaldehyde (21.0 µL, 0.25 
                                                
52. Nasveschuk, C. G.; Rovis, T. Org. Lett. 2005, 7, 2173.  
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mmol) was charged to the DME solution followed by the addition of potassium 2-(5-
formylfuran-2-yl) trifluoroborate salt (20.0 mg, 0.083 mmol).  The reaction was stirred at –
20 °C for 20 hours, quenched with 1M HCl (1.0 mL) and was stirred with ether (1.5 mL) 
for 30 minutes.  The organic layer was extracted with ether (2 x 2.0 mL), dried over 
Na2SO4, filtered through celite (ether wash) and concentrated in vacuo (ice-water bath).  
Purification by flash chromatography (silica gel, 10% ether in pentanes) yielded the title 
compound as a clear, light yellow oil (11.7 mg, 85% yield, 95% ee).  IR (film) 1719, 1670, 
1513, 1020 cm-1; 1H NMR (300 MHz, CDCl3) δ 9.75 (t, 1H, J = 1.5 Hz, CHO), 9.51 (s, 
1H, furyl CHO), 7.17 (d, 1H, J = 3.6 Hz, aryl H), 6.30 (dd, 1H, J = 0.9, 3.6 Hz, aryl H), 
3.53 (m, 1H, CHCH3), 2.81 (ddd, 2H, J = 1.5, 7.2, 17.7 Hz, CH2), 1.35 (d, 3H, J = 7.2 Hz, 
CH3); 13C NMR (75 MHz, CDCl3) δ 200.53, 177.45, 152.56, 123.72, 108.38, 49.08, 28.55, 
19.07; HRMS (EI+) exact mass calculated for [M+•] (C9H10O3) requires m/z 166.0630, 
found m/z 166.0629; [α]D= –1.09 (c = 1.17, CHCl3).  The enantiomeric excess was 
determined by SFC analysis using a Chiralpak AS-H column (5% to 10% MeCN, linear 
gradient, 100 bar, 35 °C oven, flow = 4.0 mL/min); (S) isomer tr = 2.73 min, (R) isomer tr = 
3.63 min. 
O
O
Me
 
(3R)-3-(benzofuran-2-yl)butanal (Table 8, entry 6).  Prepared according to the 
general procedure using crotonaldehyde and potassium 2-benzofuranyltrifluoroborate 
salt.53  To a plastic vial was added HF (48 wt%, 6.25 mg, 0.167 mmol) followed by DME 
                                                
53. Murphy, J. M.; Tzschucke, C. C.; Hartwig, J. F. Org. Lett. 2007, 9, 757. 
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(450 µL) and a magnetic stir bar.  The catalyst and acid co-catalyst were charged to the vial 
with the addition of (2S,5S)-2-tert-butyl-5-((1-benzyl-1H-indol-3-yl)methyl)-3-
methylimidazolidin-4-one (11.3 mg, 0.033 mmol) and HCl (4N in dioxane, 7.50 µL, 0.033 
mmol) and was then cooled to –20 °C.  Crotonaldehyde (37.3 µL, 0.45 mmol) was charged 
to the DME solution followed by the addition of potassium 2-benzofuranyltrifluoroborate 
salt (33.6 mg, 0.150 mmol).  The reaction was stirred at –20 °C for 23 hours and then 
flushed though a silica gel plug (wash with 30% ether in pentanes).  Concentration in vacuo 
(ice-water bath) provided the title compound as clear oil (25.5 mg, 90% yield, 97% ee).  IR 
(film) 1722, 1454, 1253, 1168, 750.6 cm-1; 1H NMR (300 MHz, CDCl3) δ 9.84 (s, 1H, 
CHO), 7.54–7.43 (m, 2H, aryl H), 7.29–7.19 (m, 2H, aryl H), 6.45 (t, 1H, J = 0.9 Hz, 3'-
benzofuranyl H), 3.61 (m, 1H, CHCH3), 2.85 (dd, 2H, J = 1.8, 17.1 Hz, CH2), 1.45 (d, 3H, 
J = 6.6 Hz, CH3); 13C NMR (75 MHz, CDCl3) δ 201.06, 161.47, 154.81, 128.68, 123.81, 
122.81, 120.75, 111.07, 101.58, 49.06, 28.38, 19.04; HRMS (EI+) exact mass calculated 
for [M]+• (C12H12O2) requires m/z 188.0837, found m/z 188.0844; [α]D= –17.1 (c = 1.22, 
CHCl3).  The enantiomeric excess was determined on the alcohol product, which was 
prepared by a NaBH4 reduction and analyzed by SFC analysis using a Chiralpak AS-H 
column (5% to 50% methanol, linear gradient, 100 bar, 35 °C oven, flow = 4.0 mL/min); 
(S) isomer tr = 2.17 min, (R) isomer tr = 2.40 min. 
O
O
Me
OMe  
(3R)-3-(5-methoxybenzofuran-2-yl)butanal (Table 8, entry 7).  Prepared 
according to the general procedure using crotonaldehyde and potassium 2-(5-
methoxybenzofuranyl)trifluoroborate salt.  To a plastic vial was added HF (48 wt%, 6.25 
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mg, 0.15 mmol) followed by DME (450 µL) and a magnetic stir bar.  The catalyst and acid 
co-catalyst were charged to the vial with the addition of (2S,5S)-2-tert-butyl-5-((1-benzyl-
1H-indol-3-yl)methyl)-3-methylimidazolidin-4-one (10.9 mg, 0.03 mmol) and HCl (4N in 
dioxane, 7.5 µL, 0.03 mmol) and was then cooled to –20 °C.  Crotonaldehyde (37.5 µL, 
0.45 mmol) was charged to the DME solution followed by the addition of potassium 2-(5-
methoxybenzofuranyl)trifluoroborate salt (42.4 mg, 0.15 mmol).  The reaction was stirred 
at –20 °C for 24 hours, quenched with 1M HCl (1.0 mL) and was stirred with chloroform 
(1.5 mL) for 30 minutes.  The organic layer was extracted with chloroform (2 x 2.0 mL), 
dried over Na2SO4, filtered through celite (ether wash) and concentrated in vacuo.  
Purification by flash chromatography (silica gel, 15% ether in pentanes) yielded the title 
compound as clear oil (30.7 mg, 94% yield, 92% ee).  IR (film) 1724, 1475, 1205, 1030 
cm-1; 1H NMR (300 MHz, CD2Cl2) δ 9.78 (t, 1H, J = 1.5 Hz, CHO), 7.29 (d, 1H, J = 8.4 
Hz, aryl H), 6.98 (d, 1H, J = 2.4 Hz, aryl H), 6.81 (dd, 1H, J = 2.4, 9.0 Hz, aryl H), 6.38 
(d, 1H, J = 0.9 Hz), 3.01 (s, 3H, OCH3), 3.54 (m, 1H, CHCH3), 2.79 (ddd, 2H, J = 1.5, 6.6, 
17.4 Hz, CH2), 1.39 (d, 3H, J = 0.9 Hz, CH3); 13C NMR (75 MHz, CDCl3) δ 201.32, 
163.07, 156.46, 150.05, 129.72, 112.37, 111.60, 103.72, 101.93, 56.29, 49.30, 28.78, 
19.18; HRMS (EI+) exact mass calculated for [M]+• (C13H14O3) requires m/z 218.0943, 
found m/z 218.0944; [α]D= –8.51 (c = 1.29, CHCl3).  The enantiomeric excess was 
determined by SFC using a Chiracel OJ-H column (5% to 10% MeCN, linear gradient, 100 
bar, 35 °C oven, flow = 4.0 mL/min); (S) isomer tr = 5.17 min, (R) isomer tr = 5.61 min.                 
CH2Cl2-MeOH, 0 °C
O
O
Me
OMe
O
HO
Me
OMe
NaBH4
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Determination of the absolute stereochemistry of (3R)-3-(5-
methoxybenzofuran-2-yl)butanal by correlation to (3R)-3-(5-methoxybenzofuran-2-
yl)butan-1-ol.  To a stirring solution of the aldehyde (25 mg, 0.11 mmol) in CH2Cl2 (2.0 
mL) and ethanol (20 µL) at 0 °C was added NaBH4 (13 mg, 0.34 mmol).  The reaction was 
quenched after 5 minutes by a saturated solution of Rochelle’s salt  (2.0 mL).  The organic 
was then extracted with ether (2 x 3.0 mL) and concentrated in vacuo to yield a clear oil 
(quantitative yield) with spectroscopic data matching literature values.54  IR (film) 3306 
(br), 2922, 1458, 1201, 1026 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.28 (d, 1H, J = 8.7 Hz, 
aryl H), 6.94 (d, 1H, J = 2.7 Hz, aryl H), 6.79 (dd, 1H, J = 2.7, 8.7 Hz, aryl H), 6.33 (s, 
1H, aryl H), 3.81 (s, 3H, OCH3), 3.69 (m, 2H, CH2CH2), 3.11 (m, 1H, CHCH3), 2.06–1.95 
(m, 1H, CH2OH), 1.91–1.79 (m, 1H, CH2OH), 1.57 (br s, 1H, OH), 1.34 (d, 3H, J = 7.2 
Hz, CH3); 13C NMR (75 MHz, CDCl3) δ 164.11, 155.98, 149.73, 129.48, 111.81, 111.38, 
103.45, 101.40, 60.97, 56.16, 38.53, 30.56, 19.38; HRMS (EI+) exact mass calculated for 
[M+1] (C13H16O3) requires m/z 220.1100, found m/z 220.1089; [α]D= –46.2 (c = 0.83, 
CHCl3).39  The enantiomeric excess was determined by SFC analysis using a Chiralcel OJ-
H column (5% to 10% methanol, linear gradient, 100 bar, 35 °C oven, flow = 4.0 mL/min); 
(S) isomer tr = 5.71 min, (R) isomer tr = 6.56 min. 
NEt3, DMAP, CH2Cl2, 0 °C
O
HO
Me
OMe
O
O
Me
OMe
p-bromobenzoyl chloride O
Br  
Determination of the absolute stereochemistry of (3R)-3-(5-
methoxybenzofuran-2-yl)butanal by obtaining a crystal structure of  (3R)-3-(5-
                                                
54. Hughes, C. C.; Trauner, D. Tetrahedron, 2004, 60, 9675 (reported [α]D= –33.0 (c = 1.00, CHCl3) for a product 
that was 91% ee).  
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methoxybenzofuran-2-yl)butyl 4-bromobenzoate (vide infra).  Esterification of (3R)-3-
(5-methoxybenzofuran-2-yl)butan-1-ol (22 mg, 0.10 mmol) proceeded in a solution of 
CH2Cl2 (1.0 mL) to which NEt3 (21 µL, 0.15 mmol) and DMAP (1.2 mg, 0.01 mmol) were 
added.  The solution was then cooled to 0 °C and p-bromobenzoyl chloride (24 mg, 0.11 
mmol) was added.  The ice bath was removed and after 30 minutes at room temperature, 
0.5 M HCl (2.0 mL) was added to quench the reaction.  The organic layer was dried with 
Na2SO4, triturated with diethyl ether, filtered (to remove salt impurities), and concentrated 
in vacuo to yield a yellow solid (34 mg, 85% yield).  IR (film) 2929, 1719, 1591, 1477, 
1271, 1205, 1102, 1012, 756.3 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.74 (d, 2H, J = 8.4 
Hz, aryl H), 7.47 (d, 2H, J = 8.4 Hz, aryl H), 7.22 (s, 1H, aryl H), 6.89 (d, 1H, J = 2.8 Hz, 
aryl H), 6.77 (dd, 1H, J = 2.8, 9.2 Hz, aryl H), 6.32 (s, 1H, aryl H), 4.33 (m, 2H, 
CH2OC(O)), 3.78 (s, 3H, OCH3), 3.11 (m, 1H, CH3CH), 2.25–2.01 (m, 2H, CH2), 1.37 (t, 
3H, J = 7.2 Hz, CHCH3); 13C NMR (100 MHz, CDCl3) δ 165.95, 163.18, 155.97, 149.75, 
131.76, 131.17, 129.40, 129.18, 128.11, 111.85, 111.32, 103.42, 101.62, 63.41, 56.10, 
34.32m 31.20, 19.23;  HRMS (EI+) exact mass calculated for [M+•] (C20H19BrO4) requires 
m/z 402.0467, found m/z 402.0481; [α]D= –52.7 (c = 1.02, CHCl3). 
N
O
Me
Ot-BuO
 
(3R)-tert-butyl 2-(4-oxobutan-2-yl)-1H-indole-1-carboxylate (Table 8, entry 8).  
Prepared according to the general procedure using crotonaldehyde and potassium 2-(tert-
butyl 1H-indole-1-carboxylate)trifluoroborate salt.  To a plastic vial was added HF (48 
wt%, 3.5 mg, 0.083 mmol) followed by DME (250 µL) and a magnetic stir bar.  The 
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catalyst and acid co-catalyst were charged to the vial with the addition of (2S,5S)-2-tert-
butyl-5-((1-benzyl-1H-indol-3-yl)methyl)-3-methylimidazolidin-4-one (12.4 mg, 0.033 
mmol) and HCl (4N in dioxane, 8.3 µL, 0.033 mmol) and was then cooled to –20 °C.  
Crotonaldehyde (21.0 µL, 0.25 mmol) was charged to the DME solution followed by the 
addition of potassium 2-(tert-butyl 1H-indole-1-carboxylate)trifluoroborate salt (26.9 mg, 
0.083 mmol).  The reaction was stirred at –20 °C for 24 hours and quenched with 1M HCl 
(1.0 mL) and was stirred with chloroform (1.5 mL) for 30 minutes.  The organic layer was 
extracted with chloroform (2 x 2.0 mL), dried over Na2SO4, filtered through celite (ether 
wash) and concentrated in vacuo.  Purification by flash chromatography (silica gel, 10% 
ether in pentanes) yielded the title compound as light yellow oil (19.0 mg, 79% yield, 91% 
ee).  IR (film) 1728, 1455, 1370, 1327, 1157, 747.4 cm-1; 1H NMR (300 MHz, CDCl3) δ 
9.77 (t, 1H, J = 1.8 Hz, CHO), 8.03 (dt, 1H, J = 0.6, 7.8 Hz, aryl H), 7.45 (m, 1H, aryl H), 
7.26–7.15 (m, 2H, aryl H), 6.40 (t, 1H, J = 0.9 Hz, aryl H), 4.24 (m, 1H, CHCH3), 2.57 
(dd, 1H, CH2), 2.89 (1H, dd, J = 1.8, 5.4 Hz, CH2), 1.37 (t, 3H, J = 6.9 Hz, CH3); 13C 
NMR (75 MHz, CDCl3) δ 201.95, 150.69, 145.80, 129.22, 123.96, 123.00, 120.28, 115.94, 
106.42, 84.47, 50.80, 28.45, 28.02, 21.06; HRMS (EI+) exact mass calculated for [M+•] 
(C17H21NO3) requires m/z 287.1521, found m/z 287.1533; [α]D= –6.1 (c = 0.6, CHCl3).  
The enantiomeric excess was determined by SFC analysis using a Chiralcel OD-H column 
(5% to 50% MeCN, linear gradient, 100 bar, 35 °C oven, flow = 4.0 mL/min); (S) isomer tr 
= 2.51 min, (R) isomer tr = 2.97 min. 
O
O
n-Pr
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(3R)-3-(benzofuran-2-yl) hexanal (Table 9, entry 2).  Prepared according to the 
general procedure using hexenal and potassium 2-benzofuranyltrifluoroborate salt.  To a 
plastic vial was added HF (48 wt%, 7.00 mg, 0.167 mmol) followed by DME (500 µL) and 
a magnetic stir bar.  The catalyst and acid co-catalyst were charged to the vial with the 
addition of (2S,5S)-2-tert-butyl-5-((1-benzyl-1H-indol-3-yl)methyl)-3-methylimidazolidin-
4-one (12.5 mg, 0.033 mmol) and HCl (4N in dioxane, 8.30 µL, 0.033 mmol) and was then 
cooled to 4 °C.  Hexenal (58.0 µL, 0.50 mmol) was charged to the DME solution followed 
by the addition of potassium 2-benzofuranyltrifluoroborate salt (37.3 mg, 0.167 mmol).  
The reaction was stirred at 4 °C for 12 hours and quenched with a saturated solution of 
Rochelle’s salt (1.0 mL) and was partitioned with dichloromethane (2 x 1.5 mL).  The 
combined organic layers are dried over Na2SO4, concentrated in vacuo and purified by 
flash chromatography (silica gel, 10% ether in pentanes) to yield the title compound as 
clear oil (34.9 mg, 97% yield, 93% ee).  IR (film) 2959, 2932, 2873, 1725, 1456, 1253, 
751.8 cm-1; 1H NMR (300 MHz, CDCl3) δ 9.75 (s, 1H, CHO), 7.49–7.38 (m, 2H, aryl H), 
7.24–7.14 (m, 2H, aryl H), 6.42 (s, 1H, 3'-benzofuranyl H), 3.48–3.39 (m, 1H, 
CH2CHCH2), 2.80 (ddd, 2H, J = 1.8, 7.5, 17.1 Hz, α-CH2), 1.85–1.58 (m, 2H, CH2), 1.37–
1.24 (m, 2H, CH2), 0.89 (t, 3H, J = 6.9 Hz, CH3); 13C NMR (125 MHz, CDCl3) δ 201.31, 
147.98, 132.55, 123.73, 122.82, 120.73, 111.12, 102.85, 67.13, 47.70, 35.97, 33.69, 20.48, 
14.07; HRMS (EI+) exact mass calculated for [M]+• (C14H16O2) requires m/z 216.1150, 
found m/z 216.1142; [α]D= –7.3 (c = 1.05, CHCl3).  The enantiomeric excess was 
determined on the alcohol product, which was prepared by a NaBH4 reduction and 
analyzed by SFC using a Chiralpak AS-H column (5% to 25% IPA, linear gradient, 100 
bar, 35 °C oven, flow = 4.0 mL/min); (S) isomer tr = 3.18 min, (R) isomer tr = 3.36 min. 
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O
O
OMeO
 
(3R)-methyl 2-(benzofuran-2-yl)-3-formylpropanoate (Table 9, entry 3).  
Prepared according to the general procedure using (E)-methyl 3-formylacrylate and 
potassium 2-benzofuranyltrifluoroborate salt.  To a plastic vial was added HF (48 wt%, 
7.00 mg, 0.167 mmol) followed by DME (500 µL) and a magnetic stir bar.  The catalyst 
and acid co-catalyst were charged to the vial with the addition of (2S,5S)-2-tert-butyl-5-((1-
benzyl-1H-indol-3-yl)methyl)-3-methylimidazolidin-4-one (12.5 mg, 0.033 mmol) and 
HCl (4N in dioxane, 8.30 µL, 0.033 mmol) and was then cooled to –20 °C.  (E)-Methyl 3-
formylacrylate (58.0 µL, 0.50 mmol) was charged to the DME solution followed by the 
addition of potassium 2-benzofuranyltrifluoroborate salt (37.3 mg, 0.167 mmol).  The 
reaction was stirred at –20 °C for 18 hours, quenched with 1M HCl (1.0 mL) and was 
stirred in chloroform (1.5 mL) for 30 minutes.  The organic layer was extracted with 
chloroform (2 x 2.0 mL), dried over Na2SO4, concentrated in vacuo and purified by flash 
chromatography (silica gel, 25% ether in pentanes) to yield the title compound as clear oil 
(36.0 mg, 93% yield, 88% ee).  IR (film) 1736, 1720, 1453, 1168, 750.9 cm-1; 1H NMR 
(300 MHz, CDCl3) δ 9.82 (s, 1H, CHO), 7.52–7.40 (m, 2H, aryl H), 7.28–7.17 (m, 2H, aryl 
H), 6.58 (s, 1H, 3'-benzofuranyl H), 4.42 (dd, 1H, J = 5.1, 9.0 Hz, CHCH2), 3.73 (s, 3H, 
OCH3), 3.45 (ddd, 1H, J = 0.6, 9.0, 18.6 Hz, CH2), 3.02 (ddd, 1H, J = 0.6, 5.1, 18.6 Hz, 
CH2); 13C NMR (75 MHz, CDCl3) δ 198.82, 191.57, 147.97, 132.45, 128.33, 124.52, 
123.18, 121.14, 111.42, 104.62, 53.120, 44.37, 39.39; HRMS (EI+) exact mass calculated 
for [M]+• (C13H12O4) requires m/z 232.0736, found m/z 232.0728; [α]D= –95.0 (c = 0.8, 
CHCl3).  The enantiomeric excess was determined on the diol product, which is prepared 
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by reduction of the ester and aldehyde (21.5 mg, 0.093 mmol) in THF (1.0 mL) using 
LiAlH4 (1M in THF, 200 µL, 0.2 mmol) at –60 °C.  SFC analysis was performed using a 
Chiralpak AD-H column (5% to 15% methanol, linear gradient, 100 bar, 35 °C oven, flow 
= 4.0 mL/min); (S) isomer tr = 10.23 min, (R) isomer tr = 10.80 min. 
O
O
NO2
 
(3S)-3-(Benzofuran-2-yl)-3-(4-nitrophenyl)propanal (Table 9, entry 4).  
Prepared according to the general procedure using p-nitrocinnamaldehyde and potassium 2-
benzofuranyltrifluoroborate salt.  To a plastic vial was added HF (48 wt%, 3.50 mg, 0.083 
mmol) followed by DME (250 µL) and a magnetic stir bar.  The catalyst and acid co-
catalyst were charged to the vial with the addition of (2S,5S)-2-tert-butyl-5-((1-benzyl-1H-
indol-3-yl)methyl)-3-methylimidazolidin-4-one (6.26 mg, 0.017 mmol) and HCl (4N in 
dioxane, 4.20 µL, 0.017 mmol).  p-Nitrocinnamaldehye (44.3 mg, 0.250 mmol) was 
charged to the DME solution followed by the addition of potassium 2-
benzofuranyltrifluoroborate salt (18.7 mg, 0.083 mmol).  The reaction was stirred at 
ambient temperature for 24 hours, quenched with a saturated solution of Rochelle’s salt 
(1.0 mL) and was then partitioned with dichloromethane (2 x 1.5 mL).  The combined 
organic layers were dried over Na2SO4, concentrated in vacuo and purified by 
chromatography (prep TLC, 25% dichloromethane in benzene) to yield the title compound 
as a light yellow oil (16.9 mg, 69% yield, 92% ee).  IR (film) 1724, 1519, 1454, 1347, 
1254, 752.1 cm-1; 1H NMR (300 MHz, CDCl3) δ 9.81 (s, 1H, CHO), 8.19 (d, 2H, J = 8.4 
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Hz, aryl H), 7.53–7.39 (m, 4H, aryl H), 7.28–7.18 (m, 2H, aryl H), 6.50 (s, 1H, 3'-
benzofuranyl H), 4.90 (t, 1H, J = 7.2 Hz, CH2CH), 3.32 (dd, 2H, J = 6.9, 17.7 Hz, CH2); 
13C NMR (125 MHz, CDCl3) δ 198.65, 157.20, 147.99, 129.13, 124.55, 124.30, 123.25, 
121.11, 111.32, 104.11, 47.82, 39.16; HRMS (EI+) exact mass calculated for [M]+• 
(C17H13NO4) requires m/z 295.0845, found m/z 295.0853; [α]D= 48.7 (c = 1.0, CHCl3).  
The enantiomeric excess was determined on the alcohol product, which was prepared by a 
NaBH4 reduction and analyzed by SFC using a Chiralpak AS-H column (5% to 25% 
methanol, linear gradient, 100 bar, 35 °C oven, flow = 4.0 mL/min); (S) isomer tr = 6.93 
min, (R) isomer tr = 7.22 min. 
O
O
O O
NO2
 
(3S)-2-(benzofuran-2-yl)-3-formylpropyl 4-nitrobenzoate (Table 9, entry 5). 
Prepared according to the general procedure using (E)-3-formylallyl 4-nitrobenzoate and 
potassium 2-benzofuranyltrifluoroborate salt.  To a plastic vial was added HF (48 wt%, 2.1 
mg, 0.05 mmol) followed by DME (150 µL) and a magnetic stir bar.  The catalyst and acid 
co-catalyst were charged to the vial with the addition of (2S,5S)-2-tert-butyl-5-((1-benzyl-
1H-indol-3-yl)methyl)-3-methylimidazolidin-4-one (7.51 mg, 0.02 mmol) and HCl (4N in 
dioxane, 5.0 µL, 0.02 mmol).  (E)-3-Formylallyl 4-nitrobenzoate (35.3 mg, 0.15 mmol) 
was charged to the DME solution followed by the addition of potassium 2-
benzofuranyltrifluoroborate salt (11.2 mg, 0.05 mmol).  The reaction was stirred at –20 °C 
for 23 hours, quenched with 1M HCl (1.0 mL) and was stirred with chloroform (1.5 mL) 
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for 30 minutes.  The organic layer was extracted with chloroform (2 x 2.0 mL), dried over 
Na2SO4, concentrated in vacuo and purified by chromatography (prep TLC, 40% 
dichloromethane in benzene) to yield the title compound as a yellow oil (13.3 mg, 75% 
yield, 89% ee).  IR (film) 1725, 1526, 1348, 1272, 1120, 1103, 752.6, 718.2 cm-1; 1H NMR 
(300 MHz, CDCl3) δ 9.84 (t, 1H, J = 1.2 Hz, CHO), 8.19 (dd, 4H, J = 2.1, 39.9 Hz, aryl 
H), 7.45 (dd, 2H, J = 7.5, 27.6 Hz, aryl H), 7.28–7.17 (m, 2H, aryl H), 6.57 (s, 1H, 3'-
benzofuranyl H), 4.66 (dd, 2H, J = 6.3, 10.8 Hz, CH2OBz), 4.07–3.98 (m, 1H, CHCH2), 
3.04 (ddd, 2H, J = 1.2, 6.6, 18.0 Hz, CHCH2); 13C NMR (75 MHz, CDCl3) δ 199.20, 
164.53, 156.03, 135.21, 130.98, 128.29, 124.44, 123.85 121.08, 111.25, 104.05, 66.47, 
44.23, 33.31; HRMS (EI+) exact mass calculated for [M]+• (C19H15NO6) requires m/z 
353.0899, found m/z 353.0885; [α]D= +6.29 (c = 1.06, CHCl3).  The enantiomeric excess 
was determined on the alcohol product, which was prepared by a NaBH4 reduction and 
analyzed by SFC using a Chiralpak AD-H column (30% to 50% methanol, linear gradient, 
100 bar, 35 °C oven, flow = 4.0 mL/min); (S) isomer tr = 5.78 min, (R) isomer tr = 6.34 
min. 
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Experimental 
Evaporation of a carbon disulfide solution of the compound yielded a yellow oil.  
Upon standing at room temperature for a number of hours, the oil crystallized into 
colorless bundles of intergrown plates.  A fragment approximately 0.03 mm x 0.08 mm x 
0.25 mm in size was cut from one of the plates, mounted on a glass fiber with silicone 
grease and transferred to a Nonius KappaCCD diffractometer equipped with an MSC X-
stream cryosystem and Mo Kα radiation (λ = 0.71073 Å).  Fourteen hundred and forty 
frames of data were collected at 200(2) K with an ω oscillation range of 0.5°/frame, and 
an exposure time of 60 s/deg.55  A total of 7927 reflections (θmax = 22.46°) were indexed, 
integrated and corrected for Lorentz and polarization effects using DENZO-SMN and 
SCALEPACK.56  The crystal did not exhibit any usable data beyond that θmax value.  
Therefore, a standard 0.76961 Å (θmax = 27.5°) data set was not warranted or pursued.  
Gaussian and ψ-scan absorption corrected data sets were also examined but did not lead 
to improved refinement results and were therefore not pursued further as well.  Data 
reduction yielded 2296 unique reflections (Rint = 0.066) of which 1735 had I > 2σ(I). 
Postrefinement of the unit cell parameters gave a = 5.8677(3) Å, b = 7.3771(5) Å, c = 
20.8583(14) Å, α = 90°, β = 97.998(4)°, γ = 90°, and V = 894.1(1) Å3.  Axial 
photographs and systematic absences were consistent with the compound having 
crystallized in one of two possible monoclinic space groups, i.e., P21 or P21/m.  The 
observed mean | E2-1| value was 0.948 (versus the expectation values of 0.968 and 0.736 
                                                
55. COLLECT.; Nonius BV: Delft, The Netherlands, 1998. 
56. Otwinowski, Z.; Minor, W. In Methods in Enzymology; Carter, C. W., Sweet, R. M., Eds.; MacMomolecular 
Crystallography, Part A; Academic Press: New York, 1997; pp 307–326. 
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for centric and noncentric data, respectively).  Nevertheless, the chiral space group P21 
(No. 4) was selected since the compound was indicated to be optically pure. 
The structure was solved by direct methods and refined by full-matrix least-
squares on F2 using SHELXTL.57  The asymmetric unit was found to contain only a single 
molecule of  (3R)-4-bromobenzoic acid-3-(5-methoxybenzofuran-2-yl)butyl ester.  All of 
the nonhydrogen atoms were refined with anisotropic displacement coefficients.  The 
hydrogen atoms were assigned isotropic displacement coefficients U(H) = 1.2U(C) or 
1.5U(Cmethyl), and their coordinates were allowed to ride on their respective carbons.  The 
sample was also found to be twinned with the volume fractions of the twin components 
being 0.9774(6) and 0.0226(6).  Convergence of this single molecule model gave wR(F2) 
= 0.1141 for 2296 unique reflections of which 1735 had I > 2σ(I), 227 parameters and 
199 restraints.  This model, however, gave atoms exhibiting large thermal vibrations, and 
was therefore abandoned in favor of a two-site whole molecule disorder model.  Initial 
occupancy refinement tests yielded site occupancy factors of 0.45(4) and 0.55(4) for the 
atoms of the two sites indicating that each site was half-occupied within the errors of the 
experiment.  A whole molecule disorder model consisting of two exactly half-occupied 
molecules was therefore selected.  Distance, similarity and common plane restraints were 
employed due to the close proximity of the two half molecules.  The weighting scheme 
employed was w = 1/[σ2(Fo2) + 0.1541P] where P = (Fo2 + 2Fc2)/3. The refinement 
converged to R(F) = 0.0483, wR(F2) = 0.0910, and S = 1.224 for 1735 reflections with I > 
2σ(I), and R(F) = 0.0741, wR(F2) = 0.1017, and S = 1.142 for 2296 unique reflections, 
451 parameters and 724 restraints.  The maximum |Δ/σ| in the final cycle of least-squares 
                                                
57. Sheldrick, G. M. SHELXTL, version 5.04; Siemens Analytical X-ray Instruments, Inc.: Madison, WI, 1996. 
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was 0.001, and the residual peaks on the final difference-Fourier map ranged from –0.256 
to 0.354 eÅ-3.  The R-factor ratio between the wR(F2) values for the single molecule 
model and the whole molecule disorder model is R = 0.1141/0.1017 = 1.12 while 
R224,2069,0.005 = 1.07, i.e., R > R224,2069,0.005.58  Hence, the notion that the model without whole 
molecule disorder might be preferable is convincingly rejected at the 0.005 level.  
Scattering factors were taken from the International Tables for Crystallography, Volume 
C.59 
The Flack parameter refined to 0.04(2) [vs. the expectation values of 0 for the 
correct hand and 1 for the wrong hand] indicating that the coordinates below are for the 
correct hand of the molecule and that the absolute configuration at the chiral carbon is 
unequivocally R (IUPAC Numbering: Wanted = (3R), Found = (3R);  Crystallographic 
Atom Numbering: Wanted = (10R/10'R), Found = (10R/10'R)).60  Due to the complexity 
of the molecule, the IUPAC butyl C-3 atom is given the crystallographic label C-10 in the 
atoms list below.  (The C-10' atom listed below corresponds to the chiral atom in the 
second molecule of the two-site whole molecule disorder model employed.)  
For comparison, a refinement of the inverted molecule having the wrong absolute 
structure, i.e., (3S), gave R(F) = 0.0696, wR(F2) = 0.1670, and S = 1.129 for 1735 
reflections with I > 2σ(I), and R(F) = 0.0949, wR(F2) = 0.1858, and S = 1.052 for 2296 
unique reflections, 451 parameters, and 724 restraints for the whole molecule disorder 
model.  The Flack parameter based on the wrong absolute structure was 0.95(3).  Based 
                                                
58.  Hamilton, W. C. Acta Crystallogr. 1965, 18, 502. 
59. Maslen, E. N.; Fox, A. G.; O’Keefe, M. A. International Tables for Crystallography: Mathematical, Physical and 
Chemical Tables; Wilson, A. J. C., Ed.; Kluwer: Dordrecht, The Netherlands, 1992; Vol. C, pp 476–516. 
60. Flack, H. D. Acta Crystallogr. Sect. A 1983, 39, 876. 
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on these wR(F2) and Flack values, the (3S) isomer is soundly rejected.  
Table 1.Crystal data 
C20H19BrO4 Z = 2 
Mr = 403.26 Dx = 1.498 Mg m-3 
Monoclinic, P21 (No. 4) Mo Kα radiation 
a = 5.8677 (3) Å Cell parameters from 7927 reflections 
b = 7.3771 (5) Å θ = 1.97–22.46° 
c = 20.8583 (14) Å µ = 2.32 mm-1 
β = 97.998 (4)° T = 200 (2) K 
V = 894.1 (1) Å3 Plate, Colorless 
 
Table 2. Data collection 
Nonius KappaCCD diffractomer 1735 reflections with I > 2σ(I) 
ω scans; 1440 0.5° rotations Rint = 0.066 
Absorption correction: none θmax = 22.46° 
 h = -6 → 6 
7927 measured reflections k = -7 → 7 
2296 independent reflections l = -22 → 22 
 
Table 3. Refinement 
Refinement on F2 H atoms constrained to parent site 
R[F2 > 2σ(F2)] = 0.0483  (obs data) 2296 unique reflections  
wR(F2) = 0.0910  (obs data) 451 parameters 
S = 1.224  (obs data) 724 restraints 
R[F2 > 2σ(F2)] = 0.0741  (uniq data) |Δ/σ|max = 0.001 
wR(F2) = 0.1017  (uniq data) Δρmax = 0.354 e Å-1 
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S = 1.142  (uniq data) Δρmin = -0.256 e Å-1 
Flack parameter: 0.038 (15) Extinction correction: none 
Absolute structure60 Calculated weights w = 1/[σ2(Fo2) + 0.1541P] 
where P = (Fo2 + 2Fc2)/3 
 
Table 4. Atomic site parameters for dwcm003f 
 x y z U 
Br1 -0.1992 (9) 0.8493 0.0767 (3) 0.0563 (13) 
O1 0.5174 (14) 0.2757 (12) 0.3126 (5) 0.039 (2) 
C2 0.7373 (17) 0.3442 (11) 0.3350 (5) 0.043 (3) 
C3 0.8475 (15) 0.3863 (12) 0.2851 (5) 0.041 (3) 
H3 0.9986 0.4350 0.2882 0.049 
C3A 0.7002 (15) 0.3461 (10) 0.2259 (5) 0.032 (3) 
C4 0.7143 (17) 0.3591 (12) 0.1597 (5) 0.033 (3) 
H4 0.8492 0.4047 0.1449 0.039 
C5 0.5301 (18) 0.3048 (12) 0.1170 (5) 0.039 (3) 
C6 0.3296 (17) 0.2371 (13) 0.1375 (5) 0.033 (3) 
H6 0.2042 0.2003 0.1064 0.039 
C7 0.3131 (16) 0.2233 (14) 0.2031 (6) 0.035 (3) 
H7 0.1780 0.1776 0.2178 0.042 
C7A 0.4998 (15) 0.2785 (11) 0.2463 (5) 0.034 (2) 
O8 0.5136 (20) 0.3079 (14) 0.0504 (5) 0.041 (3) 
C9 0.7208 (24) 0.3394 (23) 0.0232 (6) 0.049 (4) 
H9A 0.6869 0.3385 -0.0241 0.074 
H9B 0.8326 0.2439 0.0375 0.074 
H9C 0.7850 0.4575 0.0378 0.074 
C10 0.7945 (20) 0.3537 (14) 0.4060 (5) 0.043 (3) 
H10 0.9547 0.4025 0.4156 0.051 
C11 0.7942 (32) 0.1714 (18) 0.4365 (6) 0.050 (4) 
H11A 0.8329 0.1834 0.4836 0.075 
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H11B 0.9083 0.0940 0.4199 0.075 
H11C 0.6412 0.1169 0.4263 0.075 
C12 0.6356 (26) 0.4817 (19) 0.4395 (6) 0.046 (4) 
H12A 0.4738 0.4422 0.4279 0.055 
H12B 0.6757 0.4709 0.4870 0.055 
C13 0.6563 (22) 0.6770 (18) 0.4202 (6) 0.041 (4) 
H13A 0.5965 0.7557 0.4526 0.049 
H13B 0.8206 0.7072 0.4200 0.049 
O14 0.5282 (18) 0.7132 (15) 0.3560 (5) 0.046 (3) 
C15 0.3100 (19) 0.7738 (12) 0.3535 (5) 0.041 (3) 
O16 0.2201 (23) 0.8108 (20) 0.4005 (5) 0.054 (4) 
C17 0.1954 (17) 0.7883 (11) 0.2855 (5) 0.032 (3) 
C18 -0.0240 (18) 0.8709 (13) 0.2751 (5) 0.040 (3) 
H18 -0.0920 0.9144 0.3109 0.048 
C19 -0.1399 (16) 0.8885 (11) 0.2130 (5) 0.039 (3) 
H19 -0.2874 0.9440 0.2059 0.047 
C20 -0.0392 (15) 0.8246 (7) 0.1614 (4) 0.041 (3) 
C21 0.1767 (15) 0.7427 (11) 0.1705 (5) 0.033 (3) 
H21 0.2436 0.6994 0.1345 0.040 
C22 0.2923 (17) 0.7252 (13) 0.2325 (5) 0.038 (3) 
H22 0.4397 0.6695 0.2391 0.045 
Br1' -0.1809 (10) 0.9272 (11) 0.0755 (3) 0.0726 (15) 
O1' 0.5261 (14) 0.3606 (12) 0.3134 (5) 0.042 (3) 
C2' 0.7441 (16) 0.4309 (11) 0.3363 (5) 0.041 (3) 
C3' 0.8558 (15) 0.4738 (13) 0.2866 (5) 0.040 (4) 
H3' 1.0062 0.5237 0.2900 0.048 
C3A' 0.7102 (14) 0.4318 (10) 0.2272 (5) 0.039 (3) 
C4' 0.7269 (15) 0.4447 (13) 0.1611 (5) 0.033 (4) 
H4' 0.8618 0.4914 0.1467 0.039 
C5' 0.5443 (17) 0.3885 (12) 0.1181 (5) 0.046 (3) 
C6' 0.3443 (17) 0.3195 (14) 0.1379 (5) 0.041 (5) 
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H6' 0.2205 0.2816 0.1066 0.049 
C7' 0.3253 (17) 0.3058 (14) 0.2037 (6) 0.040 (3) 
H7' 0.1902 0.2590 0.2180 0.047 
C7A' 0.5104 (15) 0.3628 (11) 0.2471 (5) 0.039 (3) 
O8' 0.5322 (19) 0.3919 (15) 0.0515 (5) 0.049 (3) 
C9' 0.7420 (24) 0.4290 (24) 0.0260 (6) 0.046 (4) 
H9A' 0.7126 0.4279 -0.0214 0.069 
H9B' 0.8564 0.3361 0.0410 0.069 
H9C' 0.8004 0.5484 0.0410 0.069 
C10' 0.8007 (20) 0.4419 (14) 0.4073 (5) 0.046 (3) 
H10' 0.9612 0.4898 0.4170 0.055 
C11' 0.7986 (37) 0.2589 (20) 0.4377 (7) 0.074 (6) 
H11D 0.8368 0.2703 0.4848 0.111 
H11E 0.9125 0.1811 0.4210 0.111 
H11F 0.6453 0.2051 0.4272 0.111 
C12' 0.6431 (24) 0.5697 (19) 0.4409 (6) 0.047 (4) 
H12C 0.4815 0.5293 0.4299 0.056 
H12D 0.6849 0.5593 0.4884 0.056 
C13' 0.6596 (23) 0.7647 (20) 0.4219 (6) 0.050 (4) 
H13C 0.5968 0.8420 0.4540 0.060 
H13D 0.8234 0.7973 0.4222 0.060 
O14' 0.5337 (19) 0.8008 (14) 0.3575 (5) 0.049 (3) 
C15' 0.3155 (19) 0.8615 (12) 0.3539 (5) 0.050 (3) 
O16' 0.2219 (24) 0.9006 (19) 0.4000 (5) 0.074 (5) 
C17' 0.2047 (18) 0.8735 (11) 0.2853 (5) 0.037 (3) 
C18' -0.0179 (17) 0.9502 (15) 0.2740 (5) 0.041 (3) 
H18' -0.0900 0.9912 0.3093 0.050 
C19' -0.1310 (16) 0.9655 (15) 0.2116 (4) 0.044 (3) 
H19' -0.2807 1.0169 0.2038 0.052 
C20' -0.0239 (15) 0.9052 (11) 0.1605 (5) 0.043 (3) 
C21' 0.1951 (16) 0.8294 (13) 0.1707 (5) 0.041 (3) 
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H21' 0.2662 0.7886 0.1351 0.050 
C22' 0.3081 (16) 0.8140 (13) 0.2331 (5) 0.035 (3) 
H22' 0.4578 0.7624 0.2403 0.042 
 
Table 5. Anisotropic atomic displacement parameters for dwcm003f 
 U11 U22 U33 U12 U13 U23 
Br1 0.0435 (14) 0.087 (4) 0.035 (2) 0.000 (2) -0.0086 (12) 0.006 (2) 
O1 0.038 (4) 0.047 (6) 0.032 (4) -0.016 (4) 0.002 (3) -0.013 (5) 
C2 0.038 (5) 0.053 (8) 0.035 (4) -0.007 (6) -0.008 (4) -0.009 (6) 
C3 0.030 (4) 0.057 (9) 0.033 (4) -0.008 (6) -0.003 (4) -0.015 (8) 
C3A 0.028 (4) 0.034 (6) 0.032 (4) -0.016 (5) -0.001 (4) -0.007 (5) 
C4 0.032 (5) 0.038 (9) 0.026 (5) -0.015 (7) -0.003 (4) -0.005 (7) 
C5 0.034 (5) 0.050 (8) 0.031 (5) -0.016 (5) -0.008 (4) 0.000 (5) 
C6 0.026 (5) 0.033 (10) 0.036 (5) -0.007 (5) -0.003 (4) -0.008 (6) 
C7 0.029 (4) 0.038 (7) 0.037 (4) -0.011 (4) 0.003 (4) -0.006 (5) 
C7A 0.033 (4) 0.038 (6) 0.032 (4) -0.012 (4) 0.004 (3) -0.012 (5) 
O8 0.036 (4) 0.054 (7) 0.029 (4) -0.018 (5) -0.010 (4) -0.003 (5) 
C9 0.042 (6) 0.072 (11) 0.028 (6) -0.024 (7) -0.014 (5) 0.000 (7) 
C10 0.041 (5) 0.051 (8) 0.034 (5) 0.000 (7) -0.002 (4) 0.008 (7) 
C11 0.084 (9) 0.032 (9) 0.033 (7) -0.026 (9) 0.002 (7) -0.010 (7) 
C12 0.047 (6) 0.059 (9) 0.026 (5) 0.003 (6) -0.014 (5) -0.003 (6) 
C13 0.043 (5) 0.052 (9) 0.024 (6) -0.003 (7) -0.008 (5) -0.006 (7) 
O14 0.036 (4) 0.066 (8) 0.033 (4) 0.004 (5) -0.002 (3) 0.008 (5) 
C15 0.036 (5) 0.049 (8) 0.039 (5) -0.005 (6) 0.004 (4) 0.010 (6) 
O16 0.043 (6) 0.087 (11) 0.031 (5) 0.012 (6) 0.005 (5) 0.007 (6) 
C17 0.025 (4) 0.037 (8) 0.033 (4) -0.017 (5) 0.002 (4) 0.001 (5) 
C18 0.033 (4) 0.044 (8) 0.043 (5) -0.009 (6) 0.006 (4) 0.004 (7) 
C19 0.025 (4) 0.044 (8) 0.047 (4) -0.008 (6) 0.000 (4) 0.003 (6) 
C20 0.035 (5) 0.051 (8) 0.034 (5) -0.012 (5) 0.001 (4) 0.015 (6) 
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C21 0.032 (4) 0.040 (8) 0.030 (4) -0.007 (5) 0.011 (4) 0.011 (6) 
C22 0.030 (5) 0.047 (8) 0.035 (5) -0.010 (5) 0.004 (4) 0.008 (6) 
Br1' 0.053 (2) 0.122 (4) 0.040 (2) -0.006 (2) -0.0018 (13) -0.001 (3) 
O1' 0.034 (3) 0.070 (7) 0.025 (3) -0.012 (5) 0.010 (3) -0.014 (6) 
C2' 0.031 (5) 0.060 (9) 0.031 (4) -0.006 (6) 0.004 (4) -0.014 (6) 
C3' 0.033 (5) 0.061 (10) 0.027 (5) -0.006 (6) 0.005 (4) -0.017 (6) 
C3A' 0.027 (4) 0.062 (8) 0.028 (4) -0.016 (5) 0.008 (4) -0.011 (6) 
C4' 0.015 (5) 0.056 (11) 0.028 (5) -0.006 (6) 0.006 (4) -0.006 (7) 
C5' 0.028 (5) 0.083 (9) 0.030 (4) -0.020 (6) 0.012 (4) -0.006 (7) 
C6' 0.024 (5) 0.062 (14) 0.035 (5) -0.011 (6) -0.004 (4) -0.011 (6) 
C7' 0.031 (4) 0.060 (8) 0.031 (4) -0.014 (5) 0.015 (4) -0.013 (5) 
C7A' 0.030 (3) 0.065 (7) 0.025 (3) -0.014 (5) 0.012 (3) -0.011 (5) 
O8' 0.031 (4) 0.085 (9) 0.031 (4) -0.024 (6) 0.007 (3) -0.004 (6) 
C9' 0.045 (6) 0.065 (10) 0.030 (6) -0.028 (7) 0.016 (5) -0.002 (7) 
C10' 0.041 (5) 0.066 (9) 0.030 (5) 0.005 (6) 0.004 (4) -0.005 (6) 
C11' 0.120 (12) 0.060 (11) 0.041 (8) 0.000 (13) 0.007 (10) -0.016 (8) 
C12' 0.040 (6) 0.075 (10) 0.029 (6) 0.001 (8) 0.014 (5) -0.003 (6) 
C13' 0.043 (5) 0.078 (9) 0.028 (6) 0.007 (7) 0.003 (4) 0.000 (7) 
O14' 0.038 (4) 0.080 (9) 0.031 (4) 0.005 (5) 0.006 (3) -0.002 (5) 
C15' 0.035 (4) 0.077 (9) 0.038 (4) 0.004 (7) 0.007 (4) 0.001 (7) 
O16' 0.047 (6) 0.137 (15) 0.038 (5) 0.015 (9) 0.012 (5) -0.014 (9) 
C17' 0.028 (4) 0.052 (7) 0.033 (4) -0.015 (6) 0.007 (3) 0.003 (6) 
C18' 0.034 (5) 0.058 (9) 0.035 (5) -0.005 (6) 0.016 (4) 0.005 (6) 
C19' 0.028 (5) 0.055 (8) 0.047 (5) -0.009 (5) 0.002 (4) 0.009 (6) 
C20' 0.041 (5) 0.054 (7) 0.034 (4) -0.006 (6) 0.002 (4) 0.005 (6) 
C21' 0.042 (4) 0.052 (9) 0.031 (4) -0.011 (5) 0.008 (4) 0.009 (6) 
C22' 0.023 (4) 0.046 (9) 0.037 (4) -0.014 (5) 0.007 (4) 0.005 (5) 
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Table 6.  Geometric parameters (Å, °) for dwcm003f 
Br1—C20 1.890 (7) Br1'—C20' 1.889 (7) 
O1—C7A 1.374 (7) O1'—C7A' 1.374 (7) 
O1—C2 1.404 (7) O1'—C2' 1.401 (7) 
C2—C3 1.337 (8) C2'—C3' 1.340 (8) 
C2—C10 1.473 (8) C2'—C10' 1.474 (8) 
C3—C3A 1.437 (8) C3'—C3A' 1.437 (8) 
C3A—C7A 1.397 (7) C3A'—C7A' 1.393 (7) 
C3A—C4 1.397 (8) C3A'—C4' 1.398 (7) 
C4—C5 1.362 (8) C4'—C5' 1.363 (8) 
C5—O8 1.379 (7) C5'—O8' 1.380 (7) 
C5—C6 1.399 (8) C5'—C6' 1.394 (8) 
C6—C7 1.390 (8) C6'—C7' 1.395 (8) 
C7—C7A 1.379 (8) C7'—C7A' 1.379 (8) 
O8—C9 1.430 (7) O8'—C9' 1.434 (7) 
C10—C11 1.488 (12) C10'—C11' 1.492 (12) 
C10—C12 1.558 (11) C10'—C12' 1.554 (11) 
C12—C13 1.506 (13) C12'—C13' 1.499 (13) 
C13—O14 1.466 (8) C13'—O14' 1.463 (8) 
O14—C15 1.350 (8) O14'—C15' 1.348 (7) 
C15—O16 1.209 (7) C15'—O16' 1.207 (7) 
C15—C17 1.486 (8) C15'—C17' 1.489 (8) 
C17—C22 1.391 (9) C17'—C22' 1.390 (9) 
C17—C18 1.413 (8) C17'—C18' 1.413 (8) 
C18—C19 1.383 (8) C18'—C19' 1.381 (8) 
C19—C20 1.381 (8) C19'—C20' 1.382 (8) 
C20—C21 1.392 (8) C20'—C21' 1.391 (8) 
C21—C22 1.380 (9) C21'—C22' 1.381 (9) 
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C7A—O1—C2 105.5 (5) C7A'—O1'—C2' 105.6 (5) 
C3—C2—O1 110.3 (5) C3'—C2'—O1' 110.2 (5) 
C3—C2—C10 134.8 (7) C3'—C2'—C10' 134.3 (6) 
O1—C2—C10 114.9 (6) O1'—C2'—C10' 115.5 (6) 
C2—C3—C3A 108.8 (5) C2'—C3'—C3A' 108.7 (5) 
C7A—C3A—C4 119.6 (6) C7A'—C3A'—C4' 119.7 (5) 
C7A—C3A—C3 104.1 (5) C7A'—C3A'—C3' 104.3 (5) 
C4—C3A—C3 136.3 (6) C4'—C3A'—C3' 136.0 (6) 
C5—C4—C3A 118.4 (6) C5'—C4'—C3A' 118.1 (6) 
C4—C5—O8 126.3 (6) C4'—C5'—O8' 125.7 (6) 
C4—C5—C6 122.0 (6) C4'—C5'—C6' 122.2 (6) 
O8—C5—C6 111.7 (6) O8'—C5'—C6' 112.2 (6) 
C7—C6—C5 120.3 (6) C5'—C6'—C7' 120.3 (6) 
C7A—C7—C6 117.6 (6) C7A'—C7'—C6' 117.3 (6) 
O1—C7A—C7 126.5 (6) O1'—C7A'—C7' 126.4 (6) 
O1—C7A—C3A 111.3 (5) O1'—C7A'—C3A' 111.3 (5) 
C7—C7A—C3A 122.2 (6) C7'—C7A'—C3A' 122.3 (6) 
C5—O8—C9 117.2 (6) C5'—O8'—C9' 116.7 (6) 
C2—C10—C11 111.9 (6) C2'—C10'—C11' 111.3 (7) 
C2—C10—C12 114.3 (6) C2'—C10'—C12' 114.9 (6) 
C11—C10—C12 108.6 (8) C11'—C10'—C12' 108.5 (8) 
C13—C12—C10 112.7 (8) C13'—C12'—C10' 113.5 (8) 
O14—C13—C12 111.6 (8) O14'—C13'—C12' 112.0 (9) 
C15—O14—C13 117.3 (7) C15'—O14'—C13' 117.8 (7) 
O16—C15—O14 124.2 (7) O16'—C15'—O14' 124.6 (7) 
O16—C15—C17 124.6 (7) O16'—C15'—C17' 124.4 (7) 
O14—C15—C17 111.2 (6) O14'—C15'—C17' 111.0 (6) 
C22—C17—C18 119.1 (6) C22'—C17'—C18' 119.3 (6) 
C22—C17—C15 123.5 (6) C22'—C17'—C15' 123.7 (6) 
C18—C17—C15 117.4 (6) C18'—C17'—C15' 117.1 (6) 
C19—C18—C17 120.2 (6) C19'—C18'—C17' 120.2 (6) 
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C20—C19—C18 119.4 (6) C18'—C19'—C20' 119.3 (6) 
C19—C20—C21 121.4 (6) C19'—C20'—C21' 121.5 (6) 
C19—C20—Br1 119.0 (5) C19'—C20'—Br1' 118.7 (5) 
C21—C20—Br1 119.6 (6) C21'—C20'—Br1' 119.8 (6) 
C22—C21—C20 119.2 (6) C22'—C21'—C20' 119.3 (7) 
C21—C22—C17 120.7 (6) C21'—C22'—C17' 120.6 (6) 
 
Computer programs 
Data collection: COLLECT.55  Cell refinement: DENZO-SMN.55  Data reduction: 
DENZO-SMN.55  Program(s) used to solve structure: Siemens SHELXTL.57  Program(s) 
used to refine structure: Siemens SHELXTL.57  Molecular graphics: Siemens 
SHELXTL.57  Software used to prepare material for publication: Siemens SHELXTL,57 
publCIF,61 printCIF for Word.62 
 
 
                                                
61. Westrip, S. P. publCIF, version 1.0c; International Union of Crystallography, Abbey Square: Chester, U. K., 
2006.  
62. prinfCIF for word; International Union of Crystallography, Abbey Square: Chester, U. K., 2005. 
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 C h a p t e r  4  
Tota l Synthesis of (+)-Frondosin B 
 
I. Introduction 
Members of the frondosins, part of the sesquiterpene class of natural products 
(Figure 1) were first isolated by Freyer and co-workers from the marine sponge Dysidea 
frondosa off the waters of Pohnpei in the Federated States of Micronesia.1  Significantly, 
each of the frondosins exhibit inhibition of interleukin-8 (IL-8) receptors and protein kinase 
C (PKC) with IC50 values in the low micromolar range as found in preliminary in vitro 
biological investigations.1b,2  As pro-inflammatory cytokines (such as IL-8) act as a 
chemoattractant to promote the accumulation and activation of neutrophils, the resulting 
increase of monocyte superoxide anion production has been implicated in autoimmune 
disorders such as psoriasis, rheumatoid arthritis, osteoarthritis and many lung diseases.3  It 
is also known that this neutrophil-activating peptide plays an important role in tumor   
                                                
1. (a) Patil, A. D.; Freyer, A. J.; Killmer, L.; Offen, P.; Carte, B.; Jurewicz, A. J.; Johnson, R. K. Tetrahedron, 1997, 
53, 5047. (b) For an independent claim for the discovery of frondosins A and D, see: Hallock, Y. F.; Cardellina, 
J. H.; Boyd, M. R. Nat. Prod. Lett. 1998, 11, 153. 
2. Additionally, frondosins A and D were shown to demonstrate moderate HIV-inhibitory activity: Lane, B. R.; 
Lore, K.; Bock, P. J.; Andersson, J.; Coffey, M. J.; Strieter, R. M.; Markovitz, D. M. J. Virol. 2001, 75, 8195. 
3. (a) Seitz, M.; Dewald, B.; Gerber, N.; Baggiolini, M. J. Clin. Invest. 1991, 87, 463. (b) Miller, E. J.; Cohen, A. B.; 
Nagao, D.; Griffith, R. J.; Maunder, R. J.; Martin, T. R.; Weiner-Kronish, J. P. Sticherling, M.; Christophers, E.; 
Matthay, M. Am. Rev. Respir. Dis. 1992, 146, 247. 
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Figure 1.  The frondosin family of marine natural products 
      and their biological activity (IC50 = µM) 
progression and metastasis in several human cancers.4  Thus, IL-8 receptor antagonists 
represent a promising lead compound for the development of novel anti-inflammatory 
agents and cancer therapies. 
The frondosins possess a novel sesquiterpenoid skeleton that bear an incidental 
resemblance to one another with a unifying structural feature that consists of a central 
bicyclo[5.4.0] ring system appended to variously permuted hydroquinone moieties.5  Their 
relative structural features were determined by extensive NMR experiments with 
supportive IR and mass spectral data.  One major difference in this family of compounds 
was found in the optical rotations of the isolated species, which revealed that all the 
                                                
4. (a) Brat, D. J.; Bellail, A. C.; Van Meir, E. G. Neuro-Oncology 2005, 7, 122. (b) Zhu, Y. M.; Webster, S. J.; Flower, 
D.; Woll, P. J. Br. J. Cancer 2004, 91, 1970. (c) Yuan, A.; Chen, J. J.; Yao, P. L.; Yang, P. C. Front Biosci. 2005, 
853. 
5. For a review of marine sesquiterpenes and quinones, see: Capon, R. J. In Studies in Natural Products Chemistry; 
Rahman, A,U., Ed.; Elsevier: New York, 1995; Vol. 15, p 289. 
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frondosins (except for B) exist in both enantiomeric forms in nature.  Notably, the relative 
stereochemistries of the frondosins were established primarily through NMR studies, 
though the absolute configurations were not initially assigned. 
 
II. Previous Synthetic Efforts towards Frondosin B 
The frondosins have inspired a number of research groups to pursue their total 
syntheses given their interesting chemical architecture and pharmacological activity.  To 
date, only frondosin B has been synthetically made, whilst the syntheses of frondosins A6 
and C7 remain works in progress. 
The first total synthesis of frondosin B was reported by Danishefsky and co-
workers.8  In this initial racemic synthesis, a number of strategies were implemented from 
which there came two successful programs.  Both retrosynthetic plans were convergent on 
a common tricyclic cycloheptanone intermediate (Figure 2(b)) that then diverged in regards 
to installation of the final cyclohexene ring (ring A, Figure 2(a)).  Construction of tricyclic 
intermediate 1 occurred via initial formation of a known acetyl benzofuran9 and subsequent 
elaboration by a Wittig four-carbon homologation and an intramolecular Friedel-Crafts 
acylation to form the central B-ring (Figure 2 (a)).  Formation of the final A-ring occurred 
by functionalization of the ketone precursor towards either a homoprenyl group for an acid- 
                                                
6. Hu, Y.; Trost, B. M. Abstr. Pap. Am. Chem. Soc. 2006, 231, 2.  
7. (a) Martinez, I.; Alford, P. E.; Ovaska, T. V. Org. Lett. 2005, 7, 1133. (b) Li, X.; Kyne, R. E.; Ovaska, T. V. Org. 
Lett. 2006, 8, 5153. 
8. Inoue, M.; Frontier, A. J.; Danishefsky, S. J. Angew. Chem., Int. Ed. 2000, 39, 761.  
9. Landelle, H.; Godard, A. M.; Laduree, D.; Chenu, E.; Robba, M. Chem. Pharm. Bull. 1991, 39, 3057. 
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Figure 2. Danishefsky’s strategies for the (a) racemic and (c) enantiospecific 
               synthesis of frondosin B via (b) a common synthetic intermediate 
induced cyclization or into a diene to participate in a Diels-Alder reaction.  Having 
completed two full racemic syntheses of frondosin B, efforts were then shifted towards the 
enantiospecific preparation of the natural product. 
In their third total synthesis, Danishefsky and co-workers aimed to determine the 
absolute configuration of the naturally occurring enantiomer of frondosin B by correlation 
to their enantiomerically-defined synthetic product.10  On the basis of their previous 
experiences, a modified strategy was adopted to include the construction of the benzofuran 
from a chiral precursor (Figure 2(c)).  Central to this new approach was the introduction of 
the C-8 methyl stereocenter of known absolute configuration by way of a Sharpless 
asymmetric epoxidation, which would ultimately converge to the same tricyclic 
intermediate (1) from the racemic route (Figure 2(b)). 
As shown in Scheme 1, the synthesis of (+)-frondosin B commenced with the 
epoxidation of a known allylic alcohol (2)11 to provide the corresponding (S,S)-epoxy 
alcohol product 3.  Regiospecific opening of the epoxide via C-methylation serves as a 
method for introducing the C-8 methyl stereocenter with R configuration in product 4.  
                                                
10. Inoue, M.; Carson, M. W.; Frontier, A. J.; Danishefsky, S. J. J. Am. Chem. Soc. 2001, 123, 1878. 
11. Patterson, J. W. Synthesis 1985, 337. 
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Scheme 1. Danishefsky’s construction of the C-8 methyl stereocenter and the benzofuran moiety 
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Oxidative cleavage of diol 4 provides an aldehyde intermediate, which upon treatment with 
Gilbert reagent, smoothly leads to formation of terminal alkyne 5.  Subsequent construction 
of the benzofuran framework was accomplished in a one-pot procedure via a palladium-
catalyzed Sonogashira coupling reaction of alkyne 5 and 2-iodo-4-methoxyphenol (6) with 
successive heteroannulation.  Saponification of the resulting ester yields carboxylic acid 7, 
which is activated as an acyl chloride to then participate in an intramolecular Friedel-Crafts 
acylation to form the central cycloheptenone ring.  At this point, this asymmetric synthesis 
then intersects the previous racemic route towards frondosin B. 
Completion of the synthesis then proceeded by installation of the final ring of 
frondosin B via a Diels-Alder cyclization (Scheme 2).  To prepare the diene component for 
the Diels-Alder reaction, the cycloheptenone intermediate 1 was subjected first to a 
Mukaiyama reaction with acetone and then a dehydration-methylenation sequence.  
Reaction with nitroethylene afforded the A-ring in a 5:1 mixture of nitro stereoisomers  
(10) at C-3.  Final unmasking of this cycloadduct (by denitration and O-demethylation)  
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Scheme 2. Danishefsky’s synthesis and structural assignment of (+)-frondosin B. 
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produced a product that unambiguously matched all spectroscopic data for the reported 
natural product.  Thus, in this 17-linear-step natural product synthesis of frondosin B, 
Danishefsky and co-workers established the absolute configuration of the secondary methyl 
stereocenter at C-8 to be of R configuration. 12 
Closely following Danishefsky’s report, Trauner and co-workers disclosed an 
asymmetric total synthesis of frondosin B.13  Their synthetic strategy (Figure 3) utilizes a 
similar approach for the construction of the benzofuran core but uniquely features a 
palladium-mediated coupling reaction to forge the central cycloheptadiene ring.  
Installation of the key C-8 stereocenter is again established via a Sharpless epoxidation  
                                                
12. Beginning from 2-propyn-1-ol, Danshefsky’s synthesis was 17 linear steps with an overall yield of 0.7% 
13. Hughes, C. C.; Trauner, D. Angew. Chem., Int. Ed. 2002, 41, 1569.  
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Figure 3. Trauner’s strategy for the asymmetric synthesis of frondosin B 
reaction with the intention of generating the R-configured natural product. 
As shown in Scheme 3, Trauner’s synthesis begins with the establishment of the 
asymmetric stereocenter by way of a Sharpless epoxidation and subsequent epoxide-
opening reaction with a methylating reagent to yield 13.  Following a literature procedure, 
the known R-configured alkyne 14 was obtained in a straightforward manner via periodate 
Scheme 3. Trauner’s installation of the C-8 methyl stereocenter and key intermediate 
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cleavage of diol 13 and a Corey-Fuchs reaction with subsequent dehalogenation by a strong 
base.14  Next, the benzofuran core was assembled in a three-step sequence that commenced 
with: (1) a Sonogashira coupling reaction, (2) followed by an acidic deprotection of the 
primary alcohol (to yield 16), and (3) saponification of the phenolic acetate to initiate the 
Acardi-Cacchi cyclization reaction.15  Conversion of the primary alcohol to iodide 17 sets 
the scene for an alkylation event with dimethoxylithiocyclohexadiene (18) to install the A-
ring of frondosin B. 
The key step of the synthesis was achieved via conversion of dione 19 to an enol 
triflate, which undergoes oxidative insertion with Pd(0), resulting in an intramolecular  
Scheme 4. Trauner’s key cyclization step and completion of the natural product 
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14. Murai, A.; Oka, T. Tetrahedron 1998, 54, 1. 
15. Acardi, A.; Cacchi, S.; Del Rosario, M.; Fabrizi, G.; Martinelli, F. J. Org. Chem 1996, 61, 9280. 
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Heck reaction to forge the C10-C11 bond (20, Scheme 4).  The synthesis was then 
concluded with a known dialkylation procedure16 to install the gem-dimethyl group in 21, 
followed by Danishefsky’s deprotection protocol to yield frondosin B.17  However, it was 
found that this synthetic material did not match the optical rotation of Danishefsky’s R-
configured product nor that of the naturally occurring product. 
To reconcile this discrepancy, Trauner put forth a mechanistic supposition that 
Danishefsky and co-workers had unintentionally inverted the C-8 stereocenter and had 
instead synthesized the (S)-enantiomer of frondosin B.18  It was proposed that the C-8 
methyl stereocenter in Danishefsky’s starting chiral building block (24) was unintentionally 
carried through the synthesis as the S-isomer because the nucleophilic opening of epoxy 
alcohol 22 proceeded by an unnoticed double inversion (eq. 1).19  Though Trauner and co-
workers employed an analogous methodology for setting their C-8 methyl stereocenter, 
22
(1)
HO HO
OH
Me
S
O
AlMe3
O
O
OAl
Me
Me
OMe
O OMe O OMe
23 24
they assert that their epoxy alcohol substrate 11 lacks the ester functionality that was 
responsible for the neighboring group participation observed in the Danishefsky case 
(Scheme 3).  On this basis, the original stereochemical assignment of naturally occurring 
frondosin B was reassigned by Trauner to have an absolute configuration of S. 
                                                
16. Reetz, M. T.; Westermann, J.; Steinbach, R. J. Chem. Soc. Chem. Commun. 1981, 237. 
17. Beginning from propane-1,3-diol, Trauner’s synthesis was 20 linear steps with an overall yield of 7.3% 
18. Hughes, C. C.; Trauner, D. Tetrahedron 2004, 60, 9675. 
19. This type of neighboring group participation by an ester is not unprecedented, see: Suzuki, T.; Saimoto, H.; 
Tomioka, H.; Oshima, K.; Nozaki, H. Tetrahedron Lett. 1982, 23, 3597. 
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The most recent synthesis of frondosin B has been executed by Flynn and co-
workers in 2004.20  In contrast to the other approaches to frondosin B, the primary focus in 
this strategy was to enable rapid and divergent access to analogs in order to aid SAR 
studies.  To this end, a one-pot three-component coupling reaction was devised to build the 
racemic core of frondosin B in six steps from commercially available starting materials (eq. 
2).  In their key step, aryl bromide 26 is first subjected to deprotonation and then a 
25
Pd(PPh3)2Cl2, 65 °C; 
DMSO, 80 °C
MeMgBr, THF, 0 °C;
MeO Br
OH
Me
O
Br
O Me
MeO
O
MeO
Me
Me
O
MeO
OO
Me
12% yield
11% yield
7% yield
48% yield
O Me
MeO
O
(2)
2726
28
3130
29
palladium-mediated coupling with 3-methylbutenyne (27) to yield an intermediary o-
alkylnylphenolate.  Successive addition of allyl-cyclohexadione 25 at elevated 
temperatures then instigates a heteroannulation and coupling reaction to give the 
benzofuran product 31 in 48% yield.  Impressively, the desired compound is isolated as the 
major product (from a complex reaction mixture comprised of 28, 29, 30, and 31) in a key 
step that simultaneously forges four new bonds.  The tetracyclic core is then completed via 
ring-closing metathesis (RCM) to form 32 (Scheme 5).  Upon performing a selective 
hydrogenation of the central cycloheptatriene ring, the synthesis then converges onto 
Trauner’s penultimate intermediate (±)-21 in his synthesis of frondosin B.  After a  
                                                
20. Kerr, D. J.; Willis, A. C.; Flynn, B. L. Org. Lett. 2004, 6, 457.  
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Scheme 5. Flynn’s completed synthesis of (±)-frondosin B 
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straightforward dialkylation and deprotection sequence, Flynn and co-workers complete an 
expedient synthesis of the racemic natural product. 
 
III. Synthesis of (+)-Frondosin B 
We were inspired to undertake an asymmetric synthesis of frondosin B on the basis 
of its intriguing structural features and notable biological activity.  Additionally, we sought 
to unambiguously determine the absolute configuration of the C-8 methyl stereocenter and 
thereby resolve the current dissension in the literature. 
Our synthetic strategy focused on addressing the key structural elements of 
frondosin B, namely the 2,3-disubstitued benzofuran moiety fused to a norsesquiterpenoid 
framework and the C-8 methyl stereocenter (Figure 4).  Though frondosin B features only 
a single stereocenter, it inarguably remains a synthetic challenge in light of the previous 
strategies that used indirect means to introduce the enantio-defined methyl stereocenter.  
Thus, we envisioned our key disconnect to be across the C8-C9 bond, which will be forged  
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Figure 4. MacMillan’s retrosynthesis of frondosin B. 
by an enantioselective organocatalytic conjugate addition reaction (vide Chapter 3) that will 
concomitantly install the C-8 methyl stereocenter and establish the benzofuran structure.  
Like our predecessors, the other main retrosynthetic disconnection will be cleavage of the 
C10-C11 bond, which we hoped to establish via a metal-mediated π-allyl cyclization or 
alternatively an SN2′ reaction.  The final A-ring will then be incorporated through an 
alkylation event with a cyclohexene ring already functionalized with the geminal methyl 
group in position.  In this manner, a concise and convergent approach was designed to 
synthesize frondosin B. 
Our synthetic endeavors commenced by the initial establishment of all requisite 
carbons in the natural product.  As shown in Scheme 6, we began with the synthesis of the 
potassium trifluoroborate salt of 5-methoxybenzofuran (34), which was prepared from the 
commercially available boronic acid 33 using a modified Molander procedure.21  The 
enantioselective organocatalytic conjugate addition was then carried out with 34 and excess 
crotonaldehyde in the presence of a chiral secondary amine catalyst 35 to efficiently install 
the C-8 stereocenter (36, 90% yield, 93% ee).  Importantly, we were able to directly access 
the R-configured methyl stereocenter in a catalyst-controlled fashion (such that the opposite 
                                                
21. (a) Molander, G. A.; Biolatto, B. J. Org. Chem. 2003, 68, 4302. (b) Molander, G. A.; Petrillo, D. E.; Landzberg, 
N. R.; Rohanna, J. C.; Biolatto, B. Synlett 2005, 1763.  
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Scheme 6. Establishing the carbon framework of frondosin B 
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catalyst enantiomer provides the S-configured product).22  Elaboration of the resultant 
aldehyde functionality was achieved by a Shapiro reaction with known hydrazone 37 (Ar = 
2, 4, 6-triisopropylbenzene)23 to afford allylic alcohol 38 as 1:1 mixture of diastereomers at 
C-6.24  Thus, the carbon framework of frondosin B was concisely established in three linear 
steps. 
With the carbon skeleton and C-8 stereocenter of frondosin B in place, the 
completion of its total synthesis required an intramolecular cyclization to construct the 
central B-ring.  As the Shapiro reaction product 38 could be readily functionalized to an 
allylic acetate, we felt that subsequent formation of a metal π-allyl species might be 
susceptible to attack by the electron-rich benzofuran moiety (Figure 5).  We anticipated 
this unprecedented intramolecular cyclization might take place at the less hindered site C-
11 (reaction a, Figure 5) to generate the desired seven-membered ring adduct 39.  We felt  
                                                
22. The absolute configuration of intermediate 36 was unambiguously assigned as R on the basis of an X-ray 
crystal structure (vide Chapter 3) when employing (S,S)-catalyst 35. 
23. Pazos, Y.; Iglesias, B.; de Lera, A. L. J. Org. Chem. 2001, 66, 8483. 
24. (a) Shapiro, R. H.; Lipton, M. F.; Kolonko, K. J.; Buswell, R. L.; Capuano, L. A. Tetrahedron Lett. 1975, 1811. (b) 
Shapiro, R. H. Org. React. 1976, 23, 405. 
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Figure 5. Potential regioselectivity issue in the proposed intramolecular cyclization 
that the alternative, formation of a five-membered ring product (40) arising from addition 
to the C-6 position (reaction b, Figure 5), would be sufficiently disfavored due to the 
proximity of the adjacent gem-dimethyl substituents at C-4.  Additionally, we hoped that 
the resultant C5-C6 olefin in 39 from the cyclization would migrate into the more 
thermodynamically favored position (between C5-C11) as part of this single-pot operation.  
Along with Dr. Maud Reiter in our group, we sought to investigate this critical 
cyclization step.  Our initial foray into π-allyl chemistry relied on palladium-mediated 
methods due to the vast number of successful examples that are known in the literature.25,26  
Experiments were set up with a cyclization precursor prepared via functionalization of 
allylic alcohol 38 to an acetate and also a methyl carbonate—both functionalities are 
                                                
25. (a) Trost, B. M.; Crawley, M. L. Chem. Rev. 2003, 103, 2921. (b) Trost, B. M.; Van Vranken, D. L. Chem. Rev. 
1996, 96, 395. (c) Trost, B. M.; Machacek, M. R.; Aponick, A. Acc. Chem. Res. 2006, 39, 747. (d) Trost, B. M. 
Chem. Pharm. Bull. 2002, 50, 1. (e) Trost, B. M. Adv. Chem. Ser. 1992, 463.  
26. (a) Tsuji, J. Palladium Reagents and Catalysts: New Perspectives for the 21st Century, 2nd ed.; Wiley & Sons: West 
Sussex, 2004; Chapter 4. (b) Hegedus, L. S. Transition Metals in the Synthesis of Complex Organic Molecules, 2nd ed.; 
University Science Books: Sausalito, CA, 1999; Chapter 9. 
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known to react with palladium species to provide η3-allyl complexes.26  To our great 
surprise, our exploratory reactions using a variety of palladium(0) reagents and ligands, 
under a variety of reaction conditions (solvents and temperatures), all resulted in recovery 
of starting material (R = Me, OMe, eq. 3).27  We surmised that formation of the η3-
Me
Me
O
O
R
R
Pd
O
Me
Me
Me
MeO
O
Me
Me
Me
MeO
O
21
(3)Pd(0) catalyst
unfavorable
syn-pentane interaction
R
O
4
4
allylpalladium complex was inhibited by the adjacent geminal methyl groups, which 
impeded displacement of the leaving group due to an unfavorable syn-pentane interaction 
(eq. 3). 
At this juncture, we reconsidered our palladium-mediated cyclization strategy due 
to our inability to access the requisite π-allyl intermediate.  Because of the sterically 
demanding environment of the reaction site, it was apparent that the initial coordination to 
the C=C bond by palladium(0) and subsequent extrusion of the leaving group was not 
possible (eq. 4(a)). 28c  In contrast to this mechanism of oxidative addition by palladium, it 
is known that Group VI transition metals such as molybdenum and tungsten react though a 
different mechanistic manifold to form the π-allyl metal complex.28  Since these metals are 
relatively more Lewis-acidic in character, association of the metal to an allylic substrate 
occurs first with the Lewis-basic carbonyl oxygen of the leaving group, which is then 
                                                
27. Van Leeuwen, P. W. N. M.; Kamer, P. C. J.; Reek, J. N. H.; Dierkes, P. Chem. Rev. 2000, 100, 2741. 
28. (a) Belda, O.; Moberg, C. Acc. Chem. Res. 2004, 37, 159. (b) Hughes, D. L.; Krska, S. W.; Reamer, R. A.; 
Mathre, D. J.; Sun, Y. In Methodologies in Asymmetric Catalysis; American Chemical Society: Washington, DC 
2004; Vol. 880, pp 131–144. (c) Malkov, A. V.; Braxendale, I. R.; Dvorak, D.; Mansfield, D. J.; Kocovsky, P. 
J. Org. Chem. 1999, 64, 2737. 
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Mo
Pd
O O
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Pd
O O
R
Mo
(4)
(a) (b)
 
followed by coordination to the C=C bond (eq. 4(b)).28b  Thus, we hypothesized that a 
molybdenum-mediated reaction could potentially avoid the prohibitive non-bonding  
interactions that were encountered in the palladium system and thereby give rise to the 
desired η3-allylmolybdenum complex.  
Armed with a new strategy for the proposed cyclization reaction, we prepared a 
molybdenum(II) catalyst known to be highly reactive in allylic substitution reactions,28c 
namely the dibromomolybdenum tetracarbonyl dimer.29  Impressively, exposure of the 
acetyl derivative of 38 to this molybdenum catalyst (reaction a, eq. 5) resulted in an 86% 
yield (over two steps) of cycloheptadiene 21 as a single regioisomeric product.  
Additionally, the olefin had indeed migrated into conjugation and to the desired 
tetrasubstituted-position (C5-C11) as it is in the natural product.  Though notably, an 
inseparable olefinic isomer was also obtained as part of this reaction mixture.30  Delighted 
by this successful cyclization, we were encouraged to attempt a more ambitious direct 
cyclization of 38 (being that allylic alcohols have been shown to be reactive precursors to 
                                                
29. Experimental evidence in reference 28c has suggested that Mo(II) is the reactive species in allylic substitution 
reactions and is thus supposed to be a more active catalyst relative to Mo(0) reagents. 
30. Danishefsky (in reference 10) noted that 21 readily forms a 2.5:1 thermodynamic ratio with an olefin isomer 
(C=C between C1-C11) under acidic conditions. 
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metal π-allyl complexes).31  We were extremely pleased when subjection of 38 to the 
molybdenum catalyst efficiently provided the cyclized product 21 (reaction b, eq. 5). 
Having also considered a potential SN2′ reaction to forge this C10-C11 bond, we 
additionally explored a number of non-metal catalyzed alternatives.  We were pleased to 
discover that organic acids were indeed capable of effecting the desired transformation, 
O
Me
Me
Me
MeO
olefinic 
isomer
(2.5:1)
O
Me
Me
Me
MeO
OH
38 21
(5)
1. AcO2, P(n-Bu)3, Et3N
2. [MoBr2(CO)4]2 (50 mol%)
CH2Cl2, 1 hr, 86% yield
TFA (1.5 eq)
CH2Cl2, !, 100% yield
[MoBr2(CO)4]2 (10 mol%)
CH2Cl2, 6 hr, 83% yield
b
a
c
 though Lewis acids (i.e., BF3·OEt2) were found to be unreactive.  Using optimal 
conditions, a TFA-promoted reaction (reaction c, eq. 5) yielded complete conversion to the 
cyclized product 21, however again as a mixture of olefinic products.30  
Completion of the synthesis was achieved upon a final O-demethylation to reveal 
the natural product (41, eq. 6).  All spectroscopic aspects of this prepared material matched 
BBr3, –78 °C
91% yield
O
Me
Me
Me
MeO
21
(6)
O
Me
Me
Me
HO
(+)-frondosin B
5 linear steps
32% overall yield
[!]D = +16.3°
lit. [!]D = +18.5°
R
41
 that of the frondosin B, including the magnitude and absolute sense of optical rotation.  
Because the sign of the optical rotation matches that of Danishefsky’s synthetic product as 
                                                
31. (a) Stary, I.; Stara, I. G.; Kocovsky, P. Tetrahedron 1994, 50, 529. (b) Dubs, C.; Yamamoto, T.; Inagaki, A.; Akita, 
M. Chem. Commun. 2006, 1962. (c) Tsukamoto, H.; Sato, M.; Kondo, Y. Chem. Commun. 2004, 1200.  
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well as that of the natural frondosin B, we can confidently conclude naturally occurring 
frondosin B to exist as the R-enantiomer, having established the C-8 methyl stereocenter as 
being R-configured in our synthesis.  Thus, we can assume Trauner’s reassignment of 
natural frondosin B as the S-enantiomer to be invalid. 
 
IV. Resolution of the Absolute Configuration of (+)-Frondosin B 
Subsequent to the synthesis of frondosin B, we undertook an investigation to 
determine the origin of the differing enantiomeric C-8 methyl stereocenters in the 
Danishefsky and Trauner syntheses.  Our analysis of the situation began with Trauner’s 
supposition that Danishefsky and co-workers had synthesized an S-configured C-8 
stereocenter.  To test Trauner’s hypothesis, we sought to intercept an advanced 
intermediate in Danishefsky’s synthesis of frondosin B and determine its absolute 
configuration.  As shown in Scheme 7, we prepared Danishefsky’s benzofuran intermediate 
using our (R,R)-chiral imidazolidinone catalyst (42) to access the S-configured product 4. 
However, this compound had the opposite sense of rotation to that of Danishefsky’s 
intermediate.  Therefore, we can conclude that Trauner’s assertion that Danishefsky 
synthesized the S-configured natural product was incorrect.  To complete our study, we 
also synthesized Trauner’s intermediate 11 in order to validate the configuration of the 
methyl stereocenter in their synthesis (Scheme 7).  Using the (S,S) catalyst 35, we could 
obtain an R-configured product 43 that matched Trauner’s intermediate in all spectroscopic 
aspects. Thus, we conclude that both groups indeed had synthesized R-configured 
intermediates. 
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Scheme 7. Interception of Danishefsky’s (4) and Trauner’s (43) synthetic intermediates 
Me
O
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We then examined Trauner’s synthesis to pinpoint a possible mode in which the C-
8 stereocenter could have undergone an inversion of configuration.  Having verified that 
their advanced intermediate was in fact R-configured, we retraced their subsequent steps.  
The penultimate Heck-cyclization reaction was identified as a potential culprit.  In this key 
step, Trauner and co-workers propose that the reaction proceeds via a cationic palladium 
species and not through the standard Heck mechanism.32  He rules out this mechanistic 
pathway based on the fact that racemization of the stereocenter at C-8 was not observed.13  
However, we assert that this mechanism can not be ruled out on the basis of their argument.  
In their cyclization step (Scheme 8), we propose that the Heck mechanism is indeed 
operational and results in the concomitant formation of two intermediary stereocenters at 
                                                
32. Standard Heck reactions are said to involve oxidative insertion, migratory insertion, and β-hydride elimination 
(vide reference 26b). 
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the newly formed ring juncture.  Syn-elimination of this hydridopalladium species (44) 
provides enol ether 45, which retains a single stereocenter at C-10.  According to Trauner, 
Scheme 8. Hypothesized mechanism of inversion in Trauner’s synthesis of frondosin B 
(S)-20
70% yield
O
Me
MeO
Me O
TfO
O
MeO
O
H
O Me
MeO
O
H
aromatization
–H[Pd]OTf
O Me
MeO
O
TfO[Pd]
R S Pd(PPh3)4, DMA, i-Pr2NEt, 90 °C
Pd(0)
H
10
10
MM3-454544  
rearomatization ofenol ether 45 would assuredly form a racemic product.  However, we 
assert that enol ether 45 can only be protonated from its convex face (as is apparent from 
MM3-45) to yield an S-configured C-8 methyl stereocenter.  Thus, we show a convincing 
method by which Trauner synthesized the opposite enantiomer of the natural product. 
 
V. Conclusion 
In summary, an efficient five-step total synthesis of (+)-frondosin B has been 
described.  This work highlights the use of organocatalysis in the stereoselective 
construction of a natural product target.  An enantioselective, organocatalytic conjugate 
addition reaction played a critical role in setting the C-8 methyl stereocenter and was key in 
the establishment of the absolute configuration of the natural product as R.  Thus, by 
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correlation we were able to confidently reassign naturally occurring (+)-frondosin B to 
exist as the (R)-enantiomer.  And in doing so, we were able to resolve a discrepancy in the 
literature that purported the natural product to exist as the (S)-enantiomer.  We also 
demonstrated a novel intramolecular cyclization strategy that proved to be numerously 
successful in yielding the completed tetracyclic framework of frondosin B.  To date, this 
work represents the most effective synthesis of frondosin B, which can now be accessed in 
five steps and a 32% overall yield. 
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S u p p o r t i n g  I n f o r m a t i o n  
General Information.  Commercial reagents were purified prior to use following 
the guidelines of Perrin and Armarego.33  All solvents were purified according to the 
method of Grubbs.34 Organic solutions were concentrated under reduced pressure on a 
Büchi rotary evaporator using an ice-water bath for volatile compounds.  Potassium 
tri(fluoro)borate salts were synthesized from commercially available boronic acids or esters 
using a modified Molander procedure.35  Chromatographic purification of products was 
accomplished using force-flow chromatography on Silicycle silica gel according to the 
method of Still36 and where noted, Iatrobeads 6RS-8060 was used in place of silica gel.  
Thin-layer chromatography (TLC) was performed on Silicycle 250 mm silica gel plates.  
Visualization of the developed chromatogram was performed by fluorescence quenching 
and anisaldehyde stain. 
1H and 13C NMR spectra were recorded on a Varian Mercury 300 (300 MHz or 75 
MHz), Mercury 400 (400 MHz or 100 MHz), or an Inova 500 (500MHz and 125 MHz) as 
noted, and are internally referenced to residual protio solvent signals (note: CDCl3 
referenced at δ 7.24).  Data for 1H NMR are reported as follows: chemical shift (δ ppm), 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), integration, 
coupling constant (Hz), and assignment.  Data for 13C NMR are reported in terms of 
                                                
33. Perrin, D. D.; Armarego, W. L. F. Purification of Laboratory Chemicals; 3rd ed.; Pergamon Press: Oxford, 1988.  
34. Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics, 1996, 15, 1518. 
35. (a) Molander, G. A.; Ito, T. Org. Lett. 2001, 3, 393. (b)  Molander, G. A.; Biolatto, B. Org. Lett.  2002, 4, 1867.  
Note: The cited procedures were found to be more efficient when reaction slurries were sonicated. 
36. Still, W. C.; Kahn, M.; Mitra, A. J. J. Org. Chem. 1978, 43, 2923. 
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chemical shift.  IR spectra were recorded on a Perkin Elmer Paragon 1000 spectrometer 
and are reported in terms of frequency of absorption (cm-1).  Mass spectra were obtained 
from the California Institute of Technology Mass Spectral Facility and the Princeton Mass 
Spectroscopy Facility.  Gas liquid chromatography (GLC) was performed on Hewlett-
Packard 6850 and 6890 Series gas chromatographs equipped with split-mode capillary 
injection system and flame ionization detectors using Bodman Chiraldex Γ-TA (30 m x 
0.25 mm) column.  Supercritical fluid chromatography (SFC) was performed on a Berger 
Minigram equipped with a diode array UV detector (λ = 214–258 nm) using a chiral 
column (25 cm) and guard column (5 cm) as noted for each compound.  
 
O
MeO
BF3K
 
Potassium 2-(5-methoxybenzofuranyl)trifluoroborate salt (34). 2-(5-
methoxybenzofuranyl)trifluoroborate.  Prepared according to a modified procedure 
from Molander and co-workers.37  Commercially available 2-(5-methoxybenzofuranyl) 
boronic acid (33, 1.75 g, 9.0 mmol) was dissolved in anhydrous methanol (25 mL).  
Finely ground potassium hydrogenfluoride (2.44 g, 31 mmol) was added and the resulting 
suspension was sonicated for 5 minutes before being cooled down to 0 °C.  Cold H2O (8 
mL) was added drop-wise over 45 min via syringe pump and resulted in the gradual 
formation of a thick slurry.  The resulting suspension was stirred at ambient temperature 
for 2 hours and then concentrated in vacuo, azeotroped with methanol (5 x 10 mL), and 
                                                
37. (a) Molander, G. A.; Ito, T. Org. Lett. 2001, 3, 393. (b)  Molander, G. A.; Biolatto, B. Org. Lett.  2002, 4, 1867. 
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dried under high vacuum to remove all traces of moisture.  The resulting free-flowing 
white solid was then dissolved in hot acetone and filtered.  The filtrate was cooled to 
room temperature and concentrated in vacuo.  Ethyl ether was added to titurate the 
product to produce a white powder that was filtered and dried under high vacuum (1.60 g, 
70 % yield).  IR (solid) 1560 1467, 1450, 1206, 1153, 1134, 967.5, 937.3, 902.0, 848.9, 
799.9, 753.9 cm-1.  1H NMR (d6-acetone, 400 MHz) δ 7.18 (d, 1H, J = 8.7 Hz, aryl H), 
6.92 (d, 1H, J = 2.4 Hz, aryl H), 6.64 (dd, 1H, J = 8.7, 2.4 Hz, aryl H), 6.45 (s, 1H, aryl 
H), 3.54 (s, 3H, CH3); 13C NMR (d6-acetone, 125 MHz) δ 155.5, 151.5, 130.5, 110.7, 
110.2, 107.6, 102.9, 55.3; 19F NMR (d6-acetone, 282 MHz) δ –143.1 (br d, J = 44 Hz).  
HRMS (TOF ES) exact mass calculated for [M]+• (C9H7BF3O3) requires m/z 215.0491, 
found m/z 215.0462. 
 
O Me
MeO
O
 
(R)-3-(5-methoxybenzofuran-2-yl)butanal (36).38 To a plastic vial (Wheaton 
HDPE) is added HF (48 wt%, 6.25 mg, 0.15 mmol) followed by 1,2-dimethoxyethane 
(DME) (450 µL) and a magnetic stir bar.  The catalyst and acid co-catalyst are charged to 
the vial with the addition of (2S,5S)-2-tert-butyl-5-((1-benzyl-1H-indol-3-yl)methyl)-3-
methylimidazolidin-4-one (10.9 mg, 0.03 mmol) and HCl (4N in dioxane, 7.5 µL, 0.03 
mmol) and is then cooled to –20 °C.  The reaction is started with the addition of 
crotonaldehyde (37.5 µL, 0.45 mmol) to the DME solution followed by the addition of 
                                                
38. For stereochemical proofs for the title compound, see supporting information in Chapter 3 (p. 92). 
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potassium 2-(5-methoxybenzofuranyl)trifluoroborate (42.4 mg, 0.15 mmol).  The reaction 
is stirred at –20 °C for 24 hours and quenched with 1M HCl (1.0 mL) and is stirred with 
chloroform (1.5 mL) for 30 minutes.  The organic layer is extracted with chloroform (2 x 
2.0 mL), dried over Na2SO4, filtered through celite (ether wash) and concentrated in vacuo.  
Purification by chromatography (silica gel, 15% ether in pentanes) yields the title 
compound as clear oil (30.7 mg, 94% yield, 92% ee).  IR (film) 1724, 1475, 1205, 1030 
cm-1; 1H NMR (300 MHz, CD2Cl2) δ 9.78 (t, 1H, J = 1.5 Hz, CHO), 7.29 (d, 1H, J = 8.4 
Hz, aryl H), 6.98 (d, 1H, J = 2.4 Hz, aryl H), 6.81 (dd, 1H, J = 2.4, 9.0 Hz, aryl H), 6.38 
(d, 1H, J = 0.9 Hz), 3.01 (s, 3H, OCH3), 3.54 (m, 1H, CHCH3), 2.79 (ddd, 2H, J = 1.5, 6.6, 
17.4 Hz, CH2), 1.39 (d, 3H, J = 0.9 Hz, CH3);  13C NMR (75 MHz, CDCl3) δ 201.32, 
163.07, 156.46, 150.05, 129.72, 112.37, 111.60, 103.72, 101.93, 56.29, 49.30, 28.78, 
19.18;  HRMS (EI+) exact mass calculated for [M]+• (C13H14O3) requires m/z 218.0943, 
found m/z 218.0944; [α]D= –8.51 (c = 1.29, CHCl3).  The enantiomeric excess was 
determined by SFC using a Chiracel OJ-H column (5% to 10% MeCN, linear gradient, 100 
bar, 35 °C oven, flow = 4.0 mL/min); (S) isomer tr = 5.17 min, (R) isomer tr = 5.61 min.  
 
Me
O
MeO
HO
 
(3R)-3-(5-methoxybenzofuran-2-yl)butan-1-ol.  To a stirring solution of aldehyde 
36 (25 mg, 0.11 mmol) in CH2Cl2 (2.0 mL) and ethanol (20 µL) at 0 °C was added NaBH4 
(13 mg, 0.34 mmol).  The reaction was quenched after 5 minutes by a saturated solution of 
Rochelle’s salt  (2.0 mL).  The organic layer was then extracted with ether (2 x 3.0 mL) and 
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concentrated in vacuo to yield a clear oil (quantitative yield) with spectroscopic data 
matching literature values.39  IR (film) 3306 (br), 2922, 1458, 1201, 1026 cm-1; 1H NMR 
(300 MHz, CDCl3) δ 7.28 (d, 1H, J = 8.7 Hz, aryl H), 6.94 (d, 1H, J = 2.7 Hz, aryl H), 
6.79 (dd, 1H, J = 2.7, 8.7 Hz, aryl H), 6.33 (s, 1H, aryl H), 3.81 (s, 3H, OCH3), 3.69 (m, 
2H, CH2CH2), 3.11 (m, 1H, CHCH3), 2.06–1.95 (m, 1H, CH2OH), 1.91–1.79 (m, 1H, 
CH2OH), 1.57 (br s, 1H, OH), 1.34 (d, 3H, J = 7.2 Hz, CH3); 13C NMR (75 MHz, CDCl3) 
δ 164.11, 155.98, 149.73, 129.48, 111.81, 111.38, 103.45, 101.40, 60.97, 56.16, 38.53, 
30.56, 19.38; HRMS (EI+) exact mass calculated for [M+1] (C13H16O3) requires m/z 
220.1100, found m/z 220.1089; [α]D= –46.2 (c = 0.83, CHCl3).39  The enantiomeric excess 
was determined by SFC analysis using a Chiralcel OJ-H column (5% to 10% methanol, 
linear gradient, 100 bar, 35 °C oven, flow = 4.0 mL/min); (S) isomer tr = 5.71 min, (R) 
isomer tr = 6.56 min. 
Me
O
MeO
CO2Me
 
(S)-methyl-5-(5-methoxybenzofuran-2-yl)-hexanoate.  To a suspension of 
potassium tert-butoxide (30.6 mg, 0.273 mmol, 1.3 eq.) in dry THF (3.0 mL) at 0 °C was 
added methyldiethylphosphonoacetate (53.3 µL, 0.294 mmol, 1.4 mmol) portionwise.  
The resulting reaction mixture was allowed to warm up to room temperature and stirred 
for an additional 15 min, before adding a solution of (S)-3-(5-methoxybenzofuran-2-
yl)butanal (45 mg, 0.21 mmol) in THF (2.0 mL).  Upon stirring for 12 hours, the reaction 
                                                
39. Hughes, C. C.; Trauner, D. Tetrahedron, 2004, 60, 9675 (reported [α]D= –33.0 (c = 1.00, CHCl3) for a product 
that was 91% ee).  
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was diluted with diethyl ether (2.0 mL) and then quenched by the slow addition of H2O 
(1.0 mL).  The layers were separated and the aqueous phase was extracted with Et2O (3 x 
5 mL).  The combined organic extracts were washed with brine, dried over sodium 
sulfate and concentrated in vacuo to give the crude product (50 mg), which was used in 
the next step without further purification.  Crude (S,E)-methyl-(5-methoxybenzofuran-2-
yl)-hexanoate (40 mg, 0.145 mmol) was dissolved in methanol (3.0 mL) and Lindlar’s 
catalyst (15.5 mg, 0.07 mmol, 5 mol%) were added to a flame-dried flask.  The system 
flushed with hydrogen and the mixture was stirred for 12 hours at room temperature.  The 
reaction was then diluted with methanol and filtered through Celite to remove palladium.  
The solvent was removed in vacuo and the crude product was purified by column 
chromatography (silica gel, 10% ether in pentanes) to give the title compound (40 mg, 
0.145 mmol) in 88% yield over the two steps.  IR (film) 1735, 1475, 1205, 1030 cm-1.  1H 
NMR (CDCl3, 400 MHz) δ 7.29 (d, 1H, J = 9.0 Hz, aryl H), 6.96 (d, 1H, J = 2.7 Hz, aryl 
H), 6.80 (dd, 1H, J = 2.7, 9.0 Hz, aryl H), 6.32 (s, 1H, aryl H), 3.83 (s, 3H, OCH3), 3.66 
(s, 3H, CO2CH3), 2.92 (m, 1H, CHCH3), 2.32 (t, 2H, J = 7.0 Hz, CH2CO2Me; 1.80 (m, 
1H, CH2CH2CO2Me), 1.66 (m, 3H, CHCH3CH2CH2), 1.32 (d, 3H, J = 7.0 Hz, CHCH3), 
13C NMR (125 MHz, CDCl3) δ 174.2, 164.3, 155.9, 149.7, 129.6, 111.7, 111.4, 103.5, 
101.3, 56.2, 51.7, 35.0, 34.2, 33.7, 22.8, 19.2; [α]D= + 19.6 (c = 0.10, CHCl3).   
 
O
Me
Me
Me
MeO
OH
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(3R)-1-(6,6-dimethylcyclohex-1-enyl)-3-(5-methoxybenzofuran-2-yl)butan-1-ol 
(38).  2,4,6-triisopropylbenzenesulfonyl hydrazone40 (0.32 g, 0.78 mmol) was dissolved in 
anhydrous THF (1.5 mL) and cooled to –78 °C.  tert-Butyl lithium (1.3 mL, 1.3 M in 
hexanes, 1.72 mmol) was added drop-wise over 15 min during which time the reaction 
solution turned yellow and then dark orange.  The reaction was aged for 30 min at –78 °C 
and then at 0 °C for 15 min, upon which N2(g) evolution was observed.  Upon cooling the 
system to –78 °C, aldehyde 36 (0.29 g, 1.32 mmol, 1.0 mL THF solution) was added via 
cannula to the reaction.  The resulting reaction mixture was then stirred at 0 °C for 1 hour 
and at room temperature for 3 additional hours before being quenched by the addition of 
NH4Cl(aq) (5.0 mL).  The organic layer was extracted with chloroform (3 x 10 mL), dried 
over Na2SO4, filtered through celite (ether wash) and concentrated in vacuo.  Purification 
by chromatography (silica gel, 10% ethyl acetate in hexanes) yielded the title compound as 
yellow oil in a 1:1 mixture of diastereomers (dia 1 + 2, 0.22 g, 86% yield).  IR (film) 3475, 
1617, 1475, 1205, 1030 cm-1.  1H NMR (CDCl3, 400 MHz) δ 7.25 (d, 1H, J = 8.8 Hz, aryl 
H, dia 1), 7.23 (d, 1H, J = 8.8 Hz, aryl H, dia 2), 6.93 (d, 1H, J = 2.8 Hz, aryl H, dia 1), 
6.92 (d, 1H, J = 2.8 Hz, aryl H, dia 2), 6.78 (dt, 1H, J = 2.8, 8.8 Hz, aryl H, dia 1+2), 6.35 
(s, 1H, aryl H, dia 1), 6.30 (s, 1H, aryl H, dia 2), 5.82 (t, 1H, J = 4.0 Hz, C=CH, dia 1), 
5.80 (t, 1H, J = 4.0 Hz, C=CH, dia 2), 4.26 (dd, 1H, J = 2.8, 10 Hz, CHOH, dia 1), 4.02 
(dd, 1H, J = 2.8, 10 Hz, CHOH, dia 2), 3.80 (s, 3H, OCH3, dia 1), 3.79 (s, 3H, OCH3, dia 
2), 3.18 (m, 1H, CHCH3, dia 1 + 2), 2.08 (ddd, 1H, J = 4.4, 9.2, 13.6 Hz CHOHCH2, dia 
1), 1.98 (t, 2H, J = 2.4 Hz, C=CCH2, dia 1+2), 1.91 (ddd, 1H, J = 2.8, 10.0, 13.6 Hz, 
CHOHCH2, dia 2), 1.76 (ddd, 1H, J = 4.8, 10, 13.4 Hz, CHOHCH2, dia 2), 1.65 (ddd, 1H, 
                                                
40. Pazos, Y.; Iglesias, B.; de Lera, A. R. J. Org. Chem. 2001, 66, 8483. 
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J = 2.8, 9.2, 13.6 Hz, CHOHCH2, dia 1), 1.55 (m, 2H, C=CCH2CH2, dia 1 + 2) 1.40 (m, 
2H, C(CH3)2CH2, dia 1 + 2), 1.32 (d, 3H, J = 6.9 Hz, CHCH3, dia 1), 1.31 (d, 3H, J = 6.9 
Hz, CHCH3, dia 2), 1.08 (s, 3H, C(CH3)2, dia 1), 0.94 (s, 3H, C(CH3)2, dia 2), 0.93 (s, 3H, 
C(CH3)2, dia 1) 0.80 (s, 3H, C(CH3)2, dia 2);  13C NMR (125 MHz, CDCl3) δ 165.2, 164.2, 
155.9, 149.8, 129.6, 129.5, 122.7, 122.4, 111.7, 111.6, 111.3, 103.5, 101.8, 100.8, 67.9, 
67.1, 56.2, 44.9, 44.2, 39.8, 39.7, 34.0, 33.9, 31.6, 31.0, 28.6, 28.5, 28.3, 28.2, 26.0, 20.1, 
19.3, 18.5; HRMS (EI+) exact mass calculated for [M]+• (C21H28O3) requires m/z 328.2038, 
found m/z 328.2043. 
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(3R)-1-(6,6-dimethylcyclohex-1-enyl)-3-(5-methoxybenzofuran-2-yl)butyl 
ethanoate.  Prepared according to a procedure adapted from Vedejs et al.41  To a round-
bottom flask was charged 1-(6,6-dimethylcyclohex-1-eyl-)-3-(5-methoxybenzofuran-2-
yl)butan-1-ol (0.115 g, 0.35 mmol), freshly distilled tributylphosphine (13 µL, 0.05 
mmol), triethylamine (80 µL, 0.53 mmol), acetic anhydride (100 µL, 1.0 mmol), and 
anhydrous diethyl ether (13 mL).  The resulting reaction mixture was refluxed for 30 
hours, upon which the reaction was allowed to cool to room temperature and was 
quenched with addition of NH4Cl(aq) (10 mL).  The solution was partitioned with diethyl 
ether (3 x 10.0 mL).  The combined organic layers were washed with brine, dried over 
Na2SO4 and concentrated in vacuo.  Purification by chromatography (silica gel, 5% ethyl 
                                                
41. Vedejs, E.; Diver, S. T. J. Am. Chem. Soc. 1993, 115, 3358.  
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acetate in hexanes) yielded the title compound as clear oil (dia 1 + 2, 130 mg, 0.35 mmol) 
in quantitative yield.  IR (film) 1732, 1617, 1475, 1235, 1205, 1030 cm-1.  1H NMR 
(CDCl3, 500 MHz) δ 7.29 (d, 1H, J = 9.0 Hz, aryl H, dia 1), 7.28 (d, 1H, J = 9.0 Hz, aryl 
H, dia 2), 6.96 (d, 1H, J = 2.5 Hz, aryl H, dia 1 + 2), 6.81 (dd, 1H, J = 2.5, 9.0 Hz, aryl 
H, dia 1 + 2), 6.34 (s, 1H, aryl H, dia 1), 6.33 (s, 1H, aryl H, dia 2), 5.80 (t, 1H, J = 4.0 
Hz, C=CH, dia 1), 5.76 (t, 1H, J = 4.0 Hz, C=CH, dia 2), 5.48 (dd, 1H, J = 3.5, 9.5 Hz, 
CHOAc, dia 1), 5.26 (dd, 1H, J = 3.5, 9.5 Hz, CHOAc, dia 2), 3.83 (s, 3H, OCH3, dia 
1+2), 2.92 (m, 1H, CHCH3, dia 1 + 2), 2.24 (ddd, 1H, J = 4.4, 9.0, 15.0 Hz CHOHCH2, 
dia 1), 2.10 (ddd, 1H, J = 2.8, 9.0, 15.0 Hz, CHOHCH2, dia 2), 2.02 (t, 2H, J = 2.4 Hz, 
C=CCH2, dia 1 + 2), 1.76 (m, 4H, (C=O)CH3, CHOHCH2, dia 2), 1.80 (ddd, 1H, J = 2.8, 
9.0, 15.0 Hz, CHOHCH2, dia 1), 1.55 (m, 2H, C=CCH2CH2, dia 1+2) 1.42 (m, 2H, 
C(CH3)2CH2, dia 1 + 2), 1.35 (d, 3H, J = 7.0 Hz, CHCH3, dia 1+2), 1.08 (s, 3H, C(CH3)2, 
dia 1), 0.98 (s, 3H, C(CH3)2, dia 2), 0.97 (s, 3H, C(CH3)2, dia 1) 0.90 (s, 3H, C(CH3)2, dia 
2); 13C NMR (125 MHz, CDCl3) δ 170.5, 170.3, 164.2, 163.3, 155.9, 149.8, 149.7, 145.0, 
144.9, 129.6, 129.5, 124.5, 124.0, 111.8, 111.7, 111.3, 103.4, 101.9, 101.1, 70.9, 70.4, 
56.1, 42.3, 42.0, 39.9, 39.8, 33.9, 33.8, 31.4, 31.3, 28.8, 28.7, 28.2, 26.0, 25.9, 21.6, 21.5, 
19.7, 19.1; HRMS (EI+) exact mass calculated for [M]+• (C23H30O4) requires m/z 
370.2144, found m/z 370.2136. 
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(R)-O-methyl frondosin B non-conjugated olefin isomer (39).  To a round 
bottom flask was charged 1-(6,6-dimethylcyclohex-1-eyl-)-3-(5-methoxybenzofuran-2-
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yl)butan-1-ol (33 mg, 0.088 mmol) and [Mo(CO)4(Br2]2 (34 mg, 0.044 mmol).  Freshly 
distilled and degassed dichloromethane (2.0 mL) was added and the reaction was stirred 
at —20 °C for 12 hours (and monitored by TLC).  Upon reaction completion, diethyl 
ether (10 mL) was added and the solution was filtered through Fluorosil (ether wash) and 
was concentrated in vacuo.  Purification by chromatography (silica gel, 5% ethyl acetate 
in hexanes) yielded the title compound as pale yellow oil (27 mg, 0.087 mmol) in 98% 
yield as a mixture of two diastereomers in an approximate 1:1 ratio (dia 1 + 2).  IR (film) 
1613, 1475, 1205, 1030 cm-1.  1H NMR (CDCl3, 500 MHz) δ 7.27 (d, 1H, J = 8.8 Hz, aryl 
H, dia 1), 7.25 (d, 1H, J = 8.8 Hz, aryl H, dia 2), 6.87 (d, 1H, J = 3.0 Hz, aryl H, dia 1 + 
2), 6.80 (dd, 1H, J = 2.5, 9.0 Hz, aryl H, dia 1), 6.78 (dd, 1H, J = 2.5, 9.0 Hz, aryl H, dia 
2), 5.59 (dd, 1H, J = 4.4, 6.4 Hz, C=CH, dia 1), 5.55 (dd, 1H, J = 6.4, 7.6 Hz, C=CH, dia 
2), 3.85 (s, 3H, OCH3, dia 1+2), 3.70 (m, 1H, CHC=C, dia 1), 3.68 (m, 1H, CHC=C, dia 
2), 3.20 (dqd, 1H, J = 2.4, 7.2, 7.2 Hz,  CHCH3, dia 1), 3.14 (qd, 1H, J = 2.8, 7.2, 7.2 Hz, 
CHCH3, dia 2), 2.55 (dqd, 1H, J = 2.2, 4.4, 16.4 Hz, CHCH3CH2, dia 1), 2.41 (ddd, J = 
2.4, 7.2, 16.4 Hz, CHCH3CH2 , dia 2), 2.42 (m, 2H, CHCH2), 1.86 (m, 1H CHCH2CH2), 
1.66 (m, 1H CHCH2CH2), 1.58 (m, 2H, CH2C(CH3)2), 1.34 (d, 3H, J = 7.2 Hz, CHCH3, 
dia 1 + 2), 1.18 (s, 3H, C(CH3)2, dia 1 + 2), 1.14 (s, 3H, C(CH3)2, dia 1), 1.12 (s, 3H, 
C(CH3)2, dia 2); 13C NMR (125 MHz, CDCl3) δ 159.53, 158.9, 155.7, 148.6, 148.3, 
147.3, 131.2, 131.1, 117.3, 116.1, 115.6, 115.3, 111.3, 111.2, 110.7, 110.6, 102.4, 56.4, 
43.1, 42.9, 39.2, 39.0, 36.9, 36.7, 35.8, 35.7, 34.9, 33.6, 33.1, 31.0, 30.8, 26.8, 26.6, 23.7, 
23.6, 19.7, 18.4; HRMS (EI+) exact mass calculated for [M]+• (C21H26O2) requires m/z 
310.1933, found m/z 310.1928. 
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(R)-O-methyl frondosin B (21).  A round bottom flask was charged with 1-(6,6-
dimethylcyclohex-1-eyl-)-3-(5-methoxybenzofuran-2-yl)butan-1-ol (100 mg, 0.30 mmol) 
and [Mo(CO)4(Br2]2 (22.4 mg, 0.03 mmol). Freshly distilled and degassed 
dichloromethane (2.0 mL) was added and the reaction was stirred at ambient temperature 
for 6 hours.  The reaction mixture was diluted with diethyl ether and filtered through 
Fluorosil. The organic solvent was concentrated in vacuo and purification by 
chromatography (silica gel, 5% ethyl acetate in hexanes) yielded the title compound as 
pale yellow oil (77 mg, 0.25 mmol) in 83% yield, as a 2.5:1 mixture with its conjugated 
olefinic isomer.  IR (film) 1613, 1475, 1205, 1030 cm-1.  1H NMR (CDCl3, 500 MHz) δ 
7.25 (d, 1H, J = 8.8 Hz, aryl H), 7.12 (d, 1H, J = 2.5 Hz, aryl H), 6.77 (dd, 1H, J = 8.8, 
2.5 Hz, aryl H), 3.82 (s, 3H, OCH3), 3.15 (q, 1H, J = 8.5 Hz, CHCH3), 2.55 (t, 2H, J = 
7.5 Hz, C=CCH2), 2.15 (m, 1H, CH2C=C), 2.11 (m, 1H, CH2C=C), 2.08 (m, 1H, 
C=CCH2CH2), 1.82 (m, 1H, C=CCH2CH2), 160 (m, 4H, 1H, CH2CH2C(CH3)2), 1.32 (d, 
3H, J = 8.5 Hz, CHCH3), 1.06 (s, 3H, C(CH3)2), 1.02 (C(CH3)2); 13C NMR (125 MHz, 
CDCl3) δ 160.2, 155.5, 149.3, 144.6, 129.5, 124.1, 116.9, 111.1, 111.0, 105.6, 56.3, 39.8, 
39.0, 36.0, 34.9, 30.8, 29.2, 28.2, 26.3, 20.3, 20.0; HRMS (EI+) exact mass calculated for 
[M]+• (C21H26O2) requires m/z 310.1933, found m/z 310.1928. 
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(R)-frondosin B (41).  A solution of the mixture of (R)-O-methyl frondosin B and 
its olefinic conjugated isomer (125 mg, 0.40 mmol) in dichloromethane (2.0 mL) was 
cooled to –78 °C and treated with boron tribromide (1M in dichloromethane, 1.28 mL, 
1.28 mmol).  After being stirred at that temperature for 30 min, the solution was warmed 
to 0 °C and stirred at this temperature for a further hour.  The reaction mixture was 
quenched with saturated solution of NaHCO3 and partitioned with ethyl acetate (6.0 mL).  
The organic layer was washed with saturated solution of NaHCO3 (6.0 mL) and then with 
brine (6.0 mL), dried  over Na2SO4 and concentrated in vacuo.  Purification by 
chromatography (silica gel, 5% ethyl acetate in hexanes) yielded the title compound as 
pale yellow oil (105 mg, 0.36 mmol) in 90% yield, as a 2.5:1 mixture with its conjugated 
olefinic isomer.  The two isomers were separated by preparative HPLC.  IR (film) 330, 
2930, 1620, 1460, 1189 cm-1.  1H NMR (CDCl3, 500 MHz) δ 7.21 (d, 1H, J = 8.8 Hz, aryl 
H), 7.09 (d, 1H, J = 2.5 Hz, aryl H), 6.67 (dd, 1H, J = 8.8, 2.5 Hz, aryl H), 4.51 (s, 1H, 
OH), 3.17 (q, 1H, J = 8.5 Hz, CHCH3), 2.51 (t, 2H, J = 6.0 Hz, C=CCH2), 2.15 (m, 1H, 
CH2C=C), 2.11 (m, 1H, CH2C=C), 2.08 (m, 1H, C=CCH2CH2), 1.82 (m, 1H, 
C=CCH2CH2), 1.60 (m, 4H, 1H, CH2CH2C(CH3)2), 1.32 (d, 3H, J = 8.5 Hz, CHCH3), 
1.05 (s, 6H, C(CH3)2); 13C NMR (125 MHz, CDCl3) δ 160.2, 150.7, 149.1, 144.4, 129.6, 
123.7, 116.5, 111.3, 112.6, 111.1, 107.3, 39.5, 38.5, 36.6, 35.7, 34.7, 30.6, 29.7, 28.9, 
26.1, 24.7, 20.0, 19.8; [α]D= + 16.3 (c = 0.12, MeOH). 
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Table 1. 1H and 13C NMR Data for Natural1 and Synthetic (+)-Frondosin Ba 
O
Me
Me
Me
HO
8
11
1
3
5
2 4
6
7
9
10
19
20
17
16
15
14
13
12
18
 
  natural frondosin Bb  synthetic frondosin Bc 
position   13C (δ) 1H (δ), #H, m, J (Hz)  13C (δ) 1H (d), #H, m, J (Hz) 
        
 1  30.5 2.55, 2H,t, J = 5.9  30.55 2.54, 2H,t, J = 6.0 
 2  20.0 1.71, 2H, m  20.03 1.69, 2H, m 
 3  39.5 1.56, 2H, m  39.50 1.57, 2H, m 
 4  35.7 ---  35.73 --- 
 5  144.3 ---  144.40 --- 
 6  26.0 2.15, 1H, m 
2.10, 1H, m 
 26.06 2.14, 1H, m 
2.11, 1H, m 
 7  38.5 2.12, 1H, m 
1.62, 1H, m 
 38.48 2.11, 1H, m 
1.61, 1H, m 
 8  34.7 3.19, 1H, m  34.73 3.18, 1H, m 
 9  160.2 ---  160.22 --- 
 10  116.3 ---  116.47 --- 
 11  123.8 ---  123.73 --- 
 12  129.6 ---  129.62 --- 
 13  107.3 7.12, 1H, d, J = 2.5  107.27 7.11, 1H, d, J = 2.8 
 14  150.7 ---  150.70 --- 
 15  111.1 6.71, 1H, dd, J = 2.5, 8.7  111.07 6.70, 1H, dd, J = 2.8, 8.8 
 16  110.9 7.24, 1H, d, J = 8.7  110.91 7.23, 1H, d, J = 8.8 
 17  149.1 ---  149.08 --- 
 18  19.7 1.35, 3H, d, J = 7.0  19.78 1.34, 3H, d, J = 6.8 
 19  28.9 1.09, 3H, s  28.94 1.08, 3H, s 
 20  27.9 1.10, 3H, s  27.89 1.09, 3H, s 
 OH  --- 4.77, 1H, br s  --- 4.54, 1H, br s 
aSpectra were measured in CDCl3.  b 1H NMR (400 MHz); 13C (100 MHz).  c 1H NMR (500 MHz); 13C (125 MHz).   
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